US20230407357A1 - Biomanufacturing of oligosaccharides and derivatives from simple sugar - Google Patents
Biomanufacturing of oligosaccharides and derivatives from simple sugar Download PDFInfo
- Publication number
- US20230407357A1 US20230407357A1 US18/199,842 US202318199842A US2023407357A1 US 20230407357 A1 US20230407357 A1 US 20230407357A1 US 202318199842 A US202318199842 A US 202318199842A US 2023407357 A1 US2023407357 A1 US 2023407357A1
- Authority
- US
- United States
- Prior art keywords
- nucleotide
- sugar
- donor
- contacting
- catalytic amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 68
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 63
- 235000021309 simple sugar Nutrition 0.000 title abstract description 6
- 238000013406 biomanufacturing process Methods 0.000 title description 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 293
- 108090000790 Enzymes Proteins 0.000 claims abstract description 293
- 238000000034 method Methods 0.000 claims abstract description 253
- 235000000346 sugar Nutrition 0.000 claims abstract description 198
- 238000004519 manufacturing process Methods 0.000 claims abstract description 135
- 239000002773 nucleotide Substances 0.000 claims description 361
- 125000003729 nucleotide group Chemical group 0.000 claims description 179
- 230000008569 process Effects 0.000 claims description 141
- 102000004357 Transferases Human genes 0.000 claims description 135
- 108090000992 Transferases Proteins 0.000 claims description 135
- 230000003197 catalytic effect Effects 0.000 claims description 125
- 239000002243 precursor Substances 0.000 claims description 101
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 92
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 88
- 239000008103 glucose Substances 0.000 claims description 88
- 238000006243 chemical reaction Methods 0.000 claims description 83
- 229930091371 Fructose Natural products 0.000 claims description 65
- 239000005715 Fructose Substances 0.000 claims description 65
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 61
- RJTOFDPWCJDYFZ-SPVZFZGWSA-N Lacto-N-triaose Chemical group CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O RJTOFDPWCJDYFZ-SPVZFZGWSA-N 0.000 claims description 58
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 42
- 230000001172 regenerating effect Effects 0.000 claims description 26
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 25
- 230000008929 regeneration Effects 0.000 claims description 22
- 238000011069 regeneration method Methods 0.000 claims description 22
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 claims description 21
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 claims description 21
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 20
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 20
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 17
- HMQPEDMEOBLSQB-RCBHQUQDSA-N beta-D-Galp-(1->3)-alpha-D-GlcpNAc Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-RCBHQUQDSA-N 0.000 claims description 17
- 229930191176 lacto-N-biose Natural products 0.000 claims description 17
- MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 claims description 15
- 150000002016 disaccharides Chemical class 0.000 claims description 13
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 12
- PNHLMHWWFOPQLK-BKUUWRAGSA-N GDP-4-dehydro-6-deoxy-alpha-D-mannose Chemical compound O[C@H]1[C@@H](O)C(=O)[C@@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 PNHLMHWWFOPQLK-BKUUWRAGSA-N 0.000 claims description 12
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 12
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 11
- HXXFSFRBOHSIMQ-RWOPYEJCSA-L alpha-D-mannose 1-phosphate(2-) Chemical compound OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-RWOPYEJCSA-L 0.000 claims description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 4
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 3
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 2
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical group O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 2
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 73
- 230000015572 biosynthetic process Effects 0.000 abstract description 54
- 238000003786 synthesis reaction Methods 0.000 abstract description 52
- 150000008163 sugars Chemical class 0.000 abstract description 33
- 108010093096 Immobilized Enzymes Proteins 0.000 abstract description 28
- 235000020256 human milk Nutrition 0.000 abstract description 18
- 210000004251 human milk Anatomy 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 14
- 238000005580 one pot reaction Methods 0.000 abstract description 12
- 230000002255 enzymatic effect Effects 0.000 abstract description 10
- 150000002597 lactoses Chemical class 0.000 abstract description 8
- 238000006206 glycosylation reaction Methods 0.000 abstract description 5
- 230000013595 glycosylation Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 282
- 239000000047 product Substances 0.000 description 221
- 239000000370 acceptor Substances 0.000 description 102
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 95
- 229960001375 lactose Drugs 0.000 description 92
- 239000008101 lactose Substances 0.000 description 92
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 90
- 229930182830 galactose Natural products 0.000 description 90
- 229960001031 glucose Drugs 0.000 description 89
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 85
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 73
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 73
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 73
- 239000002122 magnetic nanoparticle Substances 0.000 description 70
- -1 sialic acid) Chemical compound 0.000 description 62
- 241000282414 Homo sapiens Species 0.000 description 60
- 150000004676 glycans Chemical class 0.000 description 57
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 57
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 57
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 57
- 238000012545 processing Methods 0.000 description 56
- 230000005291 magnetic effect Effects 0.000 description 52
- 239000000463 material Substances 0.000 description 50
- 229930006000 Sucrose Natural products 0.000 description 46
- 239000005720 sucrose Substances 0.000 description 46
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 43
- 102100026189 Beta-galactosidase Human genes 0.000 description 42
- 108010005774 beta-Galactosidase Proteins 0.000 description 42
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 39
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 39
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 37
- 108010059881 Lactase Proteins 0.000 description 36
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 36
- 229940116108 lactase Drugs 0.000 description 36
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 35
- 150000001720 carbohydrates Chemical class 0.000 description 35
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 32
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 31
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 31
- 239000000843 powder Substances 0.000 description 29
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 28
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 27
- 230000033581 fucosylation Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 238000012546 transfer Methods 0.000 description 27
- 108010019236 Fucosyltransferases Proteins 0.000 description 26
- 102000006471 Fucosyltransferases Human genes 0.000 description 26
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 26
- FCIROHDMPFOSFG-LAVSNGQLSA-N disialyllacto-N-tetraose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)C(O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 FCIROHDMPFOSFG-LAVSNGQLSA-N 0.000 description 26
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 26
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 24
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 24
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 24
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 24
- QUOQJNYANJQSDA-MHQSSNGYSA-N Sialyllacto-N-tetraose a Chemical group O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](OC2[C@H]([C@H](OC3[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@@H]1O QUOQJNYANJQSDA-MHQSSNGYSA-N 0.000 description 23
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 23
- 238000000110 selective laser sintering Methods 0.000 description 23
- 102000003838 Sialyltransferases Human genes 0.000 description 22
- 108090000141 Sialyltransferases Proteins 0.000 description 22
- 229950006780 n-acetylglucosamine Drugs 0.000 description 22
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 21
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 description 21
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 21
- 235000014633 carbohydrates Nutrition 0.000 description 20
- 239000002105 nanoparticle Substances 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 description 19
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 19
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 19
- 108090001066 Racemases and epimerases Proteins 0.000 description 19
- 102000004879 Racemases and epimerases Human genes 0.000 description 19
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 19
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 17
- 239000001177 diphosphate Substances 0.000 description 17
- 235000011180 diphosphates Nutrition 0.000 description 17
- TXCIAUNLDRJGJZ-UHFFFAOYSA-N CMP-N-acetyl neuraminic acid Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-UHFFFAOYSA-N 0.000 description 16
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 16
- 102000004195 Isomerases Human genes 0.000 description 16
- 108090000769 Isomerases Proteins 0.000 description 16
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 description 16
- 230000007062 hydrolysis Effects 0.000 description 16
- 238000006460 hydrolysis reaction Methods 0.000 description 16
- 239000011572 manganese Substances 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 102000005348 Neuraminidase Human genes 0.000 description 15
- 108010006232 Neuraminidase Proteins 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 14
- IERHLVCPSMICTF-XVFCMESISA-N CMP group Chemical group P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)C=C1)O)O IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 14
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 14
- 102000004316 Oxidoreductases Human genes 0.000 description 14
- 108090000854 Oxidoreductases Proteins 0.000 description 14
- 150000002772 monosaccharides Chemical class 0.000 description 14
- BJHIKXHVCXFQLS-PQLUHFTBSA-N tagatose group Chemical group OCC(=O)[C@@H](O)[C@@H](O)[C@H](O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 14
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 description 13
- 108010043934 Sucrose synthase Proteins 0.000 description 13
- 239000002131 composite material Substances 0.000 description 13
- 238000011065 in-situ storage Methods 0.000 description 13
- 230000009450 sialylation Effects 0.000 description 13
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 12
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 12
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 12
- 108700040099 Xylose isomerases Proteins 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 10
- 230000002210 biocatalytic effect Effects 0.000 description 10
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 10
- 229910044991 metal oxide Inorganic materials 0.000 description 10
- 150000004706 metal oxides Chemical class 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 229910000859 α-Fe Inorganic materials 0.000 description 10
- 102100029229 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Human genes 0.000 description 9
- 108010015776 Glucose oxidase Proteins 0.000 description 9
- 108700023372 Glycosyltransferases Proteins 0.000 description 9
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 9
- 229940077731 carbohydrate nutrients Drugs 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000005245 sintering Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 229920001169 thermoplastic Polymers 0.000 description 9
- 238000010146 3D printing Methods 0.000 description 8
- 102100021335 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Human genes 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- 108010015133 Galactose oxidase Proteins 0.000 description 8
- 108060003306 Galactosyltransferase Proteins 0.000 description 8
- 102000030902 Galactosyltransferase Human genes 0.000 description 8
- 239000004366 Glucose oxidase Substances 0.000 description 8
- 102000051366 Glycosyltransferases Human genes 0.000 description 8
- 102000004157 Hydrolases Human genes 0.000 description 8
- 108090000604 Hydrolases Proteins 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 8
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 8
- 241000588650 Neisseria meningitidis Species 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- 108010069296 ST6GalNAc V brain-specific GD1alpha synthase Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940116332 glucose oxidase Drugs 0.000 description 8
- 235000019420 glucose oxidase Nutrition 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000000696 magnetic material Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 150000004712 monophosphates Chemical class 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229910052712 strontium Inorganic materials 0.000 description 8
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 8
- 239000004416 thermosoftening plastic Substances 0.000 description 8
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 7
- 102100040842 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Human genes 0.000 description 7
- 101710168202 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 102100021700 Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Human genes 0.000 description 7
- 241000590002 Helicobacter pylori Species 0.000 description 7
- 108010018080 L-arabinose isomerase Proteins 0.000 description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 7
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 description 7
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 7
- 229940037467 helicobacter pylori Drugs 0.000 description 7
- 229940099563 lactobionic acid Drugs 0.000 description 7
- 229910052748 manganese Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101710147124 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Proteins 0.000 description 6
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 6
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 6
- 101710186842 Fucosyltransferase 3 Proteins 0.000 description 6
- 101000896564 Homo sapiens Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 Proteins 0.000 description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 6
- 108010046068 N-Acetyllactosamine Synthase Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 6
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 6
- 239000006247 magnetic powder Substances 0.000 description 6
- 150000002894 organic compounds Chemical group 0.000 description 6
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102100023993 Beta-1,3-galactosyltransferase 5 Human genes 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 101000904597 Homo sapiens Beta-1,3-galactosyltransferase 5 Proteins 0.000 description 5
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 5
- 108010070158 Lactose synthase Proteins 0.000 description 5
- 125000003047 N-acetyl group Chemical group 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 5
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012527 feed solution Substances 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 5
- 108010004902 lactose oxidase Proteins 0.000 description 5
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 4
- MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 4
- 108010083651 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase Proteins 0.000 description 4
- 101710098620 Alpha-1,2-fucosyltransferase Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102100026349 Beta-1,4-galactosyltransferase 1 Human genes 0.000 description 4
- 241000589875 Campylobacter jejuni Species 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 101000766145 Homo sapiens Beta-1,4-galactosyltransferase 1 Proteins 0.000 description 4
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 4
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- SHZGCJCMOBCMKK-PHYPRBDBSA-N alpha-D-fucose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-PHYPRBDBSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005111 flow chemistry technique Methods 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 239000005417 food ingredient Substances 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 4
- 239000000832 lactitol Substances 0.000 description 4
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 4
- 229960003451 lactitol Drugs 0.000 description 4
- 235000010448 lactitol Nutrition 0.000 description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 4
- 229960000511 lactulose Drugs 0.000 description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- 229910000510 noble metal Inorganic materials 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000011164 primary particle Substances 0.000 description 4
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000004043 trisaccharides Chemical group 0.000 description 4
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 3
- 241000219195 Arabidopsis thaliana Species 0.000 description 3
- 239000004412 Bulk moulding compound Substances 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 241000588879 Chromobacterium violaceum Species 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 102100035628 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Human genes 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 108010052085 cellobiose-quinone oxidoreductase Proteins 0.000 description 3
- 238000011960 computer-aided design Methods 0.000 description 3
- 238000005112 continuous flow technique Methods 0.000 description 3
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003869 genetically modified organism Nutrition 0.000 description 3
- 125000002566 glucosaminyl group Chemical group 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 230000005389 magnetism Effects 0.000 description 3
- 239000002069 magnetite nanoparticle Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229920001568 phenolic resin Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920002480 polybenzimidazole Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 125000000185 sucrose group Chemical group 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010092060 Acetate kinase Proteins 0.000 description 2
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 2
- 102100024296 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 2
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 2
- 102100031969 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 Human genes 0.000 description 2
- 102100031971 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 Human genes 0.000 description 2
- 102100029233 Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase Human genes 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 102100039848 Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000223453 Circinatus Species 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical group OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004641 Diallyl-phthalate Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000590006 Helicobacter mustelae Species 0.000 description 2
- 102100036269 Hexosaminidase D Human genes 0.000 description 2
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 2
- 101000874526 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 108010036197 NAD phosphite oxidoreductase Proteins 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920000299 Nylon 12 Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241001440270 Paraconiothyrium sp. Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004693 Polybenzimidazole Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- IZQZNLBFNMTRMF-UHFFFAOYSA-N acetic acid;phosphoric acid Chemical compound CC(O)=O.OP(O)(O)=O IZQZNLBFNMTRMF-UHFFFAOYSA-N 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 108010004400 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 Proteins 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000021310 complex sugar Nutrition 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 150000008267 fucoses Chemical class 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010010662 galactose epimerase Proteins 0.000 description 2
- 108010001671 galactoside 3-fucosyltransferase Proteins 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052595 hematite Inorganic materials 0.000 description 2
- 239000011019 hematite Substances 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000006450 immune cell response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229920000592 inorganic polymer Polymers 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000004377 microelectronic Methods 0.000 description 2
- 239000012229 microporous material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 108020000161 polyphosphate kinase Proteins 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 244000000040 protozoan parasite Species 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 125000005630 sialyl group Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 1
- 101710186714 2-acylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 101710186725 2-acylglycerol O-acyltransferase 2 Proteins 0.000 description 1
- 102100023287 2-acylglycerol O-acyltransferase 3 Human genes 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100035274 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5 Human genes 0.000 description 1
- 102100035277 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Human genes 0.000 description 1
- 108030001800 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferases Proteins 0.000 description 1
- 241000187843 Actinoplanes missouriensis Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100027726 Alpha-(1,3)-fucosyltransferase 11 Human genes 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 description 1
- 102100028725 Alpha-1,3-galactosyltransferase 2 Human genes 0.000 description 1
- 108010002020 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 102100026732 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 102100037995 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B Human genes 0.000 description 1
- 102100037996 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C Human genes 0.000 description 1
- 102100022724 Alpha-1,4-N-acetylglucosaminyltransferase Human genes 0.000 description 1
- 101710193556 Alpha-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 108030001769 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 108030001793 Alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 102100029231 Alpha-2,8-sialyltransferase 8B Human genes 0.000 description 1
- 102100021836 Alpha-2,8-sialyltransferase 8E Human genes 0.000 description 1
- 102100031972 Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-sialyltransferase Human genes 0.000 description 1
- 102100031970 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Human genes 0.000 description 1
- 101710183129 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Proteins 0.000 description 1
- 102100029232 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 Human genes 0.000 description 1
- 108030003364 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferases Proteins 0.000 description 1
- 108010059390 Alpha-N-acetylneuraminate alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 108030003358 Alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3-N-acetylgalactosaminide 6-alpha-sialyltransferases Proteins 0.000 description 1
- 101000972920 Arabidopsis thaliana Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 101000893749 Arabidopsis thaliana Alpha-L-fucosidase 3 Proteins 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241001530056 Athelia rolfsii Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 102100025616 Beta-1,3-N-acetylglucosaminyltransferase manic fringe Human genes 0.000 description 1
- 102100039887 Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 Human genes 0.000 description 1
- 102100032438 Beta-1,3-galactosyltransferase 1 Human genes 0.000 description 1
- 102100032440 Beta-1,3-galactosyltransferase 2 Human genes 0.000 description 1
- 102100032441 Beta-1,3-galactosyltransferase 4 Human genes 0.000 description 1
- 102100026348 Beta-1,4-galactosyltransferase 2 Human genes 0.000 description 1
- 102100026341 Beta-1,4-galactosyltransferase 3 Human genes 0.000 description 1
- 102100026340 Beta-1,4-galactosyltransferase 4 Human genes 0.000 description 1
- 102100027387 Beta-1,4-galactosyltransferase 5 Human genes 0.000 description 1
- 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 1
- 102100027321 Beta-1,4-galactosyltransferase 7 Human genes 0.000 description 1
- 102100024775 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
- 108030001771 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 108030003360 Beta-galactoside alpha-(2,6)-sialyltransferases Proteins 0.000 description 1
- 102100029963 Beta-galactoside alpha-2,6-sialyltransferase 2 Human genes 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 101710136075 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 102100031973 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Human genes 0.000 description 1
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 108010033531 CMP-N-acetylneuraminate-poly-alpha-2,8-sialosyl sialyltransferase Proteins 0.000 description 1
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 1
- 101000918297 Caenorhabditis elegans Exostosin-2 homolog Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 101710128063 Carbohydrate oxidase Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000005469 Chitin Synthase Human genes 0.000 description 1
- 108700040089 Chitin synthases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 101710104730 D-mannose isomerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- OAXMVFUPLMUHGJ-JUZXSSEISA-N Difucosyllacto-N-hexaose a Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1O[C@H]1[C@H](OC2[C@H]([C@H](O[C@H]3[C@H]([C@@H](CO[C@H]4[C@@H]([C@@H](O[C@H]5[C@H]([C@H](O)[C@H](O)[C@H](O)O5)O)[C@H](O[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)[C@@H](CO)O4)NC(C)=O)O[C@@H](OC([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@@H]3C)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O OAXMVFUPLMUHGJ-JUZXSSEISA-N 0.000 description 1
- 108030002243 Digalactosyldiacylglycerol synthases Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 102100029055 Exostosin-1 Human genes 0.000 description 1
- 108090000414 Exostosin-1 Proteins 0.000 description 1
- 108090000429 Exostosin-2 Proteins 0.000 description 1
- 102100035976 Exostosin-like 3 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108030004655 Fucosylgalactoside 3-alpha-galactosyltransferases Proteins 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223195 Fusarium graminearum Species 0.000 description 1
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 1
- 102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 101000733617 Geobacillus stearothermophilus L-arabinose isomerase Proteins 0.000 description 1
- 108030004577 Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferases Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108030002293 Glucuronosyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108030002309 Glycoprotein 3-alpha-L-fucosyltransferases Proteins 0.000 description 1
- 108010027343 Glycoprotein 6-alpha-L-fucosyltransferase Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101001115709 Homo sapiens 2-acylglycerol O-acyltransferase 3 Proteins 0.000 description 1
- 101001022183 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5 Proteins 0.000 description 1
- 101001022175 Homo sapiens 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Proteins 0.000 description 1
- 101000862213 Homo sapiens Alpha-(1,3)-fucosyltransferase 11 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000628808 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 101000951413 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B Proteins 0.000 description 1
- 101000951398 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C Proteins 0.000 description 1
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 1
- 101000616703 Homo sapiens Alpha-2,8-sialyltransferase 8E Proteins 0.000 description 1
- 101000703720 Homo sapiens Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-sialyltransferase Proteins 0.000 description 1
- 101000703728 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 101000703723 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 Proteins 0.000 description 1
- 101000703721 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 Proteins 0.000 description 1
- 101000634076 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 Proteins 0.000 description 1
- 101000634075 Homo sapiens Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 101000887635 Homo sapiens Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 Proteins 0.000 description 1
- 101000887642 Homo sapiens Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 Proteins 0.000 description 1
- 101000798380 Homo sapiens Beta-1,3-galactosyltransferase 1 Proteins 0.000 description 1
- 101000798387 Homo sapiens Beta-1,3-galactosyltransferase 2 Proteins 0.000 description 1
- 101000798401 Homo sapiens Beta-1,3-galactosyltransferase 4 Proteins 0.000 description 1
- 101000766130 Homo sapiens Beta-1,4-galactosyltransferase 2 Proteins 0.000 description 1
- 101000766180 Homo sapiens Beta-1,4-galactosyltransferase 3 Proteins 0.000 description 1
- 101000766179 Homo sapiens Beta-1,4-galactosyltransferase 4 Proteins 0.000 description 1
- 101000937496 Homo sapiens Beta-1,4-galactosyltransferase 5 Proteins 0.000 description 1
- 101000937502 Homo sapiens Beta-1,4-galactosyltransferase 6 Proteins 0.000 description 1
- 101000937508 Homo sapiens Beta-1,4-galactosyltransferase 7 Proteins 0.000 description 1
- 101001052060 Homo sapiens Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 101000863891 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 2 Proteins 0.000 description 1
- 101000836774 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 1
- 101000703758 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Proteins 0.000 description 1
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 101000652814 Homo sapiens Lactosylceramide alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 101000874528 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 3 Proteins 0.000 description 1
- 101000874530 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 Proteins 0.000 description 1
- 101000634097 Homo sapiens Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase Proteins 0.000 description 1
- 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 101000874518 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 Proteins 0.000 description 1
- 101000874523 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 Proteins 0.000 description 1
- 101000798385 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 Proteins 0.000 description 1
- 101000798377 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like protein 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000221931 Hypomyces rosellus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 101710120668 Lactosylceramide 4-alpha-galactosyltransferase Proteins 0.000 description 1
- 108030003357 Lactosylceramide alpha-2,3-sialyltransferases Proteins 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241001459558 Monographella nivalis Species 0.000 description 1
- 241001469032 Myrmecridium flexuosum Species 0.000 description 1
- 108010093077 N-Acetylglucosaminyltransferases Proteins 0.000 description 1
- 102000002493 N-Acetylglucosaminyltransferases Human genes 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 108030001818 N-acetylgalactosaminide beta-1,3-galactosyltransferases Proteins 0.000 description 1
- 108030004735 N-acetyllactosaminide 3-alpha-galactosyltransferases Proteins 0.000 description 1
- 108010015197 N-acetyllactosaminide alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 108010040630 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 102100035629 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 3 Human genes 0.000 description 1
- 102100035668 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 Human genes 0.000 description 1
- 108060005182 N-acylglucosamine 2-epimerase Proteins 0.000 description 1
- 102000002307 N-acylglucosamine 2-epimerase Human genes 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 108030002212 Neolactotriaosylceramide beta-1,4-galactosyltransferases Proteins 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108030002292 O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000894166 Penicillium amagasakiense Species 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 241000222393 Phanerochaete chrysosporium Species 0.000 description 1
- 102000030605 Phosphomannomutase Human genes 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Chemical class 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000800294 Sarocladium oryzae Species 0.000 description 1
- 241000228417 Sarocladium strictum Species 0.000 description 1
- 101001072501 Sarocladium strictum Glucooligosaccharide oxidase Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 102100029227 Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase Human genes 0.000 description 1
- 101710165315 Sialidase A Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910002402 SrFe12O19 Inorganic materials 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- 241001468239 Streptomyces murinus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241001136559 Talaromyces variabilis Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001603561 Thermoanaerobacter mathranii Species 0.000 description 1
- 241001313706 Thermosynechococcus Species 0.000 description 1
- 241001313699 Thermosynechococcus elongatus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108030004601 Type 1 galactoside alpha-(1,2)-fucosyltransferases Proteins 0.000 description 1
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 1
- 102100027960 UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 Human genes 0.000 description 1
- 102100035626 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 Human genes 0.000 description 1
- 102100035627 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 Human genes 0.000 description 1
- 102100032439 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 Human genes 0.000 description 1
- 101150110932 US19 gene Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 108010063641 Xylosylprotein 4-beta-galactosyltransferase Proteins 0.000 description 1
- QJVKUMXDEUEQLH-UHFFFAOYSA-N [B].[Fe].[Nd] Chemical compound [B].[Fe].[Nd] QJVKUMXDEUEQLH-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 108091022872 aldose 1-epimerase Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910000828 alnico Inorganic materials 0.000 description 1
- 108010090354 alpha-1,6-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- LKOHREGGXUJGKC-NTQZDHPLSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-NTQZDHPLSA-N 0.000 description 1
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WMWKTCPGFOEPBD-YGIWDPDDSA-N azane;(2s,3s,4s,5r,6r)-6-[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound N.C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WMWKTCPGFOEPBD-YGIWDPDDSA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 description 1
- DMYPRRDPOMGEAK-XWDFSUOISA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O[C@H]4[C@H]([C@H](O)[C@H](O)[C@H](C)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O DMYPRRDPOMGEAK-XWDFSUOISA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108010044698 beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase Proteins 0.000 description 1
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- KPLQYGBQNPPQGA-UHFFFAOYSA-N cobalt samarium Chemical compound [Co].[Sm] KPLQYGBQNPPQGA-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000009646 cryomilling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007849 furan resin Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 1
- DMYPRRDPOMGEAK-UHFFFAOYSA-N lacto-N-difucohexaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(C(O)C(O)C(CO)O4)O)C(OC4C(C(O)C(O)C(C)O4)O)C(CO)O3)NC(C)=O)C(O)C(CO)O2)O)C(CO)OC(O)C1O DMYPRRDPOMGEAK-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 101150038567 lst gene Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108091000115 phosphomannomutase Proteins 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003192 poly(bis maleimide) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Chemical class 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229930188195 rebaudioside Natural products 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000011029 spinel Substances 0.000 description 1
- 229910052596 spinel Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 229910003145 α-Fe2O3 Inorganic materials 0.000 description 1
- 229910006297 γ-Fe2O3 Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
- C12Y501/03001—Ribulose-phosphate 3-epimerase (5.1.3.1)
Definitions
- the invention provides methods for glycosylation and preparation of compounds.
- the compounds include galactosylated, sialylated, fucosylated, and N-acetyl glucosaminylated compounds from simple animal-derived, plant-derived, or microbe-derived oligosaccharides and sugars.
- the invention provides trinucleotide-free enzymatic production of oligosaccharides starting from simple sugars that include plant-based sugars.
- the production may be a cell-free, one-pot synthesis using enzymes, and in some embodiments, immobilized enzymes.
- the synthesis is a highly customizable and highly efficient cell-free manufacturing process.
- lactose derivatives and human milk oligosaccharides (HMOs) are produced.
- the invention also provides the enzymatic production of fucosylated oligosaccharides and fucosylated antibody-glycan conjugates from common sugars.
- the production is a cell-free, one-pot synthesis using immobilized enzymes.
- the oligosaccharide synthesis is a highly customizable and highly efficient cell-free manufacturing process.
- fucosylated human milk oligosaccharides are produced.
- HMOs Human milk oligosaccharides
- HMOs are structurally diverse, soluble and unconjugated glycans composed of between 3-22 sugars limited to a set of only 5 monosaccharides: D-glucose, D-galactose, N-acetylglucosamine, L-fucose, and N-acetylneuraminic acid (i.e., sialic acid), and are the third largest component of breast milk.
- Simple HMOs (3-4 DP) (DP is degree of polymerization) serve as metabolic substrates for specialized beneficial bacteria, thereby shaping the intestinal microbiome.
- HMOs More complex and branched HMOs (>4 DP), however, serve as soluble decoys for viral, bacterial, or protozoan parasite adhesins, thereby preventing attachment to the infant mucosal surface.
- the fucosylated fraction of human milk was shown to inhibit Campylobacter jejuni colonization ex vivo (human intestinal mucosa) and in rodents (in vivo)— C. jejuni is a leading cause of bacterial diarrhea with and incidence of roughly 1 in 4,000 among infants ⁇ 1 year of age.
- HMOs can deploy similar decoy mechanisms to protect infants from infection by other diarrhea-causing pathogens (e.g., cholera and norovirus) that initiate infection by binding cell-surface receptors. These oligosaccharides may also provide protection from Shiga toxin-induced diarrhea by competing with the toxin for binding to its extracellular target. Moreover, HMOs can also modulate epithelial and immune cell responses and reduce excessive mucosal leukocyte infiltration and activation. These properties have been associated with a lower risk for developing necrotizing enterocolitis.
- pathogens e.g., cholera and norovirus
- milk oligosaccharides form a diverse family of carbohydrates highly conserved in mammals, the profiles are not uniform amongst all species. Typically consisting of a lactose (gal+glu) core, elongated by alternate N-acetylglucosamine and galactose units, and decorated by sialylation and/or fucosylation. HMOs exhibit greater diversity than oligosaccharides found in bovine milk, the basis for most commercial baby formulas. At 0.05 g/L, the compounds are a minor component of cow's milk compared to the concentrations found in human milk which, at 5-23 g/L, puts HMOs on a par with protein content (8 g/L). Roughly 200 HMO structures have been identified, whereas less than half that number have been found in cows.
- HMO Human Milk Oligosaccharides
- CAGR compound annual growth rate
- the recent manufacturing at industrial scale of fucosylated lactose (2′FL) via fermentation with recombinant microorganisms has unlocked the market for HMOs.
- the fucosyllactose (2′FL) segment is currently largest with a CAGR of 14.4%, while the sialyllactose segment has a CAGR of 15.1%.38
- the functional food and beverages sector is also expected to experience considerable growth during this period as HMOs have numerous potential applications besides infant formula.
- HMO synthesis methods driven by usage of HMO in infant formulas.
- Key drivers of growth include growing consumer awareness and concern regarding infant health, rise in demand for infant nutrition food products, projected population growth, as well as increasing awareness of health benefits associated with the consumption of HMOs, such as promotion of beneficial microbiota in the digestive tract and enhanced brain and immune system development.
- scarce raw materials, costly and complex chemical and enzymatic synthesis techniques and lack of technical expertise are expected to continue to present challenges.
- HMOs While some simple probiotic HMOs can now be effectively produced via fermentation for infant formula (2′FL, 3DP), complex and branched HMOs are elusive and have been marginally produced at high cost via chemocatalysis. To make HMOs, sugars need to be first activated to be able to be sequentially transferred to the growing structures.
- activated fucose L-Fucose-1-GDP
- activated sialic acid Sialic acid-1-CMP
- L-fucose and L-sialic acid cost $10 and $5.5/g
- DP5 glycans for example ranges from $300,000 to $3,800,000 per gram.
- Microbe-based production Fermentation is a cost-effective method of HMO production that is currently used to produce 2′-fucosyllactose (2′-FL) at a multi-ton industrial scale (Abbott Laboratories-Jennewein Biotechnologie GmbH, Glycom-Nestle, Inbiose-DuPont). Microbial production, however, is limited to simple unbranched and short-length (DP ⁇ 4) HMOs. More complex HMOs are out of reach because of poor yields for complex carbohydrates via fermentation and the challenges of controlling the glycan sequences in living organisms.
- Enzyme-based production Cell-free production circumvents this limitation by using a glycosyltransferase that transfers a nucleotide activated donor sugar (e.g. GDP-L-fucose, CMP-sialic acid etc.) with high specificity to a large variety of acceptor sugars.
- a nucleotide activated donor sugar e.g. GDP-L-fucose, CMP-sialic acid etc.
- Combining various enzymatic steps can produce large HMO libraries, an approach that has been taken by HMO commercial suppliers (Chemily Glycoscience, Carbosynth, Santa Cruz Biotechnology). With fewer steps and robust enzymes, chemocatalysis can be used to produce defined complex glucans but still suffer from high costs of production.
- Biocatalysis as a green technology, has become increasingly popular in chemical manufacturing over traditional expensive and inefficient processes. Its applications include the production of food ingredients, flavors, fragrances, commodity and fine chemicals, and active pharmaceuticals. When producing chemicals at industrial scale, however, enzymes can suffer drastic losses in activity and loading causing a significant drop in performance.
- Continuous flow processing begins with two or more streams of different reactants pumped at specific flow rates into a single cell. A reaction takes place, and the stream containing the resultant compound is collected at the outlet. The solution may also be directed to subsequent flow reactor loops to generate the final product. Continuous flow processing provides better control and reproducibility of reactions. It is a modular, customizable approach. The high modularity allows one to configure the cells to meet the requirements of specific reactions.
- Glycans are complex carbohydrate structures that are the predominant molecules on the cell surface and serve as the first point of contact between cells, the extracellular matrix and pathogens. Glycans are involved in a number of biological processes such as cell-to cell-interactions. There is great interest in improving the accessibility and affordability of these molecules for research, preclinical and commercial applications.
- HMOs Human milk oligosaccharides
- They are of particular commercial relevance. For instance, they serve as metabolic substrates for specialized beneficial bacteria, thereby shaping the intestinal microbiome. More complex and branched HMOs (>4 DP (i.e., degree of polymerization or the number of monosaccharides linked together), however, appear mostly prophylactic. They serve as soluble decoys for viral, bacterial, or protozoan parasite adhesins and prevent their attachment to the infant, or adults, mucosal surfaces.
- HMOs can also modulate epithelial and immune cell responses and reduce excessive mucosal leukocyte infiltration and activation. These properties have been associated with a lower risk for developing necrotizing enterocolitis and other infections and autoimmune inflammations.
- HMOs While some simple probiotic HMOs can be effectively produced via fermentation for infant formula (2′FL, 3DP), complex and branched HMOs are elusive. Microbial production is limited to simple unbranched and short-length sugars and bacteria can secrete toxins that must be filtered out. Yeast fermentation does not require the removal of toxins, and the overall process involves fewer steps, reducing production costs and resulting in a more easily scaled product. Engineering organisms is intensive and does not guarantee the ability to scale-up.
- the art seeks an economical and efficient way to produce glycans.
- the art seeks an economical and efficient way to produce glycans, including HMOs, including, but not limited to, glycans of two sugar units or larger, and including glycans of 4 sugar units or larger.
- HMOs including, but not limited to, glycans of two or four sugar units or larger.
- This could overcome major hurdles in advancing these glycans, galactosylated glycan, and HMOs for probiotic, prophylactic, and therapeutic purposes.
- the economical and efficient HMO production would be an important advance for global infant nutrition and disease prevention for all ages.
- the invention provides enhanced production efficiency of sugars and complex carbohydrates, while lowering costs, hence improving the accessibility and affordability of these molecules.
- the present invention provides processes for preparing saccharides starting from common sugar building blocks. This lowers the cost of saccharide production.
- the sugars are plant derived.
- the energy source is hydrolysis of more complex sugars into more simple sugars.
- Activated sugars are the starting materials and are generated in situ.
- the activated sugars are monophosphates or diphosphates present in catalytic amounts. Examples include the nucleotide di- and monophosphates UDP, GDP, and CMP. Avoiding stoichiometric or excess nucleotide reactants, including triphosphates such as ATP, avoids the need for co-factor recycling, reduces the number of enzymes required, avoids reaction inhibition, and lowers the overall cost of the reaction over current reactions. Nucleotide di- and monophosphate are used in catalytic amounts. This is a significant improvement over prior art reactions where ATP must be used in stoichiometric amounts or in excess.
- the present invention provides methods with improved purification and yields. There is no need for acidification that leads to improved purification. Additionally, there are no inorganic phosphate biproducts to purify from the reaction mixture. In certain embodiments, sugar biproducts are formed that are useful as building blocks for various uses. Enzymes are not reactivated thus avoiding additional reactants while improving reaction efficiency.
- the invention provides a cell free biomanufacturing method for making human milk oligosaccharides and other animal-based oligosaccharides from cost-effective starting materials. In some embodiments, the reactions are done as a one-pot synthesis.
- Any compound with at least one hydroxy functional group may be glycosylated according to this invention. This includes, but is not limited to, saccharides, glycans, carbohydrates, and alcohols.
- the invention provides a method for producing a glycosylated principal product, comprising the steps of:
- the method further comprises:
- the invention provides a method for producing a glycosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- the sugar donor precursor and the nucleotide provide a sugar-nucleotide donor.
- the sugar donor precursor and the nucleotide provide a sugar-nucleotide donor precursor and an auxiliary enzyme and the sugar-nucleotide donor precursor provide the sugar-nucleotide donor.
- the sugar donor precursor is a sugar comprising 2 or more sugar units. In some embodiments, the sugar donor precursor is a sugar comprising 2, 3, or 4 sugar units. In some embodiments, sugar donor precursor is a disaccharide. In some embodiments, the sugar donor precursor is a trisaccharide. In some embodiments, the sugar donor precursor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine. In some embodiments, the galactose, sialic acid, fucose, or N-acetylglucosamine is in a terminal position in the sugar donor precursor.
- the sugar-nucleotide donor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine.
- the sugar-nucleotide donor is a galactosyl-nucleotide, sialyl-nucleotide, fucosyl-nucleotide, or N-acetylglucosaminyl-nucleotide.
- the secondary product is a monosaccharide, disaccharide, or trisaccharide.
- Some embodiments of this invention further comprise the step of contacting the secondary product and a processing enzyme to convert the secondary product to a secondary product derivative.
- the secondary product derivative in the presence of a second processing enzyme, is converted to a modified secondary product derivative.
- Some embodiments of this invention further comprise the step of contacting the principal product and a processing enzyme to convert the principal product to a principal product derivative.
- the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- the acceptor is an organic compound containing a hydroxyl group. In some embodiments, the organic compound containing a hydroxy group is a sugar. In some embodiments, the acceptor is obtained from the processing enzyme converting the secondary product into the acceptor.
- the nucleotide is a uridine diphosphate, cytidine monophosphate, or guanosine diphosphate. In some embodiments, the nucleotide is in an amount of 0.001 mol percent to 10 mol percent relative to the sugar donor precursor or the acceptor. In some embodiments, the nucleotide is in an amount of 0.01 mol percent to 1 mol percent relative to the sugar donor precursor or the acceptor.
- the transferase is any enzyme that transfers a sugar unit to the acceptor.
- the transferase is a ⁇ -1,3-galactosyl transferase, sucrase synthase, ⁇ -1,4-galactosyl transferase, sialyl transferase, fucosyl transferase, or glucosaminyl (N-acetyl) transferase 2.
- the transferase comprises a first transferase (GT1 in FIG. 6 , 7 , 13 , or 14 ) and a second transferase (GT2 in FIG. 6 , 7 , 13 , or 14 ).
- the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the glycosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- this invention provides a method for producing a galactosylated principal product, comprising the steps of:
- the method further comprises:
- the invention provides a method for producing a galactosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- the acceptor is lacto-N-triose II (LNTII), glucose, or galactooligosaccharide (GOS) and the secondary product is fructose.
- LNTII lacto-N-triose II
- GOS galactooligosaccharide
- the secondary product is fructose.
- Some embodiments comprised the step of obtaining the glucose by contacting the fructose in the presence of a glucose isomerase to obtain the glucose.
- Some embodiments comprise the step of obtaining the LNTII by contacting lactose and N-acetylglucosamine in the presence of ⁇ -N-acetylhexosaminidase (Bbh1) to obtain the LNTII.
- the sugar donor precursor is sucrose.
- the sugar donor precursor and the nucleotide provides a sugar-nucleotide donor precursor and wherein an auxiliary enzyme and the sugar-nucleotide donor precursor provides the sugar-nucleotide donor.
- the sugar-nucleotide donor precursor is a glucose nucleotide.
- the secondary product is fructose.
- the auxiliary enzyme is a galactose epimerase.
- the nucleotide is uridine diphosphate.
- the transferase is any enzyme that transfers a galactose unit to the acceptor.
- the transferase comprises a first transferase (GT1 in FIG. 6 , 7 , 13 , or 14 ) and a second transferase (GT2 in FIG. 6 , 7 , 13 , or 14 ).
- the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the galactosylated principal product
- the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- the first transferase is ⁇ -1,3-galactosyl transferase from Chromobacterium violaceum (Cvb3GalT), ⁇ -1,4-Galactosyltransferase from Neisseria meningitidis (NmLgtB), and the second transferase is sucrose synthase from Arabidopsis thaliana (AtSuSy1).
- Cvb3GalT Chromobacterium violaceum
- NmLgtB Neisseria meningitidis
- AdSuSy1 sucrose synthase from Arabidopsis thaliana
- the galactosylated principal product is lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), lactose, or galactooligosaccharide (GOS).
- the methods comprise the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative.
- the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- the processing enzyme is an oxidase and galactosylated principal product derivative is oxidized fructose or oxidized glucose.
- the invention provides a method for producing a sialylated principal product, comprising the steps of:
- the method of further comprises:
- the invention provides a method for producing a sialylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a sialylated principal product and a secondary product.
- the sugar donor precursor is 3′-sialyllactose.
- the sugar-nucleotide donor is a N-acetyl neuraminic acid-nucleotide.
- the secondary product is lactose.
- the sialylated principal product is Sialyllacto-N-tetraose a (LSTa), Sialyliacto-N-tetraose b (LSTb), Siaiyliacto-N-neoteiraose c (LSTc), Sialyilacio-N-neotetraose d (LSTd), or Disialyllacto-N-tetraose (DSLNT).
- the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- the secondary product in the presence of a processing enzyme, is converted to a secondary product derivative.
- the processing enzyme is lactase.
- the secondary product derivative is glucose and galactose.
- the processing enzyme is an enzyme that oxidizes the lactose to lactobionic acid.
- the processing enzyme is a lactose oxidase.
- the glucose in the presence of a second processing enzyme, is converted to a modified secondary product derivative.
- the second processing enzyme is D-galactose isomerase and the modified secondary product derivative is tagatose.
- the galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI).
- GsAI Geobacillus stearothermophilus
- the glucose oxidase and the modified secondary product derivative is gluconolactone.
- the processing enzyme is an oxidase, isomerase, or hydrolase and the principal product derivative is an oxidized principal product, isomerized principal product, or a hydrolyzed principal product.
- the hydrolase is ⁇ 2-3 Neuraminidase S.
- the ⁇ 2-3 Neuraminidase S and the principal product DSLNT is converted to LSTb by the neuraminidase.
- the principal product derivative is oxidized, isomerized or hydrolyzed LSTa, LSTb, LSTc, LSTd, or DSLNT.
- the nucleotide is cytidine monophosphate.
- the transferase is any enzyme that transfers a sialyl unit to the acceptor.
- the transferase comprises a first transferase (GT1 in FIG. 6 , 7 , 13 , or 14 ) and a second transferase (GT2 in FIG. 6 , 7 , 13 , or 14 .
- the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the sialylated principal product
- the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- the first transferase is beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase 3 (ST3GAL3) or Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) and second transferase is CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (ST3GAL4).
- the invention provides a method for producing a fucosylated principal product, comprising the steps of:
- the method further comprises:
- the invention provides a method for producing a fucosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a fucosylated principal product and a secondary product.
- the sugar donor precursor is a 2′-fucosyllactose.
- the sugar-nucleotide donor is a fucose nucleotide.
- the secondary product is lactose.
- the principal product is Lacto-N-fucopentaose I (LNFPI), Lacto-N-fucopentaose II (LNFPII), Lacto-N-fucopentaose III (LNFPIII), Difucosyllactose (DFL), or 3-fucosyllactose (3-FL).
- LNFPI Lacto-N-fucopentaose I
- LNFPII Lacto-N-fucopentaose II
- LNFPIII Lacto-N-fucopentaose III
- DFL Difucosyllactose
- 3-fucosyllactose 3-fucosyllactose
- the method further comprises the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative.
- the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- the secondary product in the presence of a processing enzyme, is converted to a secondary product derivative.
- the processing enzyme is an enzyme that oxidizes the lactose to lactobionic acid.
- the processing enzyme is lactose oxidase.
- the processing enzyme is lactase.
- the secondary product derivative is glucose and galactose.
- the secondary product derivative in the presence of a second processing enzyme, is converted to a modified secondary product derivative.
- the second processing enzyme is a D-galactose isomerase the modified secondary product derivative is tagatose.
- the D-galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI).
- the second processing enzyme is glucose oxidase and the modified secondary product derivative is gluconolactone.
- the principal product in the presence of a processing enzyme, is converted to a principal product derivative.
- the processing enzyme is an oxidase, isomerase, or hydrolase and the principal product derivative is an oxidized principal product, isomerized principal product, or a hydrolyzed principal product.
- the principal product derivative is oxidized, isomerized or hydrolyzed LNFPI, LNFPII, LNFPIII, DFL, or 3-FL.
- the methods comprise the further step of oxidizing the fucosylated principal product in the presence of an oxidase to provide a principal product derivative.
- the principal product derivative is oxidized LNFPI, LNFPII, LNFPIII, DFL, or 3-FL.
- the nucleotide is guanosine diphosphate.
- the transferase is any enzyme that transfers a fucose unit to the acceptor. In certain embodiments, the transferase is any enzyme that converts the sugar donor precursor into a sugar nucleotide donor and a secondary product. In some embodiments, the transferase comprises a first transferase (GT1 in FIG. 6 , 7 , 13 , or 14 ) and a second transferase (GT2 in FIG. 6 , 7 , 13 , or 14 ).
- GT1 first transferase
- GT2 second transferase
- the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the fucosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- the first transferase is ⁇ -1,2-fucosyltransferase from Thermosynechococcus vestitus (Te2FT), al-3/4-fucosyltransferase from Helicobacter pylori (Hp34FT), fucosyl transferase 9 (FUT9), or fucosyl transferase 3 (FUT3) and the second transferase is ⁇ -1,2-fucosyltransferase from Helicobacter mustelae (HmFucT) or fucosyl transferase (FUT1).
- Te2FT Thermosynechococcus vestitus
- Hp34FT al-3/4-fucosyltransferase from Helicobacter pylori
- FUT9 fucosyl transferase 9
- FUT3 fucosyl transferase 3
- the second transferase is ⁇ -1,2-fucosyltransferase from Helicobacter mustelae (HmFuc
- this invention provides a method for producing a N-acetylglucosaminylated principal product, comprising the steps of:
- the method further comprises:
- the invention provides a method for producing a N-acetylglucosaminylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a N-acetylglucosaminylated principal product and a secondary product.
- the sugar donor precursor is lacto-N-biose.
- the sugar-nucleotide donor is a N-acetylglucosamine nucleotide.
- the secondary product is galactose.
- the principal product is LNTII or ⁇ -1,6-GlcNAc-LNnT.
- the methods further comprise the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative.
- the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- the secondary product in the presence of a processing enzyme, is converted to a secondary product derivative.
- the processing enzyme is a D-galactose isomerase the secondary product derivative is tagatose.
- the D-galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI).
- the methods comprise the further step of oxidizing the N-acetylglucosaminylated principal product in the presence of an oxidase to provide a principal product derivative.
- the principal product derivative is oxidized the principal product is LNTII or ⁇ -1,6-GlcNAc-LNnT.
- the nucleotide is uridine diphophate.
- the transferase is any enzyme that transfers a N-acetylglucosamine unit to the acceptor.
- the transferase is ⁇ -1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- the transferase comprises a first transferase (GT1 in FIG. 6 , 7 , 13 , or 14 ) and a second transferase (GT2 in FIG. 6 , 7 , 13 , or 14 .
- the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the N-acetylglucosaminylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- the first transferase is glucosaminyl (N-acetyl) transferase 2 (GCNT2) and second transferase is ⁇ -1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- the further step of oxidizing the N-acetylglucosaminylated principal product in the presence of an oxidase to provide a principal product derivative.
- the principal product derivative is oxidized LNTII or oxidized ⁇ -1,6-GlcNAc-LNnT.
- the sugar is in a naturally occurring isomeric form.
- glucose is D-glucose.
- D-galactose is D-galactose.
- fucose is L-fucose.
- the invention provides a machine configured for the method of any embodiment.
- a method is within a single reaction vessel.
- a machine optimized for the processes of this invention is also provided by this invention.
- the machine is adapted so that the process is carried out within a single reaction vessel.
- one or more the enzymes are immobilized. In other embodiments, each enzyme is immobilized. In other embodiments of the invention, the process occurs in a single reaction vessel.
- LNT is prepared by a process of this invention.
- LNnT is prepared by a process of this invention.
- Lactose is prepared by a process of this invention.
- a galactooligosaccharide is by a process of this invention.
- LSTa is prepared by a process of this invention.
- LSTb is prepared by a process of this invention.
- LSTc is prepared by a process of this invention.
- LSTd is prepared by a process of this invention.
- DSLNT is prepared by a process of this invention.
- LNFPI is prepared by a process of this invention.
- LNFPII is prepared by a process of this invention.
- LNFPIII is prepared by a process of this invention.
- DFL is prepared by a process of this invention.
- 3-FL is prepared by a process of this invention.
- LNTII is prepared by a process of this invention.
- a branched HMO is prepared by a process of this invention.
- Any of the embodiments of this invention may be employed to obtain a compound from non-animal based plant materials.
- glycosylation reactions employing catalytic nucleotides are done in combination to provide a glycosylated principal product with two (2) or more sugar units that have been transferred to an acceptor via two (2) or more sugar-nucleotide donors of this invention.
- the present invention provides an integrated pathway using immobilized enzymes to perform syntheses of fucosolyated saccharides starting from common sugars, including one-pot syntheses of fucosylated saccharides. Included is a cell free biomanufacturing method of making fucosylated human milk oligosaccharides and other fucosylated oligosaccharides from fructose, glucose or a mixture of fructose and glucose. Starting from common sugars lowers the cost of production of fucosylated HMOs vs using fucose as a starting material.
- FIG. 15 - 18 depict integrated fucosylation pathways of this invention.
- the invention provides direct production of fucosylated HMOs starting from cost effective glucose or fructose instead of fucose. Regeneration of cofactors across the enzyme reactions drives efficiency and cost reduction.
- the production method allows the flexibility of production of all fucosylated HMOS (or oligosaccharides) by changing the last transferase enzyme and the acceptor backbone (biorefinery concept). The process does not require genetically modified organisms (non-GMO).
- the invention provides a process for producing a fucosylated oligosaccharide or a fucosylated antibody-glycan conjugate, comprising the steps of:
- the process comprises immobilized regeneration enzymes formate dehydrogenase, pyruvate oxidase, acetate kinase, catalase, and inorganic pyrophosphatase.
- the immobilized regeneration enzymes are phosphite dehydrogenase, pyruvate oxidase, acetate kinase, catalase, and inorganic pyrophosphatase.
- the immobilized regeneration enzymes are formate dehydrogenase, polyphosphate kinase, and inorganic pyrophosphatase.
- the immobilized regeneration enzymes are phosphite dehydrogenase, polyphosphate kinase, and inorganic pyrophosphatase.
- the enzyme that converts the glucose to mannose is an immobilized D-mannose isomerase.
- the enzyme that converts the fructose to mannose is an immobilized N-acetyl-d-glucosamine-2-epimerase.
- the enzyme that converts mannose to mannose-6-phosphate is an immobilized hexokinase.
- the enzyme that converts mannose-6-phosphate to mannose-1-phosphate is an immobilized phosphomannomutase.
- the enzyme that converts mannose-1-phophate to GDP-D-mannose is an immobilized GDP-mannose pyrophosphorylase.
- the enzyme that converts GDP-D-Man to GDP-4-keto-6-deoxymannose is an immobilized GDP-mannose-4,6-dehydratase.
- the enzyme that converts GDP-4-keto-6-deoxymannose to GDP-L-fucose is an immobilized GDP-fucose synthase.
- the enzyme that fucosylates the disaccharide, oligosaccharide, or antibody-glycan conjugate is an immobilized fucosyl transferase.
- the GDP-mannose is polymerized to mannans via transferase enzymes.
- the oligosaccharide is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-LNnH 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-(3′′ 3 ,3′′ 6 -di-O- ⁇ -Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, ⁇ -2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary si
- the glycans are 3′SL LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, 2′-FL, LNnH, DSLNnH, or DSDFLNNH. In other embodiments, the glycans are 3′SL, LNTII, 2′-FL, LNFPI, LSTa.
- the oligosaccharide is lactose, LNT, LNnT, LNnH, or LNH. In certain embodiments, the fucosylated oligosaccharide is 2′FL or 3-FL.
- the d fucosylated oligosaccharide is a fucosylated HMO. In certain embodiments, the fucosylated oligosaccharide is fucosylated LDFT, fucosylated LNFP I, fucosylated LNFP II, fucosylated LNFP V, fucosylated LNDFH I, fucosylated LNDFH II, fucosylated DFLNH a, or fucosylated DFLNHc.
- the process occurs in a single reaction vessel.
- the invention provides a machine, comprising the immobilized enzymes of any one of the invention's embodiments wherein the machine produces a fucosylated disaccharide, fucosylated oligosaccharide, or fucosylated antibody-glycan conjugate.
- immobilized enzymes are contained within a single reaction vessel.
- the pathway uses immobilized enzymes, such as enzymes that are immobilized within bionanocatalysts (BNCs) that in turn are embedded within scaffolds.
- Bionanocatalysts (BNCs) according to this invention comprise an enzyme self-assembled with magnetic nanoparticles (MNPs). The BNCs self-assemble with the scaffolds.
- each enzyme is immobilized within the BNC.
- HMOs fucosylated human milk oligosaccharides
- the one-pot integrated fucosylation synthesis may be done in batch or flow. It should be understood that modifying Examples 11-15 to be in-flow is within the scope of this invention.
- a flow reactor such as a packed bed reactor, the mixture of reagents is flowed through the flow reactor.
- the scaffolded BNCs are inside of modular flow cells for flow manufacturing.
- the invention provides continuous flow processing where each step of synthesis is conducted in modules. In production mode, these modules contain full systems of enzymes—sugar activation and sugar transfer—for specifically building glycans.
- the glycans are oligosaccharides.
- the scaffolds comprise magnetic metal oxides.
- the scaffolds are high magnetism and high porosity composite blends of thermoplastics comprising magnetic particles that form powders. They may be single-layered or multiple-layered materials that hold the BNCs. Such designed objects may be produced using 3D printing by sintering composite magnetic powders.
- Selective Laser Sintering SLS is used.
- the modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process.
- human milk oligosaccharides (HMOs) are produced.
- the immobilized enzymes are non-magnetic. In certain the immobilized enzymes do not comprise nanoparticles.
- the invention provides cell-free productions of defined glycans with combinatorial bionanocatalysts (BNCs) organized in sequential modules.
- FIG. 1 A depicts a summary of galactosylation using sucrose to obtain LNT, LNnT, or lactose and a legend relevant to all figures herein (“2: Lac Synthase” should be “1d) Lac Synthase”).
- FIG. 1 B depicts LNT obtained from LNTII.
- FIG. 1 C depicts LNnT obtained from LNTII.
- FIG. 1 D depicts LNT obtained from lactose.
- FIG. 1 E depicts lactose obtained from glucose.
- FIG. 1 F depicts GOS obtained from galactose and sucrose.
- FIGS. 2 A- 2 D depict sialylations with sialoside and lactose hydrolysis.
- FIG. 2 A depicts the route for obtaining LSTa from LNT.
- FIG. 2 B depicts the route for obtaining LSTc from LNnT.
- FIG. 2 C depicts the route for obtaining LSTd from LNnT.
- FIG. 2 D depicts the route for obtaining DSLNT from LNT.
- FIGS. 3 A- 3 C depict fucosylation using fucoside and lactose hydrolysis.
- FIG. 3 A depicts the route for obtaining LNFPI from LNT.
- FIG. 3 B depicts the route for obtaining LNFPII from LNT.
- FIG. 3 C depicts the route for obtaining LNFPII from LNnT.
- FIG. 4 depicts the addition of N-Acetylglucosamine to prepare LNTII from lactose and chitin.
- FIG. 5 depicts lactose and its functional derivatives.
- FIG. 6 depicts a general embodiment of this invention and an overview of the methods employed in this invention.
- FIG. 7 depicts a general embodiment and methods of this invention employing an auxiliary enzyme.
- FIG. 8 depicts a legend depicting the symbols used in FIGS. 9 - 12 .
- FIG. 9 A depicts a summary of galactosylation using sucrose to obtain LNT, LNnT, or lactose.
- FIG. 9 B depicts a route to LNT obtained from LNTII.
- FIG. 9 C depicts a route to LNnT obtained from LNTII.
- FIG. 9 D depicts a route to LNT obtained from lactose.
- FIG. 9 E depicts a route to lactose obtained from glucose.
- FIG. 9 F and FIG. 9 G depict routes to obtain lactose from glucose.
- FIG. 9 H depicts a route to Galactooligosaccharides obtained from galactose and sucrose.
- FIGS. 10 A- 10 D depict sialylations with sialoside and lactose hydrolysis.
- FIG. 10 A depicts the route for obtaining LSTa from LNT.
- FIG. 10 B depicts the route for obtaining LSTc from LNnT.
- FIG. 10 C depicts the route for obtaining LSTd from LNnT.
- FIG. 10 D depicts the route for obtaining DSLNT from LNT.
- FIGS. 11 A- 11 C depict fucosylation using fucoside and lactose hydrolysis.
- FIG. 11 A depicts the route for obtaining LNFPI from LNT.
- FIG. 11 B depicts the route for obtaining LNFPII from LNT.
- FIG. 11 C depicts a route for obtaining LNFPII from LNnT.
- FIG. 11 D depicts the route for obtaining DFL from 2′-FL.
- FIG. 11 E depicts a route for obtaining 3-FL from 2′-FL.
- FIG. 12 A depicts N-acetylglucosaminylation using lacto-N-biose as a GlcNAc donor.
- FIG. 12 B depicts a branched HMO from Lacto-N-biose (LNB) and LNnT.
- FIG. 13 depicts a general embodiment of this invention and an overview of the methods employed in this invention that provide a processing enzyme to convert a principal product to a principal product derivative.
- FIG. 14 depicts a general embodiment and methods of this invention employing an auxiliary enzyme and a Processing Enzyme to convert a Principal Product to a Principal Product Derivative.
- FIGS. 15 - 18 relate to the integrated fucosylation pathway provided by this invention.
- FIG. 15 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (Pyruvate-AcK/PyrOx+FDH regeneration). See Example 12.
- FIG. 16 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (Pyruvate-AcK/PyrOx+PtxD regeneration). See Example 13.
- FIG. 17 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (PolyP-PPK+FDH regeneration). See Example 14.
- FIG. 18 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (PolyP-PPK+PtxD regeneration). See Example 15.
- the present invention provides integrated streamlined pathways using enzymes and activated sugars to obtain sugar compounds, oligosaccharides, and their derivatives.
- the oligosaccharides are complex oligosaccharides, including glycans 4 sugar units or larger, and including glycans.
- the invention provides cell-free de-novo synthesis of glycans employing in situ generated activated sugar donors and catalytic amounts of nucleotides. Integrated pathways of enzymes lead to glycosylated (sugar-containing compounds) including, but not limited to, saccharides, oligosaccharides, or antibody-glycan conjugates starting from sugars, including, but not limited to, plant sugars.
- glycosylated sucrose-containing compounds
- saccharides oligosaccharides
- antibody-glycan conjugates starting from sugars, including, but not limited to, plant sugars.
- the benefits of the systems of reactants and enzymes of this aspect of the invention comprise, consist essentially of, or consist of:
- FIG. 6 depicts a general embodiment of this invention and an overview of the methods employed in this invention.
- an “acceptor” is the moiety that accepts transfer of a sugar unit from a sugar-nucleotide donor.
- a transferase designated here as GT1
- the sugar-nucleotide donor is a compound comprising a sugar unit and a nucleotide obtained from a reaction of a sugar donor precursor and a nucleotide in the presence of a transferase, here designated at GT2.
- GT2 is acting in the reverse direction relative to GT1.
- GT1 transfers a sugar unit to an acceptor form a sugar-acceptor compound.
- GT2 acts to remove a sugar unit.
- the nucleotide is present in less than stoichiometric amounts and therefore the sugar-nucleotide donor is regenerated and used in another reaction cycle.
- the reaction of a sugar donor precursor and a nucleotide in the presence of a transferase produces a secondary product in addition to the sugar-nucleotide donor.
- the breakdown of the sugar donor precursor into smaller sugar units is an energy source for the methods of this invention.
- the secondary product may be transformed into a secondary product derivative in the presence of a processing enzyme.
- this invention provides a method for obtaining a glycosylated compound (herein, “glycosylated principal product” by combining in a reaction vessel the following: a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide.
- the method involves iterative reaction cycles to produce a glycosylated principal product and a secondary product.
- the nucleotide reacts with the sugar donor precursor in the presence of a transferase to form a sugar-nucleotide donor.
- the sugar of the sugar-nucleotide donor is transferred to an acceptor to provide the glycosylated compound, a secondary product, and a regenerated nucleotide.
- the sugar-nucleotide donor will be formed in about catalytic quantities. The reaction then cycles through additional iterations of the reaction.
- FIG. 7 depicts a general embodiment and methods of this invention employing a sugar-nucleotide donor precursor.
- the product of the reaction between a nucleotide and a sugar donor precursor in the presence of a transferase provides a sugar-nucleotide donor precursor that undergoes a further reaction in the presence of an auxiliary enzyme to obtain the sugar-nucleotide donor employed in the methods of this invention.
- FIG. 13 and FIG. 14 depict general embodiments of this invention that employ a processing enzyme to convert a principal product to a principal product derivative.
- LSTb is obtained from LNT by employing this method.
- DSLNT is the Principal Product that is converted to LSTb by the neuraminidase.
- FIGS. 1 A- 1 F depict a summary of galactosylation reactions using sucrose and a legend.
- LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see ( FIG. 1 B- 1 D ).
- FIG. 1 B depicts a route for adding galactose to LNTII to obtain LNT.
- UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP.
- the UDP-galactose is obtained from UDP-glucose in the presence of GalE.
- Galactose from UDP-galactose is transferred to the LNTII in the presence of a transferase that forms a ⁇ 3 type linkage (as depicted, Cvb3GalT or B3GALT5). See Example 2a A.
- FIG. 1 C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as in FIG. 1 B . In this scheme however a transferase that forms a ⁇ 4 type linkage (as depicted NmLgtB or B4LAGT1) is present. Galactose is transferred to LNTII to provide LNnT. See Example 2a B.
- FIG. 1 D depicts a route for obtaining LNT from lactose.
- N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water.
- N-acetylglucosamine is transferred to lactose via a ⁇ 3 linkage to provide LNTII.
- FIGS. 1 A- 1 F depict a summary of galactosylation reactions using sucrose and a legend.
- LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see ( FIG. 1 B- 1 D ).
- FIG. 1 B depicts a route for adding galactose to LNTII to obtain LNT.
- UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP.
- the UDP-galactose is obtained from UDP-glucose in the presence of GalE.
- Galactose from UDP-galactose is transferred to the LNTII in the presence of a transferase that forms a ⁇ 3 type linkage (as depicted, Cvb3GalT or B3GALT5). See Example 2a A.
- FIG. 1 C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as in FIG. 1 B . In this scheme however a transferase that forms a ⁇ 4 type linkage (as depicted NmLgtB or B4LAGT1) is present. Galactose is transferred to LNTII to provide LNnT. See Example 2a B.
- FIG. 1 D depicts a route for obtaining LNT from lactose.
- N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water.
- N-acetylglucosamine is transferred to lactose via a (33 linkage to provide LNTII.
- UDP-galactose and fructose are obtained as described in FIG. Ba.
- a transferase as depicted Cvb3GalT
- galactose is transferred to the acceptor LNTII to provide LNT.
- FIG. 1 E depicts lactose obtained from glucose.
- UDP-galactose is obtained as described in FIG. 1 B .
- Galactose is transferred to glucose in the presence of lactose synthase to obtain lactose. See Example 2a D.
- FIG. 1 F depicts GOS obtained from galactose and sucrose.
- UDP-galactose and fructose are obtained as described in FIG. 1 B .
- the galactose is transferred to a galactooligosaccharide (wherein n is 3-15) to increase the galactose chain by 1.
- UDP-galactose is obtained as described in FIG. 1 B . See Example 2a E.
- FIGS. 2 A- 2 D depict sialylations with sialoside and lactose hydrolysis.
- CMP-N-acetyl neuraminic acid (Neu5Ac) is the nucleotide-sugar employed in each of FIGS. 2 A- 2 C .
- lactose is converted to galactose and glucose in the presence of lactase.
- CMP-Neu5Ac is obtained in the presence of 3′-SL and the transferase ST3GAL4.
- FIG. 2 A depicts a route for obtaining LSTa is from LNT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain LSTc.
- FIG. 2 B depicts a route for obtaining LSTc from LNnT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTc.
- FIG. 2 C depicts a route LSTd is obtained from LNnT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTd.
- D DSLNT is obtained from LNT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain DSLNT.
- FIGS. 3 A- 3 C depicts fucosylation using fucoside and lactose hydrolysis.
- GDP-1-fucose is the nucleotide-sugar used in each of FIG. 3 a - 3 c. 2′-FL in the presence of a transferase (HmFucT), lactose, lactase, and GDP provides GDP-1-fucose (GDP-Fuc), galactose, and glucose.
- FIG. 3 A depicts a route for obtaining LNFPI from LNT. GDP-Fuc in the presence of LNT and Te2FT provides LNFPI.
- FIG. 3 B depicts a route for obtaining LNFPII from LNT. GDP-Fuc in the presence of LNT and a transferase (Hp34FT) provides LNFPII.
- Hp34FT transferase
- FIG. 3 C depicts a route for obtaining LNFPIII from LNnT. GDP-Fuc in the presence of LNnT and a transferase (FUT9) provides LNFPIII.
- FIG. 4 depicts a route for adding N-acetylglucosamine to prepare LNTII from lactose and chitin.
- UDP-N-Acetylglucosamine (UDP-GlcNAc) is prepared from UDP, lactose, chitin in the presence chitin synthase and the presence of a transferase. (B3GNT2 or NmLgtA) and the GlcNAc is transferred to lactose to obtain LNTII.
- a transferase as depicted Cvb3GalT
- galactose is transferred to the acceptor LNTII to provide LNT.
- FIG. 5 depicts lactose and its functional derivatives.
- FIG. 8 depicts a legend for FIGS. 9 - 12 .
- N-acetylglucosamine (GlcNAc) is depicted by a solid black square.
- L-fucose (fuc) is depicted by a solid white triangle.
- Lactose is depicted by a solid white circle linked by a line to a hatched circle, with a 4 indicating bonding.
- D-galactose (Gal) is depicted by a solid circle.
- N-acetyl neuraminic acid (Neu5Ac) is depicted as a solid white diamond.
- D-glucose is depicted by a hatched circle.
- FIGS. 9 A- 9 H depict a summary of galactosylation reactions using sucrose.
- LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see ( FIG. 9 B- 9 D ).
- FIG. 9 B depicts a route for adding galactose to LNTII to obtain LNT.
- UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP.
- the UDP-galactose is obtained from UDP-glucose in the presence of GalE.
- FIG. 9 C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as in FIG. 9 B . In this scheme however a transferase that forms a ⁇ 4 type linkage (as depicted NmLgtB) is present. Galactose is transferred to LNTII to provide LNnT. See Example 6B.
- FIG. 9 D depicts a route for obtaining LNT from lactose.
- N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water.
- N-acetylglucosamine is transferred to lactose via a (33 linkage in the presence of an aminidase (here Bbh1) to provide LNTII.
- UDP-galactose and fructose are obtained as described in FIG. 9 B .
- a transferase as depicted Cvb3GalT
- galactose is transferred to the acceptor LNTII to provide LNT.
- FIG. 9 E depicts lactose obtained from glucose.
- UDP-galactose is obtained as described in FIG. 9 B .
- Galactose is transferred to glucose in the presence of lactose synthase to obtain lactose. See Example 6C.
- FIG. 9 F depicts lactose obtained from glucose, sucrose, and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase). See Example 7.
- FIG. 9 G depicts lactose obtained from glucose, sucrose, fructose and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase). See Example 8.
- FIG. 9 H depicts GOS obtained from galactose and sucrose.
- UDP-galactose and fructose are obtained as described in FIG. 9 B .
- the galactose is transferred to a galactooligosaccharide (wherein n is 3-15) to increase the galactose chain by 1.
- the transferase is a galactosyltransferase that catalyzes the transfer of activated UDP-Galactose (UDP-Gal) to Glucose, Galactose or GlcNAc.
- UDP-Gal activated UDP-Galactose
- the galactosyltransferase is a ⁇ -1,3-galactosyltransferase (EC 2.4.1.122).
- the ⁇ -1,3-galactosyltransferase is Cv ⁇ 3GalT from Chromobacterium violaceum , WbgO from Escherichia coli , CgtB from Campylobacter jejuni , B3GALT1 from Homo sapiens , B3GALT2 from Homo sapiens , B3GALT4 from Homo sapiens , or B3GALT5 from Homo sapiens.
- the galactosyltransferase is ⁇ -1,4-galactosyltransferase (EC 2.4.1.22, EC 2.4.1.38, EC 2.4.1.133, EC 2.4.1.275).
- the ⁇ -1,4-galactosyltransferase is NmLgtB from Neisseria meningitidis , NmLgtB-StGalE from Neisseria meningitidis and Streptococcus thermophilus , HpLgtB from Helicobacter pylori , B4GALT1 from Homo sapiens , B4GALT2 from Homo sapiens , B4GALT3 from Homo sapiens , B4GALT4 from Homo sapiens , B4GALT5 from Homo sapiens , B4GALT6 from Homo sapiens , B4GALT7 from Homo sapiens.
- the galactosyltransferase is a ⁇ -1,6-galactosyltransferase.
- the ⁇ -1,6-galactosyltransferase is GalT29A from Arabidopsis thaliana.
- the galactosyltransferase is a ⁇ -1,3-galactosyltransferase (EC 2.4.1.87, EC 2.4.1.37).
- the ⁇ -1,3-galactosyltransferase is GTB (human proteins) synthetic gene expressed in E. coli or WbnL from E. coli.
- the galactosyltransferase is a ⁇ -1,6-galactosyltransferase (EC 2.4.1.241).
- the galactosyltransferase is selected from the galactosyltransferases depicted in the Figures.
- an auxiliary enzyme is employed in a route from a sugar donor precursor to a sugar-nucleotide donor.
- a sugar donor precursor is converted to a sugar-nucleotide donor precursor in the presence of a transferase.
- the sugar-nucleotide donor precursor is then converted a sugar-nucleotide donor in the presence of the auxiliary enzyme.
- the auxiliary enzyme is a UDP-glucose 4-epimerase. In the galactosylation routes depicted in FIG. 9 A-H , the auxiliary enzyme is a UDP-glucose 4-epimerase from Bifidobacterium longum.
- an auxiliary enzyme is an oxidase (UDP-Glc-6-dehydrogenase, EC 1.1.1.22) that catalyzes the conversion of UDP-Glc to UDP-GlcA (UDP-Glucuronic acid).
- an auxiliary enzyme is an enzyme that isomerize activated sugar nucleotides.
- the enzyme that isomerizes activated sugar nucleotides is an epimerase (UDP-Gal-4-epimerase, EC 5.1.3.2) that catalyzes the conversion of UDP-Glc to UDP-Gal.
- the epimerase is EcGalE from Escherichia coli .
- the epimerase is StGalE from Streptococcus thermophilus.
- FIGS. 10 A- 10 D depict sialylations with low cost sialoside and lactose hydrolysis.
- CMP-N-acetyl neuraminic acid (Neu5Ac) is the nucleotide-sugar employed in each of FIGS. 10 A- 10 D .
- lactose is converted to galactose and glucose in the presence of lactase
- CMP-Neu5Ac is obtained in the presence of 3′-SL and the transferase ST3GAL4.
- FIG. 10 A depicts a route for obtaining LSTa from LNT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain LSTa.
- FIG. 10 B depicts a route for obtaining LSTc from LNnT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTc.
- FIG. 10 C depicts a route LSTd is obtained from LNnT.
- the transferase ST3GAL4, ST3GAL3, and lactase N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTd.
- FIG. 10 D depicts a route for obtaining DSLNT from LNT.
- N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain DSLNT.
- Some embodiments of this invention employ sialyltransferase to catalyze the transfer of CMP-sialic acid (e.g., CMP-Neu5Ac) onto either GlcNAc, Galactose or Neu5Ac.
- CMP-sialic acid e.g., CMP-Neu5Ac
- FIG. 2 A- 2 D and FIG. 10 A-D employ sialyltransferases to transfer a sialyl group from a sugar nucleotide donor to an acceptor.
- the sialyltransferase is an ⁇ -2,3-sialyltransferase (EC 2.4.99.4, EC 2.4.99.6, EC 2.4.99.7, EC 2.4.99.9).
- the ⁇ -2,3-sialyltransferase is PmST1 (wild type and mutants) from Pasteurella multocida , NmST1-NmCSS fusion from Neisseria meningitidis , ST3GAL1 from Homo sapiens , ST3GAL2 from Homo sapiens , ST3GAL3 from Homo sapiens , ST3GAL4 from Homo sapiens , or ST3GAL5 from Homo sapiens , ST3GAL6 from Homo sapiens.
- the sialyltransferase is an ⁇ -2,6-sialyltransferase (EC 2.4.99.1, EC 2.4.99.3).
- the ⁇ -2,6-sialyltransferase is Pd26ST from Photobacterium damsel, ST6GAL1 from Homo sapiens , ST6GAL2 from Homo sapiens , ST6GALNAC1 from Homo sapiens , ST6GALNAC2 from Homo sapiens , ST6GALNAC3 from Homo sapiens , ST6GALNAC4 from Homo sapiens , ST6GALNAC5 from Homo sapiens , or ST6GALNAC6 from Homo sapiens.
- the sialyltransferase ⁇ -2,8-sialyltransferase (EC 2.4.99.8).
- the ⁇ -2,8-sialyltransferase is ⁇ -2,3/8-sialyltransferase from Campylobacter jejuni , ST8SIA1 from Homo sapiens , ST8SIA2 from Homo sapiens , ST8SIA3 from Homo sapiens , ST8SIA4 from Homo sapiens , or ST8SIA5 from Homo sapiens.
- the sialyltransferae is selected from the sialylltransferases depicted in the Figures.
- FIGS. 11 A- 11 E depict fucosylation using fucoside and lactose hydrolysis.
- GDP-1-fucose is the nucleotide-sugar used in each of FIG. 11 A- 11 C .
- FIG. 11 A depicts a route for obtaining LNFPI from LNT. GDP-Fuc in the presence of 2′-FL, LNT, Te2FT, HmFucT, lactase, and GsAI provides LNFPI.
- FIG. 11 B depicts a route for obtaining LNFPII from LNT. GDP-Fuc in the presence of 2′-FL, LNT Hp34FT, HmFucT, lactase, and GsAI provides LNFPII.
- FIG. 11 C depicts a route for obtaining LNFPIII from LNnT. GDP-Fuc in the presence of 2′FL, LNnT FUT9, HmFucT, lactase, and GsAI provides LNFPIII.
- FIG. 11 D depicts a route for obtaining DFL from 2′-FL. GDP-Fuc in the presence of 2′-FL, FUT1, FUT3, lactase, GsA1, and fucosidase provides 3-FL, tagatose, and glucose.
- FIG. 11 E depicts a route for obtaining 3-FL from 2′-FL. GDP-Fuc in the presence of 2′-FL, FUT1, FUT3, lactase, and GsAI. Lactase depletes lactose in this route. Instead of lactase, any other enzymatic or nonenzymatic means may be used to deplete lactose. Additionally, GsAI may be added to convert galactose to tagatose to augment the reaction conversion. See Example 5a.D and Example 5a.E.
- a fucosyltransferase catalyzes the transfer of GDP-fucose (GDP-Fuc) onto either Galactose, Glucose, GlcNAc or GalNAc.
- GDP-Fuc GDP-fucose
- FIG. 3 A-C and FIG. 11 A-E employ fucosyltransferases to transfer a fucosyl group from a sugar nucleotide donor to an acceptor.
- the fucosyltransferase is an ⁇ -1,2-fucosyltransferase (EC 2.4.1.69).
- the ⁇ -1,2-fucosyltransferase is Te2FT from Thermosynechococcus elongatus , WbgL from Escherichia coli , HmFucT from Helicobacter mustelae , FUT1 from Homo sapiens , or FUT2 from Homo sapiens.
- the fucosyltransferase is an ⁇ -1,3-fucosyltransferase (EC 2.4.1.152, EC 2.4.1.214).
- the ⁇ -1,3-fucosyltransferase is HpFucT from Helicobacter pylori , Bf1,3FT from Bacteroides fragilis , Hp3/4FT from Helicobacter pylori , FUT3 from Homo sapiens , FUT4 from Homo sapiens , FUT5 from Homo sapiens , FUT6 from Homo sapiens , FUT7 from Homo sapiens , FUT9 from Homo sapiens , or FUT11 from Homo sapiens.
- the fucosyltransferase is an ⁇ -1,4-fucosyltransferase (EC 2.4.1.65).
- the ⁇ -1,4-fucosyltransferase is Hp3/4FT from Helicobacter pylori or FUT2 from Homo sapiens.
- the fucosyltransferase is an ⁇ -1,6-fucosyltransferase (EC 2.4.1.68).
- ⁇ -1,6-fucosyltransferase is FUT8 from Homo sapiens.
- the fucosyltransferase is selected from the fucosyltransferases depicted in the Figures.
- FIG. 12 A and FIG. 12 B depict routes N-acetylglucosaminylation using lacto-N-biose (LNB) as a GlcNAc donor.
- LNB lacto-N-biose
- FIG. 12 A depicts a route for obtaining LNTII and tagatose from LNB and lactose.
- UDP-N-Acetylglucosamine (UDP-GlcNAc) is prepared from UDP in the presence of NmLgtA and GsAI.
- FIG. 12 B depicts a route for obtaining branched human milk oligosaccharides from LNB and LNnT in the presence of UDP, NmLgtA, GCNT2, and GsAI. ⁇ -2,6-GlcNAc-LNnT and tagatose is obtained. In the route depicted GsAI is present to deplete galactose. Any other enzymatic or nonenzymatic means to deplete galactose may be used instead of GsAI.
- an N-acetylglucosaminyltransferase catalyzes the transfer of UDP-N-acetylglucosamine (UDP-GlcNAc) to Galactose, Mannose or GlcNAc.
- UDP-N-acetylglucosamine UDP-N-acetylglucosamine
- the N-acetylglucosaminyltransferase is ⁇ -1,3-N-acetylglucosaminyltransferase (EC 2.4.1.79, EC 2.4.1.149, EC 2.4.1.222).
- the ⁇ -1,3-N-acetylglucosaminyltransferase is HpLgtA form Helicobacter pylori , NmLgtA from Neisseria meningitidis , HP1105 from Helicobacter pylori , B3GNT2 from Homo sapiens , B3GNT3 from Homo sapiens , B3GNT4 from Homo sapiens , B3GNT7 from Homo sapiens , B3GNT8 from Homo sapiens , or B3GNT9 from Homo sapiens.
- the N-acetylglucosaminyltransferase ⁇ -1,4-N-acetylglucosaminyltransferase (EC 2.4.1.223, EC 2.4.1.224).
- the N-acetylglucosaminyltransferase is a ⁇ -1,2-N-acetylglucosaminyltransferase (EC 2.4.1.101, EC 2.4.1.143).
- the ⁇ -1,2-N-acetylglucosaminyltransferase is MGAT1(GlcNAcT-I) from Homo sapiens or MGAT2 (GlcNAcT-II) from Homo sapiens.
- the N-acetylglucosaminyltransferase is a ⁇ -1,4-N-acetylglucosaminyltransferase (EC 2.4.1.144, EC 2.4.1.212).
- the ⁇ -1,4-N-acetylglucosaminyltransferase is MGAT3 (GlcNAcT-III) from Homo sapiens , MGAT4A (GlcNAcT-IV) from Homo sapiens , MGAT4B (GlcNAcT-IV) from Homo sapiens , or MGAT4C (GlcNAcT-IV) from Homo sapiens.
- the N-acetylglucosaminyltransferase is a ⁇ -1,6-N-acetylglucosaminyltransferase (EC 2.4.1.102, EC 2.4.1.150, EC 2.4.1.155).
- the ⁇ -1,6-N-acetylglucosaminyltransferase is GCNT2A from Homo sapiens , GCNT2B from Homo sapiens , GCNT2C from Homo sapiens , GCNT3 from Homo sapiens , GCNT4 from Homo sapiens , or MGAT5 (G1cNACT-V) from Homo sapiens.
- the N-acetylglucosaminyltransferase is selected from the N-acetylglucosaminyltransferases depicted in the Figures.
- the starting systems of reactants and enzymes comprise, consist essentially of, or consist of those described in FIGS. 1 - 12 .
- the invention uses sugars as an energy source.
- An activated sugar sucrose-nucleotide or sugar-nucleotide compound
- the energy source is hydrolysis of more complex sugars into more simple sugars. This aids in driving reactions of this invention to completion.
- sucrose is employed for galactosylation, and hydrolysis of lactose is used for both sialylation and fucosylation.
- lacto-N-biose is used as a GlcNAc donor in N-acetylglucosaminylation reactions.
- hydrolysis of 3′-SL is used in sialylation reactions.
- 2′-FL is used in fucosylation reactions.
- the energy driver is a larger saccharide being converted to smaller saccharide.
- energy is derived from a disaccharide breaking down, hydrolyzing, into a monosaccharide, such as sucrose breaking down into fructose and glucose. That is sucrose and water being converted into fructose and glucose via hydrolysis.
- the activated sugar is regenerated in the reaction mixture. This allows the nucleotide to be present in catalytic amounts. As depicted in each Figure, transfer of a sugar to an acceptor then results in formation of a free nucleotide. The nucleotide then reacts with a sugar to form an activated sugar.
- the nucleotide is added to glucose to form UDP-glucose
- the nucleotide is added to N-acetyl neuraminic acid to form CMP-Neu5Ac
- FIG. 3 the nucleotide is added to 2′-FL to form GDP-2′-FL.
- a process of this invention employs magnesium (Mg) instead of manganese (Mn).
- Mn catalyzes the decomposition of UDP to UMP, and UMP leads to the reductive inactivation of a co-factor NAD+ in GalE.
- a process of this invention employs magnesium (Mg) instead of manganese (Mn) and relatively low concentrations of sucrose, for example, 50-100 mM.
- Manganese (Mn) and inorganic phosphate form insoluble byproducts, particularly at higher industrially relevant concentrations, that make it unsuitable for packed bed reactor applications and that result in the removal of the critical metal cofactor (Mn) from the solution phase which reduces the activity of many glycosyltransferases.
- Mn critical metal cofactor
- the activated sugar comprises, consists essentially of, or consists of: Galactose-UDP, Galactose-ADP, Sialic Acid-CMP, and Fucose-GDP.
- the activated sugar comprises, consists essentially of, or consists of: Galactose-UDP, Sialic Acid-CMP, and Fucose-GDP.
- this invention provides a biocatalytic process for preparing a saccharide-acceptor comprising the steps of:
- the saccharide is a monosaccharide.
- the monosaccharide is galactose, sialic acid, or 1-fucose.
- this invention provides a process for preparing a saccharide compound, comprising the steps of:
- this invention provides a process for preparing a saccharide compound, comprising the steps of:
- this invention provides for galactosylation of an acceptor compound, comprising the steps of:
- the galactose is obtained from sucrose in situ.
- the process is driven to high conversion via the conversion of Sucrose to Glc-UDP and fructose.
- this invention provides for a process for sialylation of an acceptor compound, comprising the steps of:
- the sialic acid is obtained from 3′-SL or 6′-SL in situ.
- the process is driven to high conversion via the conversion of lactose to galactose and glucose.
- this invention provides for a process for fucosylation of an acceptor compound, comprising the steps of:
- the fucose is 1-fucose and is obtained from 2′-FL in situ.
- the process is driven to high conversion via the conversion of sucrose to Glc-UDP and fructose.
- the acceptor compound is a monosaccharide, a disaccharide, an oligosaccharide, or a polysaccharide.
- this invention provides a process for producing LNT and fructose, comprising the step of contacting LNTII, sucrose, a transferase, a sucrose synthase, an epimerase, and UDP to produce LNT and fructose, wherein galactose-UDP is produced, and wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or the sucrose.
- the transferase is Cvb3GalT.
- the transferase transferase is B3GALT5.
- the epimerase is GalE.
- this invention provides a process for producing LNnT and fructose, comprising contacting LNTII, sucrose, a glycosyltransferase, a sucrose synthase, an epimerase, and UDP to produce LNnT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or sucrose.
- the glycosyltransferase is a LgtB. In other embodiments the LgtB is NmLgtB.
- the glycosyltransferase is B4GALT1.
- the glycosyltransferase is B4GALT1.
- the epimerase is GalE.
- this invention provides a process for preparing LNT and fructose, comprising the steps of contacting GlcNAc, 2-chloro-1,3-dimethylimidazolinium chloride, and a base to obtain a reaction mixture comprising GlcNAc-Oxa; and contacting the reaction mixture comprising GlcNAc-Oxa, lactose, sucrose, an aminidase, a transferase, a sucrose synthase, and an epimerase, to provide LNT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10% molar percent of the lactose or the sucrose.
- the aminidase is Bbh1.
- the transferase is Cvb3GalT.
- the epimerase is GalE.
- the base is triethylamine.
- this invention provides a process for preparing lactose and fructose, comprising contacting glucose, sucrose, a lactose synthase, a sucrose synthase, an epimerase, and UDP, to provide lactose and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the glucose and or the sucrose.
- the epimerase is GalE.
- this invention provides a process for preparing LSTa, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide LSTa, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- the sialyltransferase is ST3GAL3.
- this invention provides a process for preparing LSTb comprising contacting LNT, 3′-SL, and catalytic amounts of CMP in the presence of ST3GAL4, ST3GAL3, ST6GALNAC5, Lactase and ⁇ 2-3 Neuraminidase S, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL, wherein lactose is obtained and then processed to glucose and galactose by lactase, and wherein ⁇ 2-3 Neuraminidase S converts DSLNT to LSTb.
- this invention provides a process for preparing LSTc, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTc, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- the sialyltransferase is ST3GAL3.
- this invention provides a process for preparing LSTd, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTd, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- the sialyltransferase is ST3GAL3.
- this invention provides a process for preparing DSLNT, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide DSLNT, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10% molar percent of the 3′-SL.
- the sialyltransferase is ST3GAL3 and ST6GALNAC5.
- this invention provides a process for preparing LNFPI, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Te2FT, HmFucT, and lactase to provide LNFPI, galactose, and glucose wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL
- the transferase is Te2FT and HmFucT.
- this invention provides a process for preparing LNFPII, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Hp34FT, HmFucT, and lactase, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- the transferase is Hp34FT and HmFucT.
- this invention provides a process for preparing LNFPIII, galactose, and glucose, comprising contacting 2′-FL, LNnT, GDP, FUT9, HmFucT, and lactase, to provide LNFPIII, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- the transferase is FUT and HmFucT.
- this invention provides a process for preparing 3-FL, comprising contacting 2′-FL, GDP, FUT1, FUT3, lactase, GsAI, and fucosidase to provide 3-FL, tagatose, and glucose, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- this invention provides a process for preparing LNTII, comprising contacting LNB, lactose, UDP, NmLgtA, and GsAI to provide 3-FL, tagatose, and glucose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- this invention provides a process for preparing LNTII, comprising contacting LNB, lactose, UDP, NmLgtA, and GsAI to provide 3-FL, tagatose, and glucose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- this invention provides a process for preparing ⁇ -1,6-GlcNAc-LNnT, comprising contacting LNB, LNnT, UDP, NmLgtA, GCNT2, and GsAI to provide ⁇ -1,6-GlcNAc-LNnT and tagatose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- the sialic acid is N-acetyl neuraminic acid (Neu5Ac).
- the sugars are in their naturally occurring isomeric forms.
- the glucose is D-glucose.
- galactose is D-galactose.
- fucose is L-fucose.
- tagatose is D-tagatose.
- N-acetylglucosamine (GlcNAc) is N-Acetyl-D-glucosamine.
- fructose is D-fructose.
- the nucleotide is present in the catalytic amount of about 0.01 to about 10 molar percent relative to the saccharide amount.
- the relevant saccharide is either the staring saccharide or the saccharide that is generated and reacts with the nucleotide.
- nucleotide monophosphates and diphosphates used in this invention are used in catalytic amounts relative to the molarity of sugar that is bound to the monophosphate or diphosphate.
- nucleotide monophosphates and diphosphates used in this invention are used in catalytic amounts relative to the molarity of starting material sugar or other acceptor.
- nucleotides include natural, artificial, or synthetic nucleotides.
- a “catalytic amount” of nucleotide ranges are in an amount of precisely, about, up to, or less than, for example 0.01% to 10% moles of nucleotide to moles of sugar, either sugar donor or acceptor molecule.
- a “catalytic amount” of nucleotide ranges are in an amount of precisely, about, up to, or less than, for example 0.001% to 10% moles of nucleotide to moles of either sugar donor or acceptor molecule.
- the nucleotide monophosphates or nucleotide diphosphates are in an amount of precisely, about, up to, or less than, for example 0.001% to 1% (mol percent).
- the nucleotide monophosphates and diphosphates are in an amount of precisely, about, up to, or less than, for example 0.01% to 10% (mol percent).
- the nucleotide monophosphates or nucleotide diphosphates are in an amount of precisely, about, up to, or less than, for example 0.1% to 1% (mol percent). In other embodiments, precisely, about, up to, or less than, for example, the nucleotide monophosphates and nucleotide diphosphates are added in an amount of 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, or 0.09%, (mol percent).
- nucleotide monophosphates and nucleotide diphosphates are added in an amount of precisely, about, up to, or less than, for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% (mol percent).
- nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely, about, up to, or less than, for example, the monophosphates and diphosphates are added in an amount of 0.01%, 0.1%, 0.3%, 1.0%, or 10% (mol percent).
- the nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely, about, up to, or less than, for example, the monophosphates and diphosphates are added in amount of 0.1, 0.3, or 1.0% (mol percent). In other embodiments, the nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely or about 0.001%, 0.01%, 0.1%, 1.0%, or 10%. In other embodiments, the monophosphates and diphosphates are added in amounts of precisely or about 0.1%, 1.0%, or 10%. In other embodiments, the monophosphates and diphosphates are added in amounts of precisely or about 0.1%, 0.3%, or 1.0% (mol percent).
- FIG. 1 - 14 depict embodiments employing catalytic nucleotides.
- plant sugars are used to create glycosylated compounds including, but not limited to, galactosylated compounds, sialylated compounds, and fucosylated compounds, wherein the galactose, sialic acid, and fucose is added to a hydroxy group including, but not limited to, a hydroxy group of a sugar.
- lacto-N-biose is used as a GlcNAc donor to be added to a hydroxy group of a sugar in an N-acetylglucosaminylation reaction.
- plant sugars or simple HMOs produced by microbial fermentation, or from animal origin are used to create more complex saccharides including, but not limited to, oligosaccharides found in animals.
- the compounds include, but are not limited to LNT, LNnT, lactose, GOS, LSTa, LSTc, LSTd, DSLNT, LNFPI, LNFPII, LNFPIII.
- the compounds include, but are not limited to, LSTb and 3-FL.
- plant sugars are used to synthesize lactose derivatives by chemoenzymatic processes to obtain lactose derivatives including, but not limited to, lactobionic acid, lactitol, lactosucrose, galacto-oligosaccharides (GOS), lactulose, and HMOs (see FIG. 5 ).
- lactobionic acid lactitol
- lactosucrose lactosucrose
- GOS galacto-oligosaccharides
- HMOs see FIG. 5 .
- lactobionic acid is obtained from lactose via an oxidation reaction.
- Lactitol is obtained from lactose via a reduction reaction.
- Lactosucrose is obtained from lactose via fructosyl transfer.
- Galacto-oligosaccharides ⁇ -(1,4) or ( ⁇ -(1,6) linkages) are obtained from lactose via transgalactosylation.
- Lactulose is obtained from lactose via isomerization.
- the products obtained from the processes of this invention are not animal derived. Such products are advantageous in markets where animal-free products are desired.
- the activated sugars are activated galactose, activated Neu5Ac, activated fucose, or activated glucose.
- the activated sugar is N-acetylglucosamine (GlcNAc). These activated sugars are generated in situ.
- the reactions are designed to be nucleotide triphosphate free and to avoid reagent and co-factor recycling or regeneration. This reduces the number of enzymes needed to produce each oligosaccharide and avoids acidification. This reduces costs and leads to higher yields and higher purity products.
- more than one saccharide secondary product is produced in the reaction mixture.
- glucose and galactose are both produced as secondary products in a single reaction mixture.
- a processing enzyme is employed to convert a secondary product into a secondary product derivative.
- the conversion is beneficial in driving the reaction to completion towards formation of the principal product.
- the conversion can be tailored to obtain a more desired secondary product derivative for recovery and reuse.
- a processing enzyme is employed to convert a principal product to a principal product derivative.
- the conversion is beneficial to obtain a more desired principal product derivative for recovery and reuse.
- more than one processing step may be employed to further convert either a principal product derivative or a secondary product derivative.
- the number of processing steps employed depends on driving the reaction to completion and obtaining a desired final product.
- Certain galactosylation methods of this invention employs none or one processing of either the principal product or the secondary product. In certain embodiments, no processing step is employed in galactosylation methods of this invention.
- Certain sialylation, fucosylation, and N-acetylglucosaminylation methods employ none, one, or two processing of either the principal product or the secondary product. In certain sialylation, fucosylation, and N-acetylglucosaminylation embodiments, one processing step converts the principal product to a principal product derivative or the secondary product to a secondary product derivative.
- Some embodiments of this invention employ a processing enzyme that either hydrolyzes, oxidizes, or isomerizes a carbohydrate or oligosaccharide.
- the processing enzyme is an enzyme that hydrolyzes lactose.
- the enzyme the hydrolyzes lactose is Lactase ( ⁇ -galactosidase) (EC 3.2.1.23).
- the Lactase is ( ⁇ -galactosidase from Aspergillus niger , ⁇ -galactosidase from Escherichia coli , ( ⁇ -galactosidase from Aspergillus oryzae , or ⁇ -galactosidase from Kluyveromyces lactis.
- the processing enzyme is an enzyme that oxidizes lactose carbohydrates.
- the enzyme that oxidizes lactose carbohydrate is a glucose oxidase (EC 1.1.3.4).
- the glucose oxidase is Glucose oxidase from Aspergillus niger , Glucose oxidase from Penicillium amagasakiense , Glucose oxidase from Penicillium notatum ( chrysogenum ), Glucose oxidase from Penicillium variabile , Galactose oxidase (EC 1.1.3.9), Galactose oxidase from Dactylium dendroides , Galactose oxidase from Polyporus circinatus , Galactose oxidase from Fusarium graminearum , Galactose oxidase from Dros
- the enzyme that oxidizes lactose carbohydrate is an enzyme that oxidizes lactose to Lactobionic acid.
- the enzyme that oxidizes lactose carbohydrate is Carbohydrate oxidase from Microdochium nivale , Lactose oxidase from Myrmecridium flexuosum , Lactose oxidase from Sarocaldium oryzae , Lactose oxidase from Paraconiothyrium sp., Galactose oxidase (EC 1.1.3.9) from Polyporus circinatus , Cellobiose dehydrogenase (EC 1.1.99.18) from Sclerotium rolfsii , Cellobiose quinone oxidoreductase (EC 1.1.5.1) from Phanerochaete chrysosporium , Cellobiose quinone oxidore
- the processing enzyme is an enzyme that isomerizes carbohydrates.
- the enzyme that isomerizes carbohydrates is a glucose isomerase (xylose isomerase) (EC 5.3.1.5).
- the glucose isomerase is Glucose isomerase from Streptomyces murinus , Glucose isomerase from Actinoplanes missouriensis , Glucose isomerase from Bacillus coagulans , Glucose isomerase from Arthrobacter , or Glucose isomerase from Xanthomonas campestris.
- the enzyme that isomerizes carbohydrates is L-Arabinose isomerase (Galactose isomerase) (EC 5.3.1.4).
- the L-Arabinose isomerase is L-Arabinose isomerase from Geobacillus stearothermophilus L-Arabinose isomerase from Lactobacillus sakei, L-Arabinose isomerase from Bacillus subtilis , L-Arabinose isomerase from Escherichia coli or L-Arabinose isomerase from Thermoanaerobacter mathranii.
- the processing enzyme is an enzyme that hydrolyze carbohydrates.
- enzyme that hydrolyze carbohydrate is a fucosidase.
- Fucosidases are enzymes that catalyze the hydrolysis fucose from a glycan, carbohydrate, or glycan bearing moiety.
- the fucosidase is ⁇ -1,2-fucosidase (EC 3.2.1.63), ⁇ -1,3-fucosidase (EC 3.2.1.111) or ⁇ -1,4-fucosidase (EC not known).
- enzyme that hydrolyze carbohydrate is a sialidase (Neuraminidase).
- Sialidases are enzymes that catalyze the hydrolysis of sialic acid from a glycan, carbohydrate, or glycan bearing moiety.
- the sialidase is an xo- ⁇ -sialidase.
- the exo-a-sialidase is ⁇ 2-3 Neuraminidase S, ⁇ 2-3,6,8,9 Neuraminidase A, ⁇ 2-3,6,8 Neuraminidase.
- the sialidase is an Endo-a-sialidase.
- the sialidase is ⁇ 2,8 Neuraminidase.
- a processing enzyme is selected from the fucosyltransferases depicted in the Figures.
- fructose is the secondary product produced and may be recovered or processed for further use.
- sialylation and fucosylation reactions exemplified herein galactose and glucose are the secondary products produced and may be recovered or processed for further use.
- lactose or galactose are the secondary products produced and may be recovered or processed (e.g., to tagatose) for further use.
- the nucleotides may also be recovered.
- UDP or ADP may be recovered in galactosylation reactions
- CMP may be be recovered in the sialylation reactions
- GDP may be recovered in the fucosylation reactions.
- glycans are obtained in the methods of this invention.
- Glycans are carbohydrate-based compounds featuring one or more monosaccharides linked with a glycosidic bond, including N-linked and O-linked bonds. Activated monosaccharides, oligosaccharides, polysaccharides, plant glycans, animal glycans, and microbe glycans are all within the scope of this invention as are glycoconjugates, such as glycolipid, glycopeptides, glycoproteins, and proteoglycans. Glycans also include humanized glycoproteins, humanized antibodies, and glycoconjugate vaccines. Riley, et al. “Glycosylation in health and disease” Nature Reviews Nephrology volume 15, pages 346-366 (2019). Rappuoli, “Glycoconjugate vaccines: Principles and mechanisms” Science Translational Medicine 29 Aug. 2018: Vol. 10, Issue 456. The forgoing are incorporated by reference in their entirety.
- Any organic compounds comprising at least one alcohol (hydroxyl) functional group may be an acceptor and therefore glycosylated by the processes of this invention.
- Such compounds may include, but are not limited to, rare sugars, activated sugars, HMOs, glycans with sugar modifications, glycosylated small molecules, polymerized fiber sugars, inulins, levans, gluconic acid, invert sugar, flavors, and fragrances.
- Organic compounds bearing at least one alcohol functional group (organic hydroxy functional group) that may be glycosylated according to this invention include, but are not limited to, Steviol, a class of compounds called Rebaudiosides, phenolic compounds, proteins with O-glycosylation and N-glycosylation sites: serine, threonine asparagine as well as compounds related thereto.
- the present invention provides an integrated pathway using immobilized enzymes to perform a synthesis of oligosaccharides, including embodiments utilizing a one-pot synthesis of fucosolyated oligosaccharides starting from fructose or glucose. This lowers the cost of production of fucosylated HMOs vs using fucose as a starting material.
- a glycan to be fucosylated may be prepared separately for use a one-pot synthesis of this invention.
- the invention provides cell-free de-novo synthesis of fucosylated glycan starting from simple sugars.
- An integrated pathway of immobilized enzymes perform the one-pot fucosylation of oligosaccharides or antibody-glycan conjugates starting from fructose or glucose, rather than fucose.
- the system of immobilized enzymes comprises, consists essentially of, or consists of:
- the HMO 2′-FL may be produced from lactose.
- the last transferase of the enzyme cascade can be changed to fucosylate other oligosaccharides backbones.
- the switch to a different fucosyltransferase constitutes a separate HMO production, again via a one-pot system.
- one fucosyl transferase would be employed to make 2′-FL
- another fucosyl transferase would be employed LNFP1
- another fucosyl transferase would be employed SM to makes LNFPII etc.
- modularity arises from changing the last enzyme of the system (i.e., the fucosyl transferase).
- the methods provide high volumetric productivity, are cost effective, and are non-GMO label.
- the immobilized enzymes may be coupled to a processing plant producing lactose, fructose, or glucose feeds for continuous flow manufacturing.
- the invention may be integrated to a biorefinery to convert glucose or fructose to fucosylated HMOs.
- the last transferase of the enzyme cascade can be changed to transfer GDP-fucose to other oligosaccharides backbones for fucosylation reactions.
- the cascade of enzymes can produce GDP-mannose that can also be polymerized to mannans via transferase enzymes.
- glucose and/or fructose is converted to GDP-L-fucose in an integrated synthesis.
- Enzyme E1 converts glucose to mannose.
- enzyme E1′ converts fructose to mannose.
- enzyme E2 converts mannose to mannose-6-phosphate.
- Enzyme E3 converts mannose-6-phosphate to mannose-1-phosphate.
- Enzyme E4 converts mannose-1-phosphate to GDP-D-mannose.
- Enzyme E5 converts GDP-D-mannose to GDP-4-keto-6-deoxymannose.
- Enzyme E6 converts GDP-4-keto-6-deoxymannose to GDP-L-fucose.
- 2′FL is obtained from GDP-L-fucose, lactose, and enzyme E7. All enzymes are immobilized
- Regeneration enzymes are also depicted in FIG. 15 .
- Enzymes E8, E9, E10, and E11, and E12 regenerate reagents to allow for the integrated synthesis. The following reaction occur: GDP to GTP (E10), inorganic diphosphate to inorganic phosphate (E12), carbon dioxide and hydrogen peroxide to oxygen and water (E11), ADP to ATP (E10), acetate phosphate to acetate (E10), inorganic phosphate and pyruvate to acetate phosphate (E9), and formate to carbon dioxide (E8).
- enzymes used are Glk, RfbK, RfbM, Gmd, and GFS along with regeneration enzymes Pyruvate-AcK, PyrOx, and FDH.
- the enzymes convert glucose and/or fructose to mannose, then mannose to mannose-6-phosphate, then mannose-6-phosphate to mannose-1-phosphate, then mannose-1-phosphate to GDP-D-mannose, then GDP-D-mannose to GDP-4-keto-6-deoxymannose, and then GDP-4-keto-6-deoxymannose to GDP-L-fucose.
- Further reactions involve fucosylation of any sugar residue including, but not limited to, oligosaccharides or fucosylated antibody-glycan conjugates.
- fucosyl transferase In the presence a fucosyl transferase and GDP-L-fucose, lactose is converted to 2′FL via fucosyl transferase. Similarly, an oligosaccharide is converted to a fucosylated oligosaccharide or an antibody-glycan conjugate is converted to a fucosylated antibody-glycan conjugate.
- the depicted fucosyl transferase of the enzyme cascade may be changed to transfer GDP-fucose to other oligosaccharides backbones for fucosylation reactions to provide fucosylated products.
- Pi both from the PtxD step (in the examples using phosphite) and the PmPpa step will be used by PyrOx.
- Lactose, fructose, pyruvate and phosphite are primary reactants in the integrated synthesis.
- Buffers including, but not limited to, Tris may be used.
- the buffer maintains the pH between about pH 6.5 and about 8.5 or about 7.5.
- FIG. 16 depicts the same structural transformations of FIG. 15 with a different regeneration system.
- the regeneration enzymes are E8′, E9, E10, E11, and E12.
- E8′ converts phosphite to inorganic phosphate and NADP+ to NADPH.
- Enzymes that may be employed are pyruvate-AcK, PyrOx, and PtxD.
- FIG. 17 depicts the same structural transformations of FIG. 15 with a different regeneration system employing E8, E9′, and E12.
- the regeneration enzymes are PolyP-PPK and FDH.
- FIG. 18 depicts the same structural transformations of as in FIG. 15 , with a different regeneration system.
- the regeneration enzymes are E8′, E9′, and E12.
- E9′ is involved in converting ADP to ATP and GDP to GTP, and E8′ converts phosphite to Pi.
- E12 converts PPi to Pi and converts NADP+ to NADPH.
- Enzymes that may be used include PolyP-PPK and PtxD.
- Feed solutions are also employed in the reactions depicted in FIGS. 15 - 18 .
- the feed solution comprises lactose, fructose, formate, MgCl 2 , Tris, pyruvate, NADP+, GDP, and ATP ( FIG. 15 - 18 ).
- a feed solution comprises lactose, fructose, phosphite, MgCl 2 , a buffer (e.g., Tris buffer), GDP, NADP+, pyruvate, and ATP ( FIG. 16 ).
- a buffer e.g., Tris buffer
- the feed solution comprises lactose, fructose, formate, MgCl 2 , Tris, polyphosphate, a buffer (such as Tris buffer), GDP, NADP+, and ATP ( FIG. 17 ).
- the feed solution comprises lactose, fructose, phosphite, MgCl 2 , a buffer (such as Tris buffer), GDP, NADP+, polyphosphate, and ATP ( FIG. 18 ).
- Glucose or fructose are interchangeable, however the first enzyme must match the starting sugar. Accordingly, either glucose and fructose are interchangeable with the addition of appropriate enzymes E1 or E1′, respectively.
- compounds that may be fucosylated according to methods of this invention include, but are not limited to, rare sugars, activated sugars, HMOs, and glycans.
- a process of this invention employs magnesium (Mg) instead of manganese (Mn) and does not include UMP. Under these conditions, high sucrose does not lead to reductive inactivation of GalE.
- the sugars are plant derived. Accordingly, any of the embodiments of this invention may be employed to obtain a compound from non-animal based plant materials.
- the products obtained from the processes of this invention are not animal derived. Such products are advantageous in markets where animal-free products are desired.
- Glycans synthesized as described herein may be simple or complex glycan that may be linear or branched.
- the glycans to be fucosylated may be simple glycans or complex glycan, including linear or branched.
- Glycans having one or more sugar units are included.
- the glycans have two, three, four, or five sugar units or more units.
- the glycans have 1-18 units.
- the glycans have 1-10 units.
- the glycans have 1-5 units.
- the glycans have five sugar units or more.
- the glycans have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 units. In certain embodiments, the glycans have 1 unit, 2 units, 3 units, 4 units, 5 units, or 6 units. In some embodiments, the glycans are oligosaccharides. In some embodiments, the glycans are straight chained or branched chained. In certain embodiments, the glycans have 1-6 units and are straight chained. In other embodiments, the glycans have 1-6 units and are branched. In certain embodiments, the glycans have 1-5 units and are straight chained. In other embodiments, the glycans have 1-5 units and are branched. In FIG. 1 F n is 3-15. In certain embodiments, n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
- compounds obtained according to this invention including, but not limited to, galactosylated, sialylated, fucosylated, and N-acetylglucosaminylation compounds, may be used as components in the synthesis of any glycan-containing compound.
- compounds obtained according to this invention include, but are not limited to, galactosylated compounds.
- the materials functionalized with enzymes, or enzyme systems have applications for the production of pharmaceuticals, biologicals, nutraceuticals, cosmeceuticals, and food ingredients.
- the sugars and oligosaccharides are non-animal derived.
- fucosylated compounds obtained according to this invention may be used as components in the synthesis of any glycan-containing compound.
- the materials functionalized with enzymes, or enzyme systems have applications for the production of pharmaceuticals, biologicals, actives nutraceutical, actives cosmeceutical and food ingredients.
- the methods provide fucosylated oligosaccharides or fucosylated antibody-glycan conjugates.
- fucosylated human milk oligosaccharides HMOs are produced.
- the methods provide galactosylated oligosaccharides or galactosylated antibody-glycan conjugates.
- galactosylated human milk oligosaccharides are produced.
- the glycan to be reacted is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-LNnH 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-(3′′ 3 ,3′′ 6 -di-O- ⁇ -Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, ⁇ -2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N
- the glycan to be fucosylated is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-LNnH 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-(3′′3,3′′6-di-O- ⁇ -Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, ⁇ -2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary si
- the glycans are 3′SL LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, 2′-FL, LNnH, DSLNnH, or DSDFLNNH. In other embodiments, the glycans are 3′SL, LNTII, 2′-FL, LNFPI, LSTa.
- the glycan to be reacted is 2′-FL, 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, LNnH, 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-LNnH 3′′′ 3 ,3′′′ 6 -di-O- ⁇ -Sia-(3′′ 3 ,3′′ 6 -di-O- ⁇ -Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, ⁇ -2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pent
- enzymes used herein may be natural or synthetic, bioengineered enzymes, including fusion enzymes.
- enzymes may be engineered for affinity towards immobilization scaffolds (tags).
- Enzymes may also be engineered for improved kinetic properties (e.g., lower Km).
- the enzymes are immobilized.
- the immobilization of the enzymes may be through covalent immobilization, entrapment, adsorption, molecular tagging with affinity tags, protein affinity tags, noncovalent adsorption, noncovalent deposition, entrapment, physical entrapment, bioconjugation, chelation, cross-linking, or disulfide bonds. See, e.g., Basso & Serban Mol. Catal. 479 (2019) 110607; Xu et al. Frontiers in Bioeng & Biotech ., Published 30 Jun. 2020 publdoi: and Sheldon & van Pelt Chem. Soc. Rev., 2013, 42, 6223. The foregoing are incorporated by reference herein in their entirety.
- such enzymes include, but are not limited to, enzymes immobilized within bionanocatalysts (BNCs) that in turn are embedded within scaffolds.
- Bionanocatalysts (BNCs) according to this invention comprise an enzyme self-assembled with magnetic nanoparticles (MNPs). The BNCs self-assemble with the scaffolds.
- MNPs magnetic nanoparticles
- the immobilized enzymes are non-magnetic. In certain embodiments, such as for oligosaccharides to be used in food ingredients, the immobilized enzymes do not comprise nanoparticles.
- the immobilized enzymes involve permanent molecular entrapment of enzymes within self-assembling nanoparticle (NP) clusters.
- NP nanoparticle
- the self-assembly is purely driven by the materials' electrostatic and magnetic interactions. Ionic strength, buffer pH, and NP concentration are the main parameters impacting the immobilization yield and optimized enzyme activity.
- the clusters are then magnetically templated onto magnetic scaffolds or shapeable magnetic scaffolds.
- immobilized bionanocatalysts are magnetic materials with one or more enzymes that are immobilized and associated with scaffolds.
- the scaffolds are high magnetism and high porosity metal oxides or composite blends of thermoplastics or thermosets comprising magnetic particles that form powders.
- Selective Laser Sintering is used to design and produce objects via 3D printing by sintering composite magnetic powders.
- Bionanocatalysts comprise an enzyme self-assembled with magnetic nanoparticles (MNPs).
- Self-assembled mesoporous aggregate of magnetic nanoparticles comprise a glycan synthesis enzyme, wherein the mesoporous aggregate is immobilized on a magnetic macroporous scaffold.
- the immobilized enzymes comprise (i.) a glycan synthesis enzyme self-assembled in magnetic nanoparticles, and (ii.) a magnetic scaffold.
- a glycan enzyme is immobilized on nanoparticles where the nanoparticles coat a scaffold, and the enzyme is immobilized in or on the mesoporous structure formed by the nanoparticles.
- the nanoparticles comprise magnetite (Fe 3 O 4 ) or maghemite (Fe 2 O 3 ).
- the nanoparticles comprise a product synthesized from FeCl 2 and FeCl 3 , particularly synthesized via continuous coprecipitation of FeCl 2 *4H 2 O and FeCl 3 .
- FeCl 2 *4H 2 O Iron (II) chloride tetrahydrate
- FeCl 3 *6H 2 O Iron (III) chloride hexahydrate.
- the nanoparticles comprise magnetite (Fe 3 O 4 ).
- a glycan synthesis enzyme is any enzyme that can be used in the synthesis of a glycan. Steps in glycan synthesis may include activating a sugar, transferring a sugar unit thereby extending a sugar, cofactor recycling, and equilibrium shifting.
- Glycan synthesis enzymes include, but are not limited to, a sugar activation enzyme, a sugar extension enzyme, a reagent regeneration enzyme, and a sugar functionalization enzyme.
- glycan synthesis enzymes include, but are not limited to, a sugar activation enzyme, a sugar extension enzyme, a reagent regeneration enzyme, a sugar functionalization enzyme, a sugar support enzyme, a sugar removal enzyme.
- Some immobilized enzyme materials, and in particular, magnetic materials, for producing glycans use one or more enzymes that are immobilized within bionanocatalysts (BNCs) which in turn are embedded within macroporous scaffolds to provide scaffolded bionanocatalysts (scaffolded BNCs).
- BNCs bionanocatalysts
- the scaffolded BNCs may be inside of modular flow cells for flow manufacturing.
- the modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing processes.
- the scaffolded BNCs are used in reactions for synthesizing glycans by contacting a glycan subunit or substrate with a scaffolded BNC to produce a second glycan, contacting a first glycan subunit and a second glycan subunit to produce a glycan comprising the first and second glycan subunits, or contacting a first glycan with a scaffolded BNC to produce a second glycan. Included are processes to modifying a glycan subunit and to connect glycans.
- Magnetic enzyme immobilization involves the entrapment of enzymes in mesoporous magnetic clusters that self-assemble around the enzymes (level 1).
- the immobilization efficiency depends on a number of factors that include the initial concentrations of enzymes and nanoparticles, the nature of the enzyme surface, the electrostatic potential of the enzyme, the nature of the nanoparticle surface, and the time of contact.
- Enzymes used for industrial purposes in biocatalytic processes should be highly efficient, stable before and during the process, reusable over several biocatalytic cycles, and economical.
- Mesoporous aggregates of magnetic nanoparticles may be incorporated into continuous or particulate macroporous scaffolds (level 2).
- the scaffolds may or may not be magnetic.
- Such scaffolds are discussed in, e.g., WO2014/055853, WO2017/180383, and Corgie et al., Chem. Today 34(5):15-20 (2016), incorporated by reference herein in their entirety.
- Highly magnetic scaffolds are designed to immobilize, stabilize, and optimize any enzyme. This includes full enzyme systems, at high loading and full activity, and for the production of, e.g., small molecules.
- Immobilized enzymes may be employed in process of this invention (WO2022/119982).
- immobilized enzymes may be prepared as follows.
- SFE strontium ferrite
- MNPs magnetic nanoparticles
- a second step the glycan synthesis enzymes are added to the product from the first step to the scaffolded BNCs.
- Type B scaffolded BNC compositions are made by this method.
- Certain immobilized enzymes are prepared when glycan synthesis enzymes are contacted with magnetic nanoparticles to form a bionanocatalyst (“BNC”) and then the BNCs are contacted with a magnetic scaffold material.
- BNC bionanocatalyst
- Type A scaffolded BNC compositions are made by this method.
- the magnetic scaffold material is strontium ferrite.
- the strontium ferrite is a spherical particle with a tight size distribution of an average particle diameter of either 20 ⁇ m (S20) or 40 ⁇ m (S40W; wrinkled).
- Strontium ferrite in accordance with this invention available upon request from Powdertech International.
- scaffold-MNP complex As used herein, scaffold-MNP complex, scaffold-MNP matrix, and scaffold-MNP material each indicate the combination of a scaffold and a MNP according to this invention, comprising, consisting essentially of, or consisting of, magnetite nanoparticles and a strontium ferrite matrix.
- this invention employs enzymes immobilized using iron oxide materials including, but not limited to, hematite, magnetite, and strontium ferrite.
- the immobilized enzyme is a Type A scaffolded BNC or a Type B scaffolded BNC.
- this invention provides a glycan synthesis enzyme scaffolded BNC made by the process of contacting strontium ferrite with magnetite nanoparticles to form a scaffold-MNP Complex and adding a glycan synthesis enzyme to the scaffold-MNP Complex to form the scaffolded BNC.
- Another embodiment provides a glycan synthesis enzyme scaffolded BNC made by the process of combining magnetite nanoparticles and a glycan synthesis enzyme to form a BNC and then contacting the BNC with a scaffold or matrix to form a scaffolded BNC.
- the bionanocatalyst coats the magnetic microporous scaffold material.
- a scaffolded BNC composition comprises a self-assembled mesoporous aggregate of magnetic nanoparticles and a glycan synthesis enzyme and a magnetic microporous material.
- a scaffolded BNC according to this invention comprises a glycan synthesis enzyme immobilized on magnetic nanoparticles, wherein the magnetic nanoparticles coat a magnetic macroporous material.
- the scaffolded BNCs comprises a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme
- the scaffolded BNCs consists of, or consists essentially of, a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme.
- the scaffolded BNC comprises any elementary enzyme module described herein or is in a system module.
- a scaffolded BNC composition comprises a self-assembled mesoporous aggregate of magnetic nanoparticles and a glycan synthesis enzyme and a magnetic microporous material.
- a scaffolded BNC that may be used in the methods of this invention comprises a glycan synthesis enzyme immobilized on magnetic nanoparticles, wherein the magnetic nanoparticles coat a magnetic macroporous material.
- the scaffolded BNCs consist of a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme.
- the scaffolded BNC is used in an integrated pathway as disclosed herein.
- the invention provides for the ability to perform syntheses in one-pot reactions.
- the one-pot synthesis may be done in batch or flow including, but not limited to, repetitive batch or continuous flow.
- a flow reactor such as a packed bed reactor, the mixture of reagents is passed through the flow.
- the invention provides a commercially applicable biocatalysis in flow.
- the immobilized enzymes provide a series of highly tunable materials and processes for universal enzyme immobilization based on magnetic metamaterials.
- the unique enzyme hierarchical immobilization platform provides optimal conditions to immobilize single and full systems of enzymes and allows optimal conditions to be found and adapted for single and full systems of enzymes. It affords enzyme stability, maximal use of substrates (including co-factors) and imparts modularity to flow processes. Accordingly, certain methods of this invention use a stabilized enzyme composition comprising a bionanocatalyst and a magnetic scaffold, wherein the bionanocatalyst comprises a glycan synthesis enzyme and magnetic nanoparticles and the magnetic scaffold stabilizes the bionanocatalyst.
- One embodiment provides a modular process for producing a glycan, comprising a module that may be a flow cell wherein: the module comprises a magnetic macroporous powder comprising magnetic microparticles, wherein the powder has immobilized a preparation of self-assembled mesoporous aggregates of magnetic nanoparticles containing a glycan synthesis enzyme; wherein a substrate is introduced into the module (or passed through a flow cell) and the substrate is modified to provide a glycan.
- Continuous flow reactors include, but are not limited to, packed-bed and fixed-bed reactors in tubular format can be combined with upstream and downstream processes that are not continuous making the overall process semi-continuous.
- the reaction feed for the LNTII reaction (Example 3c-A) may be produced in a continuous stirred tank reactor, the product of which is continuously added to the flow reactor.
- Microfluidic reactors may also be employed in connection with this invention.
- Certain embodiments involve methods comprising 1 or more modules.
- a first substrate is passed through the first modular flow cell to create a modified substrate; wherein the modified substrate is a second substrate to pass through a second module to create a second modified substrate.
- the invention provides for sets of modules to be combined allowing the synthesis of complex glycans.
- the invention provides methods for making glycans by immobilizing an enzyme with magnetic nanoparticles and contacting the immobilized enzyme with appropriate synthetic reagents.
- the methods may be conducted in batch, flow, semi-continuous, or continuous-flow.
- the magnetic macroporous material comprises a metal oxide or a metal oxide complex.
- the scaffold comprises a metal oxide.
- the metal oxide is strontium ferrite (SrFe 12 O 19 ).
- the magnetic macroporous material is a metal oxide and consists essentially of, or consists of, metallic materials or ceramic and does not include a polymer.
- the scaffold is a metal oxide and is not a nanoparticle.
- the invention also provides a process for preparing a scaffolded bionanocatalyst by combining a magnetic nanoparticle and a glycan synthesis enzyme to form a bionanocatalyst and then contacting the bionanocatalyst with a scaffold to obtain the scaffolded bionanocatalyst, and a process for preparing a scaffolded bionanocatalyst by combining a scaffold and a magnetic nanoparticle to form a scaffolded magnetic nanoparticle complex and then contacting the scaffolded magnetic nanoparticle complex with a glycan synthesis enzyme. Also provided is a scaffolded BNC made by either of these processes.
- the process for preparing the magnetic scaffolds is flexible as employed in this invention provides for convenient, flexible glycosylation reactions.
- the process for preparing the magnetic scaffolds is flexible as employed in this invention provides for convenient, flexible fucosylation reactions.
- the process for preparing the magnetic scaffolds is flexible and tunable to manufacture objects using 3D designs that magnetically capture the BNCs. A large surface area may result from the sintering process itself. Materials can also be recycled by removing the BNCs and then re-functionalized them for repeated use. See PCT/US19/53307, incorporated by reference herein in its entirety.
- thermoplastics are Polyethylene (PE) (varying densities, e.g. LDPE, HDPE), Polypropylene (PP), Acrylics: Polyacrylic acids (PAA), Poly(methyl methacrylate) (PMMA), Polyvinyl alcohol (and polyvinyl acetals), Polyamides (Nylon), Polylactic acid (PLA), Polycarbonate (PC), Polyether sulfone (PES), Polystyrene (PS), Polyvinyl chloride (PVC), Acrylonitrile butadiene styrene (ABS), Polybenzimidazole (PBI), Polyoxymethylene (POM), Polyetherether ketone (PEEK), Polyetherimide (PEI), Polyvinylidene fluoride (PVDF), Polytetrafluoroethylene (PTFE/Teflon), Polyacrylonitrile (PAN)) blended with magnetic materials (e.g. magnetite MMP) via melting/extrusion or via coating of the magnetic material by
- Selective laser sintering is an additive manufacturing (AM) technique that uses a laser as the power source to sinter powdered materials such as plastic, metal, ceramic, glass powders, nylon or polyamide.
- a laser automatically aimed at points in space, defined by a 3D model (e.g. an Additive Manufacturing File, AMF, or a CAD file), binds the material together to create a solid structure. After each cross-section is scanned, the powder bed is lowered by a one-layer thickness, a new layer of material is applied on top, and the process is repeated until the part is completed.
- a 3D model e.g. an Additive Manufacturing File, AMF, or a CAD file
- SLS is similar to direct metal laser sintering (DMLS) but differs in technical details.
- DSLM uses a comparable concept, but in DSLM the material is fully melted rather than sintered. This allows one to manufacture materials with different properties (e.g. crystal structure and porosity).
- SLS is a relatively new technology that may be expanded into commercial-scale manufacturing processes.
- polypropylene-magnetite materials can be 3D-printed in any shape and form via SLS.
- an extruded composite material is size reduced via cryomilling or another form of milling.
- composite powders are sieved to an ideal particle size.
- the particle sizes are 60+/ ⁇ 20 ⁇ m.
- Powders or 3D printed objects can be functionalized with BNCs containing one or more enzymes or enzyme systems.
- BNCs are magnetically trapped at the surface of the powders or 3D printed objects.
- the modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process.
- Composite powders may also be optimized for flowability.
- 3D objects can be printed to optimize flow within to be used in flow reactors.
- 3D objects and composite powders can be washed from the BNCs by an acid wash, rinsed with water, and then re-functionalized with fresh BNCs.
- Highly magnetic scaffolds are designed to immobilize, stabilize and optimize any BNCs containing enzymes. This includes full enzyme systems at high loading and full activity for the production of small molecules. By combining natural or engineered enzymes, and in some embodiments with cofactor recycling systems, the scaffolds allow one to scale up biocatalysis to innovations to manufacturing scale and production.
- thermoplastics with magnetic particles to form powders that may be single-layered or multiple-layered materials that hold the BNCs.
- Such designed objects may be produced using 3D printing by sintering composite magnetic powders.
- SLS Selective Laser Sintering
- the modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process.
- MMP made of thermoplastic and magnetic materials of the invention can take the form of magnetic powders that are suitable for flow chemistry application. These powders can be 3D printed by SLS as structures, as functional objects, or as flow cells or plate reactors. High surface areas allow one to maximize the enzyme loading and flow can be engineered within the materials to enable biocatalysis at maximal productivity.
- SLS can be used to process nearly any kind of material from metals, ceramics, plastics, and combinations thereof, for tailor-made composite materials. It is critical, however, that the material is available in fine powder form and that the powder particles are operative to fuse when exposing them to heat (Kruth et al., Assembly Automation 23(4):357-371(2003), incorporated by reference herein in its entirety.
- the addition of a sacrificial binder can make this process still feasible for that material.
- polymers are used as sacrificial binders in order to expand the range of materials suitable for this technology. After sintering, the sacrificial binder can be either removed by thermal decomposition or kept as part of the composition.
- This concept applies to magnetite that loses its permanent magnetic properties above 585° C. This is significantly lower than its melting temperature (1538° C.).
- Another advantage of using a polymeric matrix to incorporate magnetite particles is that the former can act as a protective barrier to prevent oxidation and corrosion as well as aiding to disperse the magnetite particles. Also, magnetite can mechanically reinforce the polymer. (Shishkovsky et al., Microelectronic Engineering 146:85-91 (2015), incorporated by reference herein in its entirety).
- Laser sintering of plastic parts is one of two additive manufacturing processes used for Rapid Manufacturing (Wegner, Physics Procedia 83:1003-1012 (2016), incorporated by reference herein in its entirety).
- Polymer properties that determine its capability to be sintered and produce good quality 3D objects. These include structural properties such crystalline structure (i.e. thermal properties such as Tm, Tg, and Tc), mechanical properties (Young's modulus and elongation at break, etc.), density, particle size, and shape.
- the temperature-processing window is determined from the difference between the melting and crystallization temperatures of the polymer.
- nylon 12 PA 12
- PA 12 nylon 12
- a low polymer crystallization rate is desired together with a melt index that provides a suitable rheology and surface tension.
- the bulk density, particle shape, and size distribution of the powder are key factors (Wegner, Physics Procedia 83:1003-1012 (2016), incorporated by reference herein in its entirety). It has been determined that the in certain embodiments, the optimal particle size range is about 40 to about 90 microns. Smaller particles prevent flowability and their rapid vaporization is detrimental to the optical sensors of the sintering device. This can fog the device and lead to inaccurately sintered parts (Goodridge et al. Materials Science 57:229-267 (2012), incorporated by reference herein in its entirety).
- the powders should have good flowing properties and preferably an approximately round particle shape. This allows good powder spreading during the process. High heat conductivity of the material is desired at the CO 2 laser beam wavelength (10.6 microns).
- additives such as high-energy absorption materials, e.g. carbon black, to improve heat absorption, and fume silica nanoparticles (talc) to aid the particle flowability with irregularly-shaped particles.
- additive manufacturing also referred to as 3D printing
- 3D printing involves manufacturing a part by depositing material layer-by-layer. This differs from conventional processes such as subtractive processes (i.e., milling or drilling), formative processes (i.e., casting or forging), and joining processes (i.e., welding or fastening).
- subtractive processes i.e., milling or drilling
- formative processes i.e., casting or forging
- joining processes i.e., welding or fastening
- 3D printing a valuable tool for both prototyping and industrial manufacturing.
- the three most common types of 3D printers are fused filament fabrication, stereolithography, and selective laser sintering.
- FFF Fused filament fabrication
- PLA polylactic acid
- ABS acrylonitrile butadiene styrene
- Stereolithography uses a laser to polymerize photosensitive resins. Uncured liquid resin is placed in a vat where a laser is used to cure resin into solid plastic and build the object layer by layer. SLA printers have a much higher resolution than FFF printers due to the fine spot size of the laser and thus can print intricate features and complex shapes. The resins, however, are more expensive than filaments and completed prints currently require post processing with solvents to optimize the surface finish and material characteristics.
- SLS Selective laser sintering
- CAD computer-aided design
- STL stereolithography
- SLS provides advantages for printing objects with magnetic properties that can be used for immobilizing BNCs. This is because the printing process creates porosity and a high surface area.
- the surrounding, unsintered powder acts as a natural support that eliminates the need for dedicated support structures.
- the lack of support structures allows for complex geometries that would otherwise be impossible to manufacture using alternative 3D printing methods.
- the nature of sintering itself creates macro and microporous volumes.
- the laser flashes thermoplastic crystalline thermoplastic powders (e.g. Polypropylene, polystyrene) between their glass transition temperature and melting temperature to generate stiff parts.
- powders are sintered in place to form small bonds amongst themselves.
- the low-density powders trap air in their structures resulting in remarkable porosity and surface area in three dimensions. These pores increase the surface area for enzyme immobilization.
- the invention has many benefits over the prior art. It enables the efficient and economical production of glycans, such as complex polysaccharides, including but not limited to, HMOs using enzymes captured in modular flow processing cells.
- the flow cells may contain materials having large macropores or a high magnetic surface area for BNC immobilization.
- Flexible compositions for sintered magnetic scaffolds can be made with any meltable thermoplastics and magnetic material composition.
- the flow cells can have one or multiple enzyme systems that may be pieced together for particular sugar manufacturing processes.
- Biocatalytic flow cells are scaffolds containing immobilized enzymes for use in reactors such as continuous stirred tank reactors (CSTRs) and packed bed reactors (PBRs). Both types of reactors are known in the art but are primarily chosen based on the type of immobilization used. With a total market value of $5.8B in 2010, immobilized enzymes are used in a diverse range of large-scale processes including high fructose corn syrup production (10 7 tons/year), transesterification of food oils (10 5 tons/year), biodiesel synthesis (10 4 tons/year), and chiral resolution of alcohols and amines (10 3 tons/year) (DiCosimo et al., Chem.
- the methods of this invention employ biocatalytic systems for small-to-large scale manufacturing using BNCs in scaffolds that are shaped by 3D printing.
- the biocatalytic systems are continuous flow.
- Scaffolds may comprise cross-linked water-insoluble polymers and an approximately uniform distribution of embedded magnetic microparticles (MMP).
- the scaffolds may contain thermoset resins including Epoxy resins, Polyesters, Polyurethanes, Melamine resins, Vinyl esters, Silicones (polysiloxanes), Furan resins, Polyurea, Phenolic resins, phenol-formaldehyde, Urea-formaldehyde, Diallyl-phthalate (DAP), Benzoxazine, Polyimides and bismaleimides, Cyanate esters can be used.
- thermoset resins including Epoxy resins, Polyesters, Polyurethanes, Melamine resins, Vinyl esters, Silicones (polysiloxanes), Furan resins, Polyurea, Phenolic resins, phenol-formaldehyde, Urea-formaldehyde, Diallyl-phthalate (DAP), Benzoxazine, Polyimides and bismaleimides
- the scaffold technology disclosed herein allows one to quickly translate innovation in biocatalysis to innovation in production for batch and flow processes.
- the magnetic powders are suitable for use flow chemistry applications such as pack-bed reactors.
- Level 1 is the self-assembly of enzymes with magnetic nanoparticles (MNP) for the synthesis of magnetic mesoporous nanoclusters. This level uses a mechanism of molecular self-entrapment to immobilize and stabilize enzymes.
- Level 2 is the stabilization of the MNPs into other matrices.
- Level 3 is product conditioning and packaging for Level 1+2 delivery.
- BNC bionanocatalyst
- MNPs allow for a broader range of operating conditions such as temperature, ionic strength and pH.
- the size and magnetization of the MNPs affect the formation and structure of the NPs, all of which have a significant impact on the activity of the entrapped enzymes.
- MNPs can be used as improved enzymatic or catalytic agents where other such agents are currently used. Furthermore, they can be used in other applications where enzymes have not yet been considered or found applicable.
- the BNC contains mesopores that are interstitial spaces between the magnetic nanoparticles.
- the enzymes are preferably embedded or immobilized within at least a portion of mesopores of the BNC.
- magnetic encompasses all types of useful magnetic characteristics, including permanent magnetic, superparamagnetic, paramagnetic, ferromagnetic, and ferrimagnetic behaviors.
- the magnetic nanoparticle or BNC has a size in the nanoscale, i.e., generally no more than 500 nm.
- size can refer to a diameter of the magnetic nanoparticle when the magnetic nanoparticle is approximately or substantially spherical. In a case where the magnetic nanoparticle is not approximately or substantially spherical (e.g., substantially ovoid or irregular), the term “size” can refer to either the longest the dimension or an average of the three dimensions of the magnetic nanoparticle. The term “size” may also refer to an average of sizes over a population of magnetic nanoparticles (i.e., “average size”).
- the magnetic nanoparticle has a size of precisely, about, up to, or less than, for example, 500 nm, 400 nm, 300 nm, 200 nm, 100 nm, 50 nm, 40 nm, 30 nm, 25 nm, 20 nm, 15 nm, 10 nm, 5 nm, 4 nm, 3 nm, 2 nm, or 1 nm, or a size within a range bounded by any two of the foregoing exemplary sizes.
- the individual magnetic nanoparticles can be considered to be primary nanoparticles (i.e., primary crystallites) having any of the sizes provided above.
- the aggregates of nanoparticles in a BNC are larger in size than the nanoparticles and generally have a size (i.e., secondary size) of at least about 5 nm.
- the aggregates have a size of precisely, about, at least, above, up to, or less than, for example, 5 nm, 8 nm, 10 nm, 12 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 200 nm, 300 nm, 400 nm, 500 nm, 600 nm, 700 nm, or 800 nm, or a size within a range bounded by any two of the foregoing exemplary sizes.
- the primary and/or aggregated magnetic nanoparticles or BNCs thereof have a distribution of sizes, i.e., they are generally dispersed in size, either narrowly or broadly dispersed. In different embodiments, any range of primary or aggregate sizes can constitute a major or minor proportion of the total range of primary or aggregate sizes.
- a particular range of primary particle sizes (for example, at least about 1, 2, 3, 5, or 10 nm and up to about 15, 20, 25, 30, 35, 40, 45, or 50 nm) or a particular range of aggregate particle sizes (for example, at least about 5, 10, 15, or 20 nm and up to about 50, 100, 150, 200, 250, or 300 nm) constitutes at least or above about 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% of the total range of primary particle sizes.
- a particular range of primary particle sizes (for example, less than about 1, 2, 3, 5, or 10 nm, or above about 15, 20, 25, 30, 35, 40, 45, or 50 nm) or a particular range of aggregate particle sizes (for example, less than about 20, 10, or 5 nm, or above about 25, 50, 100, 150, 200, 250, or 300 nm) constitutes no more than or less than about 50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% of the total range of primary particle sizes.
- the aggregates of magnetic nanoparticles i.e., “aggregates” or BNCs thereof can have any degree of porosity, including a substantial lack of porosity depending upon the quantity of individual primary crystallites they are made of.
- the aggregates are mesoporous by containing interstitial mesopores (i.e., mesopores located between primary magnetic nanoparticles, formed by packing arrangements).
- the mesopores are generally at least 2 nm and up to 50 nm in size.
- the mesopores can have a pore size of precisely or about, for example, 2, 3, 4, 5, 10, 12, 15, 20, 25, 30, 35, 40, 45, or 50 nm, or a pore size within a range bounded by any two of the foregoing exemplary pore sizes. Similar to the case of particle sizes, the mesopores typically have a distribution of sizes, i.e., they are generally dispersed in size, either narrowly or broadly dispersed. In different embodiments, any range of mesopore sizes can constitute a major or minor proportion of the total range of mesopore sizes or of the total pore volume.
- a particular range of mesopore sizes (for example, at least about 2, 3, or 5, and up to 8, 10, 15, 20, 25, or 30 nm) constitutes at least or above about 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% of the total range of mesopore sizes or of the total pore volume.
- a particular range of mesopore sizes (for example, less than about 2, 3, 4, or 5 nm, or above about 10, 15, 20, 25, 30, 35, 40, 45, or 50 nm) constitutes no more than or less than about 50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% of the total range of mesopore sizes or of the total pore volume.
- the magnetic nanoparticles can have any of the compositions known in the art.
- the magnetic nanoparticles are or include a zerovalent metallic portion that is magnetic.
- Some examples of such zerovalent metals include cobalt, nickel, and iron, and their mixtures and alloys.
- the magnetic nanoparticles are or include an oxide of a magnetic metal, such as an oxide of cobalt, nickel, or iron, or a mixture thereof.
- the magnetic nanoparticles possess distinct core and surface portions.
- the magnetic nanoparticles may have a core portion composed of elemental iron, cobalt, or nickel and a surface portion composed of a passivating layer, such as a metal oxide or a noble metal coating, such as a layer of gold, platinum, palladium, or silver.
- a passivating layer such as a metal oxide or a noble metal coating, such as a layer of gold, platinum, palladium, or silver.
- metal oxide magnetic nanoparticles or aggregates thereof are coated with a layer of a noble metal coating.
- the noble metal coating may, for example, reduce the number of charges on the magnetic nanoparticle surface, which may beneficially increase dispersibility in solution and better control the size of the BNCs.
- the noble metal coating protects the magnetic nanoparticles against oxidation, solubilization by leaching or by chelation when chelating organic acids, such as citrate, malonate, or tartrate are used in the biochemical reactions or processes.
- the passivating layer can have any suitable thickness, and particularly, at least, up to, or less than, about for example, 0.1 nm, 0.2 nm, 0.3 nm, 0.4 nm, 0.5 nm, 0.6 nm, 0.7 nm, 0.8 nm, 0.9 nm, 1 nm, 2 nm, 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, or 10 nm, or a thickness in a range bounded by any two of these values.
- Non-limiting examples comprise ferromagnetic and ferromagnetic materials including ores such as iron ore (magnetite or lodestone), cobalt, and nickel.
- rare earth magnets are used.
- Non-limiting examples include neodymium, gadolinium, sysprosium, samarium-cobalt, neodymium-iron-boron, and the like.
- the magnets comprise composite materials.
- Non-limiting examples include ceramic, ferrite, and alnico magnets.
- the magnetic nanoparticles have an iron oxide composition.
- the iron oxide composition can be any of the magnetic or superparamagnetic iron oxide compositions known in the art, e.g., magnetite (Fe 3 O 4 ), hematite ( ⁇ -Fe 2 O 3 ), maghemite ( ⁇ -Fe 2 O 3 ), or a spinel ferrite according to the formula AB 2 O 4 , wherein A is a divalent metal (e.g., Xn 2 +, Ni 2 +, Mn 2+ , Co 2+ , Ba 2+ , Sr 2+ , or combination thereof) and B is a trivalent metal (e.g., Fe 3+ , Cr 3+ , or combination thereof).
- A is a divalent metal (e.g., Xn 2 +, Ni 2 +, Mn 2+ , Co 2+ , Ba 2+ , Sr 2+ , or combination thereof)
- B is a trivalent metal (e.g., Fe 3+ , Cr 3+ , or combination thereof).
- the individual magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable degree of magnetism.
- the magnetic nanoparticles, BNCs, or BNC scaffold assemblies can possess a saturated magnetization (Ms) of at least or up to about 5, 10, 15, 20, 25, 30, 40, 45, 50, 60, 70, 80, 90, or 100 emu/g.
- the magnetic nanoparticles, BNCs, or BNC-scaffold assemblies preferably possess a permanent magnetization (Mr) of no more than (i.e., up to) or less than 5 emu/g, and more preferably, up to or less than 4 emu/g, 3 emu/g, 2 emu/g, 1 emu/g, 0.5 emu/g, or 0.1 emu/g.
- Mr permanent magnetization
- the surface magnetic field of the magnetic nanoparticles, BNCs, or BNC-scaffold assemblies can be about or at least, for example, about 0.5, 1, 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 Gauss (G), or a magnetic field within a range bounded by any two of the foregoing values. If microparticles are included, the microparticles may also possess any of the above magnetic strengths.
- the magnetic nanoparticles or aggregates thereof can be made to adsorb a suitable amount of enzyme, up to or below a saturation level, depending on the application, to produce the resulting BNC.
- the magnetic nanoparticles or aggregates thereof may adsorb about, at least, up to, or less than, for example, 1, 5, 10, 15, 20, 25, or 30 pmol/m2 of enzyme.
- the magnetic nanoparticles or aggregates thereof may adsorb an amount of enzyme that is about, at least, up to, or less than, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of a saturation level.
- the magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable pore volume.
- the magnetic nanoparticles or aggregates thereof can possess a pore volume of about, at least, up to, or less than, for example, about 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1 cm3/g, or a pore volume within a range bounded by any two of the foregoing values.
- the magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable specific surface area.
- the magnetic nanoparticles or aggregates thereof can have a specific surface area of about, at least, up to, or less than, for example, about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 m 2/g.
- the magnetic macroporous matrix material for use according to this invention has a size of precisely, about, up to, or less than, for example, 100-1000, 50-100, 10-50 ⁇ m, or 5-10, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, less than 5, greater than 100, an average size of 150, an average size of 75, an average size of 40, an average size of 20 or an average size of about 15.
- the material has an average particle diameter of precisely, about, up to, or less than, 20-40 ⁇ m, 20 ⁇ m, or 40 ⁇ m.
- the material has a tight size distribution of an average particle diameter of either 20 ⁇ m or 40 ⁇ m.
- the methods described herein use recombinant cells that express the enzymes used in the invention.
- Recombinant DNA technology is known in the art.
- cells are transformed with expression vectors such as plasmids that express the enzymes.
- the vectors have one or more genetic signals, e.g., for transcriptional initiation, transcriptional termination, translational initiation and translational termination.
- nucleic acids encoding the enzymes may be cloned in a vector so that they are expressed when properly transformed into a suitable host organism.
- Suitable host cells may be derived from bacteria, fungi, plants, or animals as is well-known in the art.
- BNCs (Level 1) provide the bulk of enzyme immobilization capability, they are sometimes too small to be easily captured by standard-strength magnets.
- sub-micrometric magnetic materials (Level 2) are used to provide bulk magnetization and added stability to Level 1.
- Commercially available free magnetite powder with particle sizes ranging from 50-500 nm, is highly hydrophilic and tends to stick to plastic and metallic surfaces, which, over time, reduces the effective amount of enzyme in a given reactor system.
- powdered magnetite is extremely dense, thus driving up shipping costs. It is also rather expensive—especially at particle sizes finer than 100 nm.
- low-density hybrid materials consisting of magnetite, non-water-soluble cross-linked polymers such as poly(vinylalcohol) (PVA) and carboxymethylcellulose (CMC), have been developed. These materials are formed by freeze-casting and freeze-drying water-soluble polymers followed by cross-linking. These materials have reduced adhesion to external surfaces, require less magnetite, and achieve Level 1 capture that is at least comparable to that of pure magnetite powder.
- PVA poly(vinylalcohol)
- CMC carboxymethylcellulose
- the continuous macroporous scaffold has a cross-linked polymeric composition.
- the polymeric composition can be any of the solid organic, inorganic, or hybrid organic-inorganic polymer compositions known in the art, and may be synthetic or a biopolymer that acts as a binder.
- the polymeric s scaffold does not dissolve or degrade in water or other medium in which the hierarchical catalyst is intended to be used.
- synthetic organic polymers include the vinyl addition polymers (e.g., polyethylene, polypropylene, polystyrene, polyacrylic acid or polyacrylate salt, polymethacrylic acid or polymethacrylate salt, poly(methylmethacrylate), polyvinyl acetate, polyvinyl alcohol, and the like), fluoropolymers (e.g., polyvinylfluoride, polyvinylidenefluoride, polytetrafluoroethylene, and the like), the epoxides (e.g., phenolic resins, resorcinol-formaldehyde resins), the polyamides, the polyurethanes, the polyesters, the polyimides, the polybenzimidazoles, and copolymers thereof.
- vinyl addition polymers e.g., polyethylene, polypropylene, polystyrene, polyacrylic acid or polyacrylate salt, polymethacrylic acid or polymethacrylate salt, poly(methylmethacrylate),
- biopolymers include the polysaccharides (e.g., cellulose, hemicellulose, xylan, chitosan, inulin, dextran, agarose, and alginic acid), polylactic acid, and polyglycolic acid.
- the cellulose may be microbial- or algae-derived cellulose.
- inorganic or hybrid organic-inorganic polymers include the polysiloxanes (e.g., as prepared by sol gel synthesis, such as polydimethylsiloxane) and polyphosphazenes.
- any one or more classes or specific types of polymer compositions provided above are excluded as macroporous scaffolds.
- the 3D model is an electronic file.
- compositions and methods may be used in the embodiments of this invention to immobilize an enzyme.
- a biocatalytic process for preparing a saccharide-acceptor comprising the steps of:
- a process for preparing a saccharide compound comprising the steps of:
- a process for preparing a saccharide compound comprising the steps of:
- a process for galactosylation of an acceptor compound comprising the steps of:
- a process for sialylation of an acceptor compound comprising the steps of:
- a process for fucosylation of an acceptor compound comprising the steps of:
- a process for producing LNT and fructose comprising the step of contacting LNTII, sucrose, a transferase, a sucrose synthase, an epimerase, and UDP to produce LNT and fructose, wherein galactose-UDP is produced, and wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or the sucrose.
- a process for producing LNnT and fructose comprising contacting LNTII, sucrose, a glycosyltransferase, a sucrose synthase, an epimerase, and UDP to produce LNnT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or sucrose.
- a process for preparing LNT and fructose comprising the steps of contacting GlcNAc, 2-chloro-1,3-dimethylimidazolinium chloride, and a base to obtain a reaction mixture comprising GlcNAc-Oxa; and contacting the reaction mixture comprising GlcNAc-Oxa, lactose, sucrose, an aminidase, a transferase, a sucrose synthase, and an epimerase, to provide LNT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10% molar percent of the lactose or the sucrose.
- a process for preparing lactose and fructose comprising contacting glucose, sucrose, a lactose synthase, a sucrose synthase, an epimerase, and UDP, to provide lactose and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the glucose and or the sucrose.
- a process for preparing LSTa, galactose, and glucose comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide LSTa, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- a process for preparing LSTc, galactose, and glucose comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTc, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- a process for preparing LSTd, galactose, and glucose comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTd, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- a process for preparing DSLNT, galactose, and glucose comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide DSLNT, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10% molar percent of the 3′-SL.
- a process for preparing LNFPI, galactose, and glucose comprising contacting 2′-FL, LNT, GDP, Te2FT, HmFucT, and lactase to provide LNFPI, galactose, and glucose wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- a process for preparing LNFPII, galactose, and glucose comprising contacting 2′-FL, LNT, GDP, Hp34FT, HmFucT, and lactase, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- a process for preparing LNFPIII, galactose, and glucose comprising contacting 2′-FL, LNnT, GDP, FUT9, HmFucT, and lactase, to provide LNFPIII, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- LNnT prepared by the process according to any one of embodiments 1-7, 14-16, 21-30, and 47-49.
- LSTa prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 33-34, and 47-49.
- LSTc prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 35-36, and 47-49.
- LSTd prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 37-38, and 47-49.
- DSLNT prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 39-40, and 47-49.
- LNFPI prepared by a process according to any one of embodiments 1-4, 10-15, 41-42, and 47-49.
- LNFPII prepared by a process according to any one of embodiments 1-4, 10-16, 43-44, and 47-49.
- LNFPIII prepared by a process according to any one of embodiments 1-7, 10-16, and 45-49.
- a lactose derivative prepared by a process according to any one of embodiments 1-7, 14-16, and 47-49.
- the lactose derivative according to embodiment 62 selected from Lactobionic Acid, Lactitol, Lactosucrose, Galacto-oligosaccharides, Lactulose, and a HMO.
- 64. A compound prepared by a process according to any one of embodiments 1-49, wherein the compound is obtained from non-animal based plant materials.
- a method for producing a glycosylated principal product comprising the steps of:
- a method for producing a glycosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- the sugar donor precursor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine.
- sugar-nucleotide donor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine
- sugar-nucleotide donor is a galactosyl-nucleotide, sialyl-nucleotide, fucosyl-nucleotide, or N-acetylglucosaminyl-nucleotide.
- nucleotide is a uridine diphosphate, cytidine monophosphate, or guanosine diphosphate.
- nucleotide is in an amount of 0.001 mol percent to 10 mol percent relative to the sugar donor precursor or the acceptor.
- nucleotide is in an amount of 0.01 mol percent to 1 mol percent relative to the sugar donor precursor or the acceptor.
- transferase is a ⁇ -1,3-galactosyl transferase, sucrase synthase, ⁇ -1,4-galactosyl transferase, sialyl transferase, fucosyl transferase, or glucosaminyl (N-acetyl) transferase 2.
- a method for producing a galactosylated principal product comprising the steps of:
- a method for producing a galactosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- auxiliary enzyme is a galactose epimerase.
- a method for producing a sialylated principal product comprising the steps of:
- a method for producing a sialylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a sialylated principal product and a secondary product.
- nucleotide is cytidine monophosphate
- first transferase beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase (ST3GAL3) or Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) and second transferase is CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (ST3GAL4).
- first transferase is beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase
- a method for producing a fucosylated principal product comprising the steps of:
- a method for producing a fucosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a fucosylated principal product and a secondary product.
- first transferase is ⁇ -1,2-fucosyltransferase from Thermosynechococcus vestitus (Te2FT), fucosyl transferase 9 (FUT9) or fucosyl transferase 3 (FUT3) and second transferase is ⁇ -1,2-fucosyltransferase from Helicobacter mustelae (HmFucT) or fucosyl transferase (FUT1).
- first transferase is ⁇ -1,2-fucosyltransferase from Thermosynechococcus vestitus (Te2FT), fucosyl transferase 9 (FUT9) or fucosyl transferase 3 (FUT3)
- second transferase is ⁇ -1,2-fucosyltransferase from Helicobacter mustelae (HmFucT) or fucosyl transferase (FUT1).
- a method for producing a N-acetylglucosaminylated principal product comprising the steps of:
- a method for producing a N-acetylglucosaminylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a N-acetylglucosaminylated principal product and a secondary product.
- first transferase is glucosaminyl (N-acetyl) transferase 2 (GCNT2) and second transferase is ⁇ -1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- first transferase is glucosaminyl (N-acetyl) transferase 2 (GCNT2)
- second transferase is ⁇ -1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- a N-acetylglucosaminylated compound prepared according to any one of embodiments 1-25, 67-78, or 79-81.
- lactose derivative according to claim 87 selected from lactobionic acid, lactitol, lactosucrose, galacto-oligosaccharides, lactulose, and an HMO.
- the following chemicals reagents are used to synthesize the carbohydrates, glycans or human milk oligosaccarides: Sucrose (Carbosynth: OS02339), Glucose ( ⁇ -D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine 5′-monophosphate disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), GDP (Guanosine 5′-diphosphate disodium salt; Carbosynth: NG09782), 2′-Fucosyllactose (2′-FL; Carbosynth: OF06739), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate
- ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, B3GNT2, FUT9 and ST6GalNAc5 are purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase is purchased from Sunson Enzymes, and human a-lactalbumin is purchased from Athens Research & Technology.
- SuSy (Sucrose synthase; source: Glycine Max ), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum ), NmLgtB ( ⁇ -1,4-Galactosyltransferase; source: Neisseria meningitidis ), Cv ⁇ 3GalT ( ⁇ -1,3-galactosyl transferase; source: Chromobacterium violaceum ), Te2FT ( ⁇ -1,2-fucosyltransferase; source: Thermosynechococcus vestitus ), HmFucT ( ⁇ -1,2-fucosyltransferase; source: Helicobacter mustelae ), and Hp34FT ( ⁇ 1-3/4-fucosyltransferase; source: Helicobacter pylori ) are produced in-house recombinantly in E.
- the enzymes are purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer is exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes are supplemented with 10% (w/w) glycerol and frozen at ⁇ 80° C. for storage.
- the plasmids used for protein expression are produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- Reagents and materials The following chemicals reagents were used to synthesize Lactose, LSTa and LNT: Sucrose (Carbosynth: OS02339), Glucose ( ⁇ -D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Tris (TRIS, 1.0M buffer solution, pH 7.5; Alfa Aesar: J62993AP), HEPES (Thermo Scientific: AAA1477730), PIPES (Thermo Scientific: AC172615000
- ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, B3GNT2, FUT9 and ST6GalNAc5 were purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase was purchased from Sunson Enzymes, and human a-lactalbumin was purchased from Athens Research & Technology.
- SuSy (Sucrose synthase; source: Glycine max ), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum ), NmLgtB ( ⁇ -1,4-Galactosyltransferase; source: Neisseria meningitidis ), Cv ⁇ 3GalT ( ⁇ -1,3-galactosyl transferase; source: Chromobacterium violaceum ), Te2FT ( ⁇ -1,2-fucosyltransferase; source: Thermosynechococcus vestitus ), HmFucT ( ⁇ -1,2-fucosyltransferase; source: Helicobacter mustelae ), and Hp34FT ( ⁇ 1-3/4-fucosyltransferase; source: Helicobacter pylori ) were produced in-house recombinantly in E.
- the enzymes were purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer was exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes were supplemented with 10% (w/w) glycerol and frozen at ⁇ 80° C. for storage.
- the plasmids used for protein expression were produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- Example 2a Production of LNT, LNnT, and Lactose Via Galactosylation
- the target glycans may be synthesized step-by-step by sequentially combining below examples.
- the target glycans may be synthesized from any advanced glycan building block.
- LNT is produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, SuSy and GalE ( FIG. 1 B ).
- the reaction mixture is composed of 25 mM LNTII, 50 mM sucrose, 5 mM UDP, 400 ⁇ g/ml SuSy, 800 ⁇ g/ml Cvb3GalT, 400 ⁇ g/m1GalE and 10 mM MgCl 2 in 50 mM Tris pH 7.0 at 37° C.
- LNnT is produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB or B4GALT1, SuSy and GalE ( FIG. 1 C ).
- the reaction mixture is composed of 25 mM LNTII, 50 mM sucrose, 0.1-10 mM UDP, 400 ⁇ g/ml SuSy, 800 ⁇ g/ml Cvb3GalT, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- Lactose is produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes B4GALT1, ⁇ -lactalbumin, SuSy and GalE ( FIG. 1 E ).
- the reaction mixture is composed of 25 mM Glucose, 100 mM sucrose, 0.1-10 mM UDP, 100 ⁇ g/ml B4GALT1, 100 ⁇ g/ml ⁇ -lactalbumin, 400 ⁇ g/ml SuSy, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- GOS is produced from sucrose and catalytic amounts of UDP using the three enzymes ⁇ -1,4-galactosyltransferase, SuSy and GalE ( FIG. 1 F ).
- the reaction mixture is composed of 2 M sucrose, 0.1-10 mM UDP, 400 ⁇ g/ml SuSy, 800 ⁇ g/ml ⁇ -1,4-galactosyltransferase, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- Example 2b Production of LSTa, LSTc, LSTd, and DSLNT. Sialylation
- LSTa is produced from LNT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase ( FIG. 2 A ).
- the reaction mixture is composed of 25 mM LNT, 30 mM 3′-SL, 0.1-10 mM CMP, 100 ⁇ g/ml ST3GAL4, 150 ⁇ g/ml ST3GAL3, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LSTc is produced from LNnT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST6GAL1 and Lactase ( FIG. 2 B ).
- the reaction mixture is composed of 25 mM LNnT, 30 mM 3′-SL, 0.1-10 mM CMP, 400 ⁇ g/ml ST3GAL4, 400 ⁇ g/ml ST6GAL1, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LSTd is produced from LNnT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase ( FIG. 2 C ).
- the reaction mixture is composed of 25 mM LNnT, 30 mM 3′-SL, 0.1-10 mM CMP, 400 ⁇ g/ml ST3GAL4, 400 ⁇ g/ml ST3GAL3, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- DSLNT is produced from LNT, 3′-SL, and catalytic amounts of CMP using the four enzymes ST3GAL4, ST3GAL3, ST6GALNAC5 and Lactase ( FIG. 2 D ).
- the reaction mixture is composed of 25 mM LNT, 60 mM 3′-SL, 0.1-10 mM CMP, 400 ⁇ g/ml ST3GAL4, 400 ⁇ g/ml ST3GAL3, 400 ⁇ g/ml ST6GALNAC5, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LNFPI is produced from LNT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, Te2FT and Lactase ( FIG. 3 A ).
- the reaction mixture is composed of 25 mM LNT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Te2FT, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LNFPII is produced from LNT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, Hp34FT or FUT5, and Lactase ( FIG. 3 B ).
- the reaction mixture is composed of 25 mM LNT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Hp34FT or FUT5, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LNFPIII is produced from LNnT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, FUT9 and Lactase ( FIG. 3 C ).
- the reaction mixture is composed of 25 mM LNnT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml FUT9, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- LNT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, SuSy and GalE ( FIG. 1 B ).
- the reaction mixture was composed of 25 mM LNTII, 50 mM sucrose, 5 mM UDP, 400 ⁇ g/ml SuSy, 800 ⁇ g/ml Cvb3GalT, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 50 mM Tris pH 7.0 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Thermo Vanquish, Trinity P1 column, charged aerosol detector). Conversions of 10.6%, 37.4% and 77.7% were observed at 0.5 hr, 1 hr and 17 hrs, respectively.
- Lactose was produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes B4GALT1, ⁇ -lactalbumin, SuSy and GalE ( FIG. 1 E ) in a four-steps process.
- step one the lactose synthase complex was assembled in the mixture composed of 25 mM Glucose, 200 ⁇ g/ml B4GALT1, 80 ⁇ g/ml ⁇ -lactalbumin, 10 mM MnCl2, 1 mM CaCl2, and 50 mM HEPES pH 6.8, incubated at 4° C. for 1 hour.
- step two UDP-galactose was synthesized in a s reaction mixture composed of 100 ⁇ g/ml SuSy, 100 ⁇ g/ml GalE, 6 mM UDP, 50 mM Sucrose and 10 mM MnCl2 in 50 mM HEPES pH 6.8, incubated for 1 hour at 37° C.
- step three equal volumes of the two mixtures from step one and step two were combined and incubated at 4° C. for 30 minutes. In this, the UDP-galactose produced in step two was used to stabilize the lactose synthase complex.
- step four the reaction mixture was transferred to 37° C. to facilitate the conversion of glucose to lactose.
- LSTa was produced from LNT, 3′-SL, and catalytic amounts of CMP using
- the reaction mixture was composed of 25 mM LNT, 30 mM 3′-SL, 5 mM CMP, 100 ⁇ g/ml ST3GAL4, 150 ⁇ g/ml ST3GAL3, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 50 mM Tris pH 7.0 at 37° C. Conversion from LNT to LSTa was monitored by HPLC (Thermo Vanquish, Trinity P1 column, charged aerosol detector). A conversion of approximately 5% was observed after 21 hours.
- glycans or human milk oligosaccarides Sucrose (Carbosynth: OS02339), Glucose ( ⁇ -D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), GDP (Guanosine 5′-diphosphate disodium salt; Carbosynth: NG09782), 2′-Fucosyllactose (2′-FL; Carbosynth: OF06739), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Lacto-N-biose (LNB; Chemily
- Mammalian enzymes ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, GCNT2, B3GNT2, FUT1, FUT3, FUT9 and ST6GalNAc5 are purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase is purchased from Sunson Enzymes, and human a-lactalbumin is purchased from Athens Research & Technology.
- SuSy (Sucrose synthase; source: Glycine max ), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum ), NmLgtB ( ⁇ -1,4-Galactosyltransferase; source: Neisseria meningitidis ), NmLgtA ( ⁇ -1,3-N-Acetyl-Hexosaminyl-transferase; source: Neisseria meningitidis ), Cv ⁇ 3GalT ( ⁇ -1,3-galactosyl transferase; source: Chromobacterium violaceum ), Te2FT ( ⁇ -1,2-fucosyltransferase; source: Thermosynechococcus vestitus ), HmFucT ( ⁇ -1,2-fucosyltransferase; source: Helicobacter mustelae ), GsAI (D-Galactose is
- the enzymes are purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer is exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes are supplemented with 10% (w/w) glycerol and frozen at ⁇ 80° C. for storage.
- the plasmids used for protein expression are produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- Lactose LNT and LNnT: Sucrose (Carbosynth: OS02339), Glucose ( ⁇ -D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Sodium Phosphate Dibasic Heptahydrate (Fisher Chemical: S373-500) and MgCl 2 (Magnesium Chloride; Cell Fine Chemicals: 595804). All water was obtained from a BarnStead Nanopure water purifier (Thermo Scientific, 18.5 MOhm-cm). LNTII was produced in-house from lactose.
- AtSuSy1 (Sucrose synthase; source: Arabidopsis thaliana ), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum ), NmLgtB ( ⁇ -1,4-Galactosyltransferase; source: Neisseria meningitidis ) and Cv ⁇ 3GalT galactosyl transferase; source: Chromobacterium violaceum ) were produced in-house recombinantly in E. coli (BL21/DE3).
- the enzymes were purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer was exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes were supplemented with 10% (w/w) glycerol and frozen at ⁇ 80° C. for storage.
- the plasmids used for protein expression were produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- Example 5a Fucosylation to Produce LNFPI, LNFPII, LNFPIII, DFL, and 3-FL
- LNFPI is produced from LNT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, Te2FT, Lactase and GsAI ( FIG. 11 A ).
- the reaction mixture is composed of 25 mM LNT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Te2FT, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- LNFPII is produced from LNT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, Hp34FT, Lactase and GsAI ( FIG. 11 B ).
- the reaction mixture is composed of 25 mM LNT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Hp34FT or FUT5, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- LNFPIII is produced from LNnT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, FUT9, Lactase and GsAI ( FIG. 11 C ).
- the reaction mixture is composed of 25 mM LNnT, 30 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml FUT9, 400 ⁇ g/ml lactase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- HP34FT Lactase and GsAI ( FIG. 11 D ).
- the reaction mixture is composed of mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Hp34FT, 400 ⁇ g/ml lactase, 400 ⁇ g/ml GsAI and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- 3-FL is produced from 2′-FL and catalytic amounts of GDP using the five enzymes HmFucT, HP34FT, Lactase, GsAI and Fucosidase ( FIG. 11 E ).
- the reaction mixture is composed of 50 mM 2′-FL, 0.1-10 mM GDP, 400 ⁇ g/ml HmFucT, 400 ⁇ g/ml Hp34FT, 400 ⁇ g/ml lactase, 400 ⁇ g/ml GsAI, 400 ⁇ g/ml Fucosidase and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- LNTII is produced from LNB, lactose, and catalytic amounts of UDP using the two enzymes NmLgtA, and GsAI ( FIG. 12 A ).
- the reaction mixture is composed of 25 mM LNB, 30 mM lactose, 0.1-10 mM UDP, 400 ⁇ g/ml NmLgtA and 400 ⁇ g/ml GsAI and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- ⁇ -1,6-GlcNAc-LNnT is produced from LNnT, LNB, and catalytic amounts of UDP using the three enzymes NmLgtA (or B3GNT2), GCNT2, and GsAI ( FIG. 12 B ).
- the reaction mixture is composed of 25 mM LNnT, 30 mM LNB, 0.1-10 mM UDP, 400 ⁇ g/ml NmLgtA, 400 ⁇ g/ml GCNT2 and 400 ⁇ g/ml GsAI and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C.
- LNT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, AtSuSy1, and GalE ( FIG. 9 B ).
- the reaction mixture was composed of 250 mM LNTII, 1.0 M sucrose, 1 mM UDP, 250 ⁇ g/ml AtSuSy1, 500 ⁇ g/ml Cvb3GalT, 500 ⁇ g/ml GalE and 10 mM MgCl 2 in 50 mM phosphate buffer pH 6.6 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Agilent 1100, amino column, evaporative light scattering detector). Conversion of 86% was observed after 16 hrs., 1 hr and 17 hrs.
- LNnT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB, AtSuSy1 and GalE ( FIG. 9 C ).
- the reaction mixture was composed of 500 mM LNTII, 1.0 M sucrose, 5 mM UDP, 400 ⁇ g/ml AtSuSy1, 200 ⁇ g/ml NmLgtB, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Agilent 1100, amino column, evaporative light scattering detector). Conversions of 36%, 64%, 77% and 96% were observed at 2 hrs, 4 hrs, 6 hrs. and 24 hrs., respectively resulting in the production of 500 mg of LNnT product.
- Lactose was produced from Glucose, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB, AtSuSy1 and GalE ( FIG. 9 E ).
- the reaction mixture was composed of 500 mM Glucose, 1.0 M sucrose, 5 mM UDP, 400 ⁇ g/ml NmLgtB, 400 ⁇ g/ml AtSuSy1, 400 ⁇ g/ml GalE and 10 mM MgCl 2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose was monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 50% was observed after 24 hrs. resulting in the production of 2.5 g of lactose product.
- Lactose is produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase) ( FIG. 9 F ).
- the reaction mixture is composed of 500 mM Glucose, 1.0 M sucrose, 5 mM UDP, 400 ⁇ g/ml NmLgtB, 400 ⁇ g/ml AtSuSy1, 400 ⁇ g/ml GalE, 400 ⁇ g/ml Glucose isomerase and 10 mM MgCl 2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose is monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 70% is observed after 24 hrs. resulting in the production (predicted) of 3.0 g of lactose product.
- Lactose is produced from Glucose, sucrose, fructose and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase) ( FIG. 9 G ).
- the reaction mixture is composed of 500 mM Glucose, 500 mM fructose, 500 mM sucrose, 5 mM UDP, 400 ⁇ g/ml NmLgtB, 400 ⁇ g/ml AtSuSy1, 400 ⁇ g/ml GalE, 400 ⁇ g/ml Glucose isomerase and 10 mM MgCl 2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose is monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 70% is observed after 24 hrs. resulting in the production (predicted) of 3.0 g of lactose product.
- LSTa was produced from LNT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase.
- the reaction mixture was composed of 5 mM LNT, 25 mM 3′-SL, 5 mM CMP, 300 ⁇ g/ml ST3GAL4, 300 ⁇ g/ml ST3GAL3, 300 ⁇ g/ml lactase and 20 mM MgCl 2 in 25 mM Phosphate pH 6.0 at 37° C.
- LSTa Formation of LSTa was confirmed by comparing it with the commercially purchased LSTa (purchased from Biosynth) via silica gel TLC using a butanol/water/acetic acid mobile phase system (4:2.5:2) with Rf (LSTa) 0.16 and Rf (LNT) 0.33Sss.
- LSTa synthesis was performed by varying buffers (50 mM NaOAc; pH 5.5 and 50 mM Na 3 PO 4 ; pH 6.0), equivalents of 3′-SL (500 mM and 1M), CMP (5 mM and 25 mM) at 250 mM LNT with and without lactase in the reaction mixture. It was observed that presence of lactase and using higher concentration of 3′-SL (1M as compared to 500 mM) led to greater conversion LSTa ( ⁇ 20-25% based on TLC). Both 5 mM and 25 mM CMP reactions gave similar results. Both NaOAc buffer (pH 5.5) and Na 3 PO 4 (pH 6.0) buffer gave similar results as well.
- LSTb is produced from LNT, 3′-SL, and catalytic amounts of CMP using the five enzymes ST3GAL4, ST3GAL3, ST6GALNAC5, Lactase and ⁇ 2-3 Neuraminidase S.
- the reaction mixture is composed of 25 mM LNT, 60 mM 3′-SL, mM CMP, 400 ⁇ g/ml ST3GAL4, 400 ⁇ g/ml ST3GAL3, 400 ⁇ g/ml ST6GALNAC5, 400 ⁇ g/ml lactase. 100 ⁇ g/ml ⁇ 2-3 Neuraminidase S and 10 mM MgCl 2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C.
- Table 1 The enzymes in Table 1 are used in the methods of the invention. Other enzymes are disclosed herein. Table 1 provides the E number, enzyme name, E.C. number, and an example of an enzyme that may be used. Table 1 may refer to enzymes or genes encoding the enzymes.
- Enzymes E1, E1′, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11, and E12 used in Example 1 are immobilized. All reagents and cofactors, buffer, salts are added at the beginning. The enzymes are immobilized, and in an example of a flow reactor (e.g. packed bed reactor) the above mixture of reagents is flowed through this flow reactor. Glucose, fructose, or a mixture of glucose and fructose along with feed stock and immobilized enzymes are introduced into the reactor.
- the FIG. 15 depicted conversions are carried out to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate.
- D-mannose isomerase converts glucose or converts fructose to mannose.
- Glk coverts mannose into mannose-6-phosphate, along with ATP conversion to ADP.
- RfbK ManB
- RfbM ManC
- Gmd converts GDP-D-Man to GDP-4-keto-6-deoxymannose.
- GFS (WcaG) converts GDP-4-keto-6-deoxymannose to GDP-L-fucose along with conversion of NADPH to NADP+.
- Fucosyl transferase converts lactose and GDP-L-fucose to 2′FL.
- PmPpa converts inorganic diphosphate to inorganic phosphate.
- AcK and pyruvate oxidase converts pyruvate and inorganic phosphate (generated by PmPpa) to CO 2 and peroxide (with catalase converting the CO 2 and peroxide to oxygen and water).
- FDH converts formate to CO 2 along with conversion of NADP+ to NADPH.
- GDP is converted to GTP. 2′FL is obtained. See FIG. 15 .
- Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8′, E9, E10, E11, and E12 are combined with feedstock to carry out the reactions depicted in FIG. 16 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate.
- Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8, E9′, and E12 are combined with feedstock to carry out the reactions depicted in FIG. 17 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate.
- Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8′, E9′, and E12 are combined with feedstock to carry out the reactions depicted in FIG. 18 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate.
- Table 2 The enzymes in Table 2 are used in the methods of the invention.
- Table 2 provides the E number used in FIGS. 15 - 18 , enzyme name, E.C. number, and an example of an enzyme that may be used.
- Table 2 may refer to enzymes or genes encoding the enzymes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides methods for glycosylation and preparation of compounds. The compounds include galactosylated, sialylated, fucosylated, and N-acetylglucosaminylated compounds from simple animal-derived, plant-derived, or microbe-derived oligosaccharides and sugars. In certain embodiments, the invention provides trinucleotide-free enzymatic production of oligosaccharides starting from simple sugars that include plant-based sugars. The invention also provides the enzymatic production of fucosylated oligosaccharides and fucosylated antibody-glycan conjugates from common sugars. The production may be a cell-free, one-pot synthesis using enzymes, and in some embodiments, immobilized enzymes. The synthesis is a highly customizable and highly efficient cell-free manufacturing process. In some embodiments, lactose derivatives and human milk oligosaccharides (HMOs) are produced.
Description
- This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63/430,271, filed Dec. 5, 2022, to U.S. Provisional Application No. 63/344,507, filed May 20, 2022, and to U.S. Provisional Application No. 63/448,175, filed Feb. 24, 2023, and each are incorporated herein by reference in their entirety.
- The invention provides methods for glycosylation and preparation of compounds. The compounds include galactosylated, sialylated, fucosylated, and N-acetyl glucosaminylated compounds from simple animal-derived, plant-derived, or microbe-derived oligosaccharides and sugars. In certain embodiments, the invention provides trinucleotide-free enzymatic production of oligosaccharides starting from simple sugars that include plant-based sugars. The production may be a cell-free, one-pot synthesis using enzymes, and in some embodiments, immobilized enzymes. The synthesis is a highly customizable and highly efficient cell-free manufacturing process. In some embodiments, lactose derivatives and human milk oligosaccharides (HMOs) are produced.
- The invention also provides the enzymatic production of fucosylated oligosaccharides and fucosylated antibody-glycan conjugates from common sugars. The production is a cell-free, one-pot synthesis using immobilized enzymes. The oligosaccharide synthesis is a highly customizable and highly efficient cell-free manufacturing process. In some embodiments, fucosylated human milk oligosaccharides (HMOs) are produced.
- Human milk oligosaccharides (HMOs) are particularly commercially relevant glycan models. HMOs are structurally diverse, soluble and unconjugated glycans composed of between 3-22 sugars limited to a set of only 5 monosaccharides: D-glucose, D-galactose, N-acetylglucosamine, L-fucose, and N-acetylneuraminic acid (i.e., sialic acid), and are the third largest component of breast milk. Simple HMOs (3-4 DP) (DP is degree of polymerization) serve as metabolic substrates for specialized beneficial bacteria, thereby shaping the intestinal microbiome. More complex and branched HMOs (>4 DP), however, serve as soluble decoys for viral, bacterial, or protozoan parasite adhesins, thereby preventing attachment to the infant mucosal surface. For example, the fucosylated fraction of human milk was shown to inhibit Campylobacter jejuni colonization ex vivo (human intestinal mucosa) and in rodents (in vivo)— C. jejuni is a leading cause of bacterial diarrhea with and incidence of roughly 1 in 4,000 among infants <1 year of age. In addition to their protective effects against Campylobacter, evidence suggests fucosylated HMOs can deploy similar decoy mechanisms to protect infants from infection by other diarrhea-causing pathogens (e.g., cholera and norovirus) that initiate infection by binding cell-surface receptors. These oligosaccharides may also provide protection from Shiga toxin-induced diarrhea by competing with the toxin for binding to its extracellular target. Moreover, HMOs can also modulate epithelial and immune cell responses and reduce excessive mucosal leukocyte infiltration and activation. These properties have been associated with a lower risk for developing necrotizing enterocolitis.
- While milk oligosaccharides form a diverse family of carbohydrates highly conserved in mammals, the profiles are not uniform amongst all species. Typically consisting of a lactose (gal+glu) core, elongated by alternate N-acetylglucosamine and galactose units, and decorated by sialylation and/or fucosylation. HMOs exhibit greater diversity than oligosaccharides found in bovine milk, the basis for most commercial baby formulas. At 0.05 g/L, the compounds are a minor component of cow's milk compared to the concentrations found in human milk which, at 5-23 g/L, puts HMOs on a par with protein content (8 g/L). Roughly 200 HMO structures have been identified, whereas less than half that number have been found in cows.
- The global Human Milk Oligosaccharides (HMO) market size is anticipated to expand at a compound annual growth rate (CAGR) of 21.9% over the next 8 years, reaching USD 71.2 billion by 2025.38 The recent manufacturing at industrial scale of fucosylated lactose (2′FL) via fermentation with recombinant microorganisms has unlocked the market for HMOs. Regarding HMO product types, the fucosyllactose (2′FL) segment is currently largest with a CAGR of 14.4%, while the sialyllactose segment has a CAGR of 15.1%.38 The functional food and beverages sector is also expected to experience considerable growth during this period as HMOs have numerous potential applications besides infant formula.
- There is a need for improved HMO synthesis methods driven by usage of HMO in infant formulas. Key drivers of growth include growing consumer awareness and concern regarding infant health, rise in demand for infant nutrition food products, projected population growth, as well as increasing awareness of health benefits associated with the consumption of HMOs, such as promotion of beneficial microbiota in the digestive tract and enhanced brain and immune system development. On the other hand, scarce raw materials, costly and complex chemical and enzymatic synthesis techniques and lack of technical expertise are expected to continue to present challenges.
- While some simple probiotic HMOs can now be effectively produced via fermentation for infant formula (2′FL, 3DP), complex and branched HMOs are elusive and have been marginally produced at high cost via chemocatalysis. To make HMOs, sugars need to be first activated to be able to be sequentially transferred to the growing structures. For example, activated fucose (L-Fucose-1-GDP) and activated sialic acid (Sialic acid-1-CMP) cost $35,000 and $8,000/g respectively, while L-fucose and L-sialic acid cost $10 and $5.5/g, putting the cost of any complex glycans in hundreds of thousand dollars per gram−the cost of defined pentaoses (5 carbon sugars) DP5 glycans for example ranges from $300,000 to $3,800,000 per gram. Production of HMOs has been achieved in three main ways besides extraction from rare human milk:
- Chemical production: The chemical synthesis of HMOs is flexible but entails a larger number of steps, poor yields and specialized equipment that results in high costs of production. Furthermore, complex HMOs require the synthesis of chemically protected monosaccharide that each require laborious deprotections adding up to typically 20-50 chemical manipulations (Lacto-N-tetraose synthesis). For these reasons, large-scale production of HMOs has not been implemented.
- Microbe-based production: Fermentation is a cost-effective method of HMO production that is currently used to produce 2′-fucosyllactose (2′-FL) at a multi-ton industrial scale (Abbott Laboratories-Jennewein Biotechnologie GmbH, Glycom-Nestle, Inbiose-DuPont). Microbial production, however, is limited to simple unbranched and short-length (DP<4) HMOs. More complex HMOs are out of reach because of poor yields for complex carbohydrates via fermentation and the challenges of controlling the glycan sequences in living organisms.
- Enzyme-based production: Cell-free production circumvents this limitation by using a glycosyltransferase that transfers a nucleotide activated donor sugar (e.g. GDP-L-fucose, CMP-sialic acid etc.) with high specificity to a large variety of acceptor sugars. Combining various enzymatic steps can produce large HMO libraries, an approach that has been taken by HMO commercial suppliers (Chemily Glycoscience, Carbosynth, Santa Cruz Biotechnology). With fewer steps and robust enzymes, chemocatalysis can be used to produce defined complex glucans but still suffer from high costs of production.
- Biocatalysis, as a green technology, has become increasingly popular in chemical manufacturing over traditional expensive and inefficient processes. Its applications include the production of food ingredients, flavors, fragrances, commodity and fine chemicals, and active pharmaceuticals. When producing chemicals at industrial scale, however, enzymes can suffer drastic losses in activity and loading causing a significant drop in performance.
- Continuous flow processing begins with two or more streams of different reactants pumped at specific flow rates into a single cell. A reaction takes place, and the stream containing the resultant compound is collected at the outlet. The solution may also be directed to subsequent flow reactor loops to generate the final product. Continuous flow processing provides better control and reproducibility of reactions. It is a modular, customizable approach. The high modularity allows one to configure the cells to meet the requirements of specific reactions.
- Glycans are complex carbohydrate structures that are the predominant molecules on the cell surface and serve as the first point of contact between cells, the extracellular matrix and pathogens. Glycans are involved in a number of biological processes such as cell-to cell-interactions. There is great interest in improving the accessibility and affordability of these molecules for research, preclinical and commercial applications.
- A recent study by the CDC found that roughly 1-in-5 mothers of newborns never initiate breastfeeding and the majority (>70%) do not meet the 6-month target, instead relying extensively or exclusively on commercially available infant formula. Non-compliance with breastfeeding recommendations is estimated to add an additional $2.5 billion to pediatric healthcare costs (direct) in the US with the total burden of morbidity and mortality totaling $13.8 billion. (Vera MK NG, “Implementation of Mother-friendly Workplace Policies in Hong Kong”, Hong Kong J Gynaecol Obstet. Midwifery 2015; 15(1) 11.
- Human milk oligosaccharides (HMOs) are the third largest component of breast milk. They are of particular commercial relevance. For instance, they serve as metabolic substrates for specialized beneficial bacteria, thereby shaping the intestinal microbiome. More complex and branched HMOs (>4 DP (i.e., degree of polymerization or the number of monosaccharides linked together), however, appear mostly prophylactic. They serve as soluble decoys for viral, bacterial, or protozoan parasite adhesins and prevent their attachment to the infant, or adults, mucosal surfaces.
- Moreover, HMOs can also modulate epithelial and immune cell responses and reduce excessive mucosal leukocyte infiltration and activation. These properties have been associated with a lower risk for developing necrotizing enterocolitis and other infections and autoimmune inflammations.
- While some simple probiotic HMOs can be effectively produced via fermentation for infant formula (2′FL, 3DP), complex and branched HMOs are elusive. Microbial production is limited to simple unbranched and short-length sugars and bacteria can secrete toxins that must be filtered out. Yeast fermentation does not require the removal of toxins, and the overall process involves fewer steps, reducing production costs and resulting in a more easily scaled product. Engineering organisms is intensive and does not guarantee the ability to scale-up.
- Cell free systems have been of interest in biomanufacturing, but there are challenges (M. P. Cordoso Marque et al., Adv. Biochem. Eng. Biotechnol., https://doi.org/10.1007/10_2020_160 and C. You, Adv. Biochem. Engl, DOI: 10.1007/10_2012_159 (2012)). Hokke, Cornelis H., et al. “One-pot enzymatic synthesis of the Galα1→3Galβ1→4GlcNAc sequence within situ UDP-Gal regeneration.” Glycoconjugate journal 13.4 (1996): 687-692. Zervosen, Astrid, and Lothar Elling. “A Novel Three-Enzyme Reaction Cycle for the Synthesis of N-Acetyllactosamine with in Situ Regeneration of Uridine 5′-Diphosphate Glucose and Uridine 5′-Diphosphate Galactose.” Journal of the American Chemical Society 118.8 (1996): 1836-1840. The foregoing are incorporated by reference in their entirety.
- Thus, the art seeks an economical and efficient way to produce glycans. Thus, the art seeks an economical and efficient way to produce glycans, including HMOs, including, but not limited to, glycans of two sugar units or larger, and including glycans of 4 sugar units or larger. This includes HMOs including, but not limited to, glycans of two or four sugar units or larger. This could overcome major hurdles in advancing these glycans, galactosylated glycan, and HMOs for probiotic, prophylactic, and therapeutic purposes. This includes, but is not limited to, medical foods, food additives, and supplements. The economical and efficient HMO production would be an important advance for global infant nutrition and disease prevention for all ages. Importantly, the invention provides enhanced production efficiency of sugars and complex carbohydrates, while lowering costs, hence improving the accessibility and affordability of these molecules.
- The present invention provides processes for preparing saccharides starting from common sugar building blocks. This lowers the cost of saccharide production. In certain embodiments the sugars are plant derived. The energy source is hydrolysis of more complex sugars into more simple sugars. Activated sugars are the starting materials and are generated in situ. The activated sugars are monophosphates or diphosphates present in catalytic amounts. Examples include the nucleotide di- and monophosphates UDP, GDP, and CMP. Avoiding stoichiometric or excess nucleotide reactants, including triphosphates such as ATP, avoids the need for co-factor recycling, reduces the number of enzymes required, avoids reaction inhibition, and lowers the overall cost of the reaction over current reactions. Nucleotide di- and monophosphate are used in catalytic amounts. This is a significant improvement over prior art reactions where ATP must be used in stoichiometric amounts or in excess.
- The present invention provides methods with improved purification and yields. There is no need for acidification that leads to improved purification. Additionally, there are no inorganic phosphate biproducts to purify from the reaction mixture. In certain embodiments, sugar biproducts are formed that are useful as building blocks for various uses. Enzymes are not reactivated thus avoiding additional reactants while improving reaction efficiency. The invention provides a cell free biomanufacturing method for making human milk oligosaccharides and other animal-based oligosaccharides from cost-effective starting materials. In some embodiments, the reactions are done as a one-pot synthesis.
- Any compound with at least one hydroxy functional group may be glycosylated according to this invention. This includes, but is not limited to, saccharides, glycans, carbohydrates, and alcohols.
- Thus, in some embodiments, the invention provides a method for producing a glycosylated principal product, comprising the steps of:
-
- a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor in the presence of a transferase to obtain a glycosylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain the regenerated sugar-nucleotide donor and a secondary product.
- In some embodiments, the method further comprises:
-
- a. contacting a catalytic amount of the regenerated sugar-nucleotide donor and a stoichiometric amount of an acceptor in the presence of a transferase to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain the regenerated sugar-nucleotide donor and the secondary product.
- In other embodiments, the invention provides a method for producing a glycosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product. In certain embodiments, the sugar donor precursor and the nucleotide provide a sugar-nucleotide donor.
- In certain embodiments, the sugar donor precursor and the nucleotide provide a sugar-nucleotide donor precursor and an auxiliary enzyme and the sugar-nucleotide donor precursor provide the sugar-nucleotide donor.
- In some embodiments, the sugar donor precursor is a sugar comprising 2 or more sugar units. In some embodiments, the sugar donor precursor is a sugar comprising 2, 3, or 4 sugar units. In some embodiments, sugar donor precursor is a disaccharide. In some embodiments, the sugar donor precursor is a trisaccharide. In some embodiments, the sugar donor precursor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine. In some embodiments, the galactose, sialic acid, fucose, or N-acetylglucosamine is in a terminal position in the sugar donor precursor.
- In some embodiments, the sugar-nucleotide donor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine. In some embodiments the sugar-nucleotide donor is a galactosyl-nucleotide, sialyl-nucleotide, fucosyl-nucleotide, or N-acetylglucosaminyl-nucleotide. In some embodiments, the secondary product is a monosaccharide, disaccharide, or trisaccharide.
- Some embodiments of this invention further comprise the step of contacting the secondary product and a processing enzyme to convert the secondary product to a secondary product derivative. In some embodiments, the secondary product derivative, in the presence of a second processing enzyme, is converted to a modified secondary product derivative. Some embodiments of this invention further comprise the step of contacting the principal product and a processing enzyme to convert the principal product to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, an isomerase, or a hydrolase.
- In some embodiments, the acceptor is an organic compound containing a hydroxyl group. In some embodiments, the organic compound containing a hydroxy group is a sugar. In some embodiments, the acceptor is obtained from the processing enzyme converting the secondary product into the acceptor.
- In some embodiments, the nucleotide is a uridine diphosphate, cytidine monophosphate, or guanosine diphosphate. In some embodiments, the nucleotide is in an amount of 0.001 mol percent to 10 mol percent relative to the sugar donor precursor or the acceptor. In some embodiments, the nucleotide is in an amount of 0.01 mol percent to 1 mol percent relative to the sugar donor precursor or the acceptor.
- In certain embodiments, the transferase is any enzyme that transfers a sugar unit to the acceptor. In some embodiments, the transferase is a β-1,3-galactosyl transferase, sucrase synthase, β-1,4-galactosyl transferase, sialyl transferase, fucosyl transferase, or glucosaminyl (N-acetyl)
transferase 2. In some embodiments, the transferase comprises a first transferase (GT1 inFIG. 6, 7, 13 , or 14) and a second transferase (GT2 inFIG. 6, 7, 13 , or 14). In some embodiments, the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the glycosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product. - In certain embodiments, this invention provides a method for producing a galactosylated principal product, comprising the steps of:
-
- a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a galactosylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- In some embodiments, the method further comprises:
-
- a. contacting a catalytic amount of the regenerated sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- In some embodiments, the invention provides a method for producing a galactosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- In some embodiments, the acceptor is lacto-N-triose II (LNTII), glucose, or galactooligosaccharide (GOS) and the secondary product is fructose. Some embodiments comprised the step of obtaining the glucose by contacting the fructose in the presence of a glucose isomerase to obtain the glucose. Some embodiments comprise the step of obtaining the LNTII by contacting lactose and N-acetylglucosamine in the presence of β-N-acetylhexosaminidase (Bbh1) to obtain the LNTII.
- In some embodiments, the sugar donor precursor is sucrose. In some embodiments, the sugar donor precursor and the nucleotide provides a sugar-nucleotide donor precursor and wherein an auxiliary enzyme and the sugar-nucleotide donor precursor provides the sugar-nucleotide donor. In some embodiments, the sugar-nucleotide donor precursor is a glucose nucleotide. In some embodiments, the secondary product is fructose. In some embodiments, the auxiliary enzyme is a galactose epimerase. In some embodiments, the nucleotide is uridine diphosphate.
- In certain embodiments, the transferase is any enzyme that transfers a galactose unit to the acceptor. In some embodiments, the transferase comprises a first transferase (GT1 in
FIG. 6, 7, 13 , or 14) and a second transferase (GT2 inFIG. 6, 7, 13 , or 14). In particular embodiments, the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the galactosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product. In some embodiments, the first transferase is β-1,3-galactosyl transferase from Chromobacterium violaceum (Cvb3GalT), β-1,4-Galactosyltransferase from Neisseria meningitidis (NmLgtB), and the second transferase is sucrose synthase from Arabidopsis thaliana (AtSuSy1). - In some embodiments, the galactosylated principal product is lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), lactose, or galactooligosaccharide (GOS). In some embodiments, the methods comprise the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, an isomerase, or a hydrolase. In some embodiments, the processing enzyme is an oxidase and galactosylated principal product derivative is oxidized fructose or oxidized glucose.
- In some embodiments, the invention provides a method for producing a sialylated principal product, comprising the steps of:
-
- a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a sialylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- In some embodiments, the method of further comprises:
-
- a. contacting a catalytic amount of the regenerated sugar-nucleotide donor and the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- In some embodiments, the invention provides a method for producing a sialylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a sialylated principal product and a secondary product.
- In some embodiments, the sugar donor precursor is 3′-sialyllactose. In some embodiments, the sugar-nucleotide donor is a N-acetyl neuraminic acid-nucleotide. In some embodiments, the secondary product is lactose. In some embodiments, the sialylated principal product is Sialyllacto-N-tetraose a (LSTa), Sialyliacto-N-tetraose b (LSTb), Siaiyliacto-N-neoteiraose c (LSTc), Sialyilacio-N-neotetraose d (LSTd), or Disialyllacto-N-tetraose (DSLNT). In some embodiments, the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, an isomerase, or a hydrolase. In some embodiments, the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative. In some embodiments, the processing enzyme is lactase. In some embodiments, the secondary product derivative is glucose and galactose. In some embodiments, the processing enzyme is an enzyme that oxidizes the lactose to lactobionic acid. In some embodiments, the processing enzyme is a lactose oxidase. In some embodiments, the glucose, in the presence of a second processing enzyme, is converted to a modified secondary product derivative. In some embodiments, the second processing enzyme is D-galactose isomerase and the modified secondary product derivative is tagatose. In some embodiments, the galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI). In some embodiments, the glucose oxidase and the modified secondary product derivative is gluconolactone. In some embodiments, the processing enzyme is an oxidase, isomerase, or hydrolase and the principal product derivative is an oxidized principal product, isomerized principal product, or a hydrolyzed principal product. In some embodiments, the hydrolase is α2-3 Neuraminidase S. In some embodiments, the α2-3 Neuraminidase S and the principal product DSLNT is converted to LSTb by the neuraminidase.
- In some embodiments, the principal product derivative is oxidized, isomerized or hydrolyzed LSTa, LSTb, LSTc, LSTd, or DSLNT. In some embodiments, the nucleotide is cytidine monophosphate.
- In certain embodiments, the transferase is any enzyme that transfers a sialyl unit to the acceptor. In some embodiments, the transferase comprises a first transferase (GT1 in
FIG. 6, 7, 13 , or 14) and a second transferase (GT2 inFIG. 6, 7, 13 , or 14. In particular embodiments, the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the sialylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product. In some embodiments, the first transferase is beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase 3 (ST3GAL3) or Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) and second transferase is CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (ST3GAL4). In some embodiments, the first transferase ST3GAL3 and ST6GALNAC5. - In some embodiments, the invention provides a method for producing a fucosylated principal product, comprising the steps of:
-
- a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a fucosylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- In some embodiments, the method further comprises:
-
- a. contacting a catalytic amount of the regenerated sugar-nucleotide donor and the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with the stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain the regenerated sugar-nucleotide donor and the secondary product.
- In some embodiments, the invention provides a method for producing a fucosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a fucosylated principal product and a secondary product. In some embodiments, the sugar donor precursor is a 2′-fucosyllactose. In some embodiments, the sugar-nucleotide donor is a fucose nucleotide. In some embodiments, the secondary product is lactose.
- In some embodiments, the principal product is Lacto-N-fucopentaose I (LNFPI), Lacto-N-fucopentaose II (LNFPII), Lacto-N-fucopentaose III (LNFPIII), Difucosyllactose (DFL), or 3-fucosyllactose (3-FL).
- In some embodiments, the method further comprises the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, an isomerase, or a hydrolase. In some embodiments, the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative. In some embodiments, the processing enzyme is an enzyme that oxidizes the lactose to lactobionic acid. In some embodiments, the processing enzyme is lactose oxidase. In some embodiments, the processing enzyme is lactase. In some embodiments, the secondary product derivative is glucose and galactose. In some embodiments, the secondary product derivative, in the presence of a second processing enzyme, is converted to a modified secondary product derivative. In some embodiments, the second processing enzyme is a D-galactose isomerase the modified secondary product derivative is tagatose. In some embodiments, the D-galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI). In some embodiments, the second processing enzyme is glucose oxidase and the modified secondary product derivative is gluconolactone.
- In some embodiments, the principal product, in the presence of a processing enzyme, is converted to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, isomerase, or hydrolase and the principal product derivative is an oxidized principal product, isomerized principal product, or a hydrolyzed principal product. In some embodiments, the principal product derivative is oxidized, isomerized or hydrolyzed LNFPI, LNFPII, LNFPIII, DFL, or 3-FL. In some embodiments, the methods comprise the further step of oxidizing the fucosylated principal product in the presence of an oxidase to provide a principal product derivative. In some embodiments, the principal product derivative is oxidized LNFPI, LNFPII, LNFPIII, DFL, or 3-FL. In some embodiments, the nucleotide is guanosine diphosphate.
- In certain embodiments, the transferase is any enzyme that transfers a fucose unit to the acceptor. In certain embodiments, the transferase is any enzyme that converts the sugar donor precursor into a sugar nucleotide donor and a secondary product. In some embodiments, the transferase comprises a first transferase (GT1 in
FIG. 6, 7, 13 , or 14) and a second transferase (GT2 inFIG. 6, 7, 13 , or 14). In particular embodiments, the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the fucosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product. In some embodiments, the first transferase is α-1,2-fucosyltransferase from Thermosynechococcus vestitus (Te2FT), al-3/4-fucosyltransferase from Helicobacter pylori (Hp34FT), fucosyl transferase 9 (FUT9), or fucosyl transferase 3 (FUT3) and the second transferase is α-1,2-fucosyltransferase from Helicobacter mustelae (HmFucT) or fucosyl transferase (FUT1). - In some embodiments, this invention provides a method for producing a N-acetylglucosaminylated principal product, comprising the steps of:
-
- a. contacting a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a N-acetylglucosaminylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting the catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- In some embodiments, the method further comprises:
-
- a. contacting a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- In some embodiments, the invention provides a method for producing a N-acetylglucosaminylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a N-acetylglucosaminylated principal product and a secondary product.
- In some embodiments, the sugar donor precursor is lacto-N-biose. In some embodiments, the sugar-nucleotide donor is a N-acetylglucosamine nucleotide. In some embodiments, the secondary product is galactose. In some embodiments, the principal product is LNTII or β-1,6-GlcNAc-LNnT. In some embodiments, the methods further comprise the step of contacting the secondary product or the principal product and a processing enzyme to convert the secondary product to a secondary product derivative or the principal product to a principal product derivative. In some embodiments, the processing enzyme is an oxidase, an isomerase, or a hydrolase. In some embodiments, the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative. In some embodiments, the processing enzyme is a D-galactose isomerase the secondary product derivative is tagatose. In some embodiments, the D-galactose isomerase is sourced from Geobacillus stearothermophilus (GsAI). In some embodiments, the methods comprise the further step of oxidizing the N-acetylglucosaminylated principal product in the presence of an oxidase to provide a principal product derivative. In some embodiments, the principal product derivative is oxidized the principal product is LNTII or β-1,6-GlcNAc-LNnT.
- In some embodiments, the nucleotide is uridine diphophate.
- In certain embodiments, the transferase is any enzyme that transfers a N-acetylglucosamine unit to the acceptor. In some embodiments, the transferase is β-1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA). In some embodiments, the transferase comprises a first transferase (GT1 in
FIG. 6, 7, 13 , or 14) and a second transferase (GT2 inFIG. 6, 7, 13 , or 14. In particular embodiments, the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the N-acetylglucosaminylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product. In some embodiments, the first transferase is glucosaminyl (N-acetyl) transferase 2 (GCNT2) and second transferase is β-1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA). In some embodiments, the further step of oxidizing the N-acetylglucosaminylated principal product in the presence of an oxidase to provide a principal product derivative. In some embodiments, the principal product derivative is oxidized LNTII or oxidized β-1,6-GlcNAc-LNnT. In some embodiments, the sugar is in a naturally occurring isomeric form. - In some embodiments, glucose is D-glucose. In some embodiments, is D-galactose. In some embodiments, fucose is L-fucose.
-
- 1. In some embodiments, this invention provides a compound prepared by a method according to any of the methods herein. In some embodiments, this invention provides a glycosylated compound prepared according to any of the methods of this invention. In some embodiments, this invention provides a galactosylated compound prepared according any of the methods of this invention. In some embodiments, this invention provides a sialylated compound prepared according to any of the methods of this invention. In some embodiments, this invention provides a fucosylated compound prepared according to any of the methods of this invention. In some embodiments, this invention provides a N-acetylglucosaminylated compound prepared according to any of the methods of this invention. In some embodiments, this invention provides a lactose derivative prepared according to any of the methods of this invention. In some embodiments, this invention provides lactose derivative according to any of the methods of this invention selected from lactobionic acid, lactitol, lactosucrose, galacto-oligosaccharides, lactulose, and an HMO. In some embodiments, this invention provides a lactose, DSLNT, LNnT, LSTs, LSTb, LSTc, or LSTd. In some embodiments, the compounds are obtained from non-animal based plant materials.
- In some embodiments, the invention provides a machine configured for the method of any embodiment. In certain embodiments, a method is within a single reaction vessel. Also provided by this invention is a machine optimized for the processes of this invention. In certain embodiments, the machine is adapted so that the process is carried out within a single reaction vessel.
- In some embodiments of the invention, one or more the enzymes are immobilized. In other embodiments, each enzyme is immobilized. In other embodiments of the invention, the process occurs in a single reaction vessel.
- The invention also provides compounds prepared according to the processes of the invention. In one embodiment, LNT is prepared by a process of this invention. In another embodiment, LNnT is prepared by a process of this invention. In another embodiment, Lactose is prepared by a process of this invention. In another embodiment, a galactooligosaccharide is by a process of this invention. In another embodiment, LSTa is prepared by a process of this invention. In another embodiment, LSTb is prepared by a process of this invention. In another embodiment, LSTc is prepared by a process of this invention. In another embodiment, LSTd is prepared by a process of this invention. In another embodiment, DSLNT is prepared by a process of this invention. In another embodiment, LNFPI is prepared by a process of this invention. In another embodiment, LNFPII is prepared by a process of this invention. In another embodiment, LNFPIII is prepared by a process of this invention. In another embodiment, DFL is prepared by a process of this invention. In another embodiment, 3-FL is prepared by a process of this invention. In another embodiment, LNTII is prepared by a process of this invention. In another embodiment, a branched HMO is prepared by a process of this invention.
- Any of the embodiments of this invention may be employed to obtain a compound from non-animal based plant materials.
- In another embodiment, glycosylation reactions employing catalytic nucleotides are done in combination to provide a glycosylated principal product with two (2) or more sugar units that have been transferred to an acceptor via two (2) or more sugar-nucleotide donors of this invention.
- In another aspect, the present invention provides an integrated pathway using immobilized enzymes to perform syntheses of fucosolyated saccharides starting from common sugars, including one-pot syntheses of fucosylated saccharides. Included is a cell free biomanufacturing method of making fucosylated human milk oligosaccharides and other fucosylated oligosaccharides from fructose, glucose or a mixture of fructose and glucose. Starting from common sugars lowers the cost of production of fucosylated HMOs vs using fucose as a starting material.
FIG. 15-18 depict integrated fucosylation pathways of this invention. - The invention provides direct production of fucosylated HMOs starting from cost effective glucose or fructose instead of fucose. Regeneration of cofactors across the enzyme reactions drives efficiency and cost reduction. The production method allows the flexibility of production of all fucosylated HMOS (or oligosaccharides) by changing the last transferase enzyme and the acceptor backbone (biorefinery concept). The process does not require genetically modified organisms (non-GMO).
- In some embodiments, the invention provides a process for producing a fucosylated oligosaccharide or a fucosylated antibody-glycan conjugate, comprising the steps of:
-
- a. contacting glucose or fructose in the presence of an enzyme that converts the fructose or glucose to mannose;
- b. contacting the mannose with an enzyme that converts mannose to mannose-6-phosphate;
- c. contacting the mannose-6-phosphate with an enzyme that converts mannose-6-phosphate to mannose-1-phosphate;
- d. contacting the mannose-1-phophate with an enzyme that converts the mannose-1-phophate to GDP-D-mannose;
- e. contacting the GDP-D-mannose with an enzyme that converts GDP-D-mannose to GDP-4-keto-6-deoxymannose;
- f. contacting the GDP-4-keto-6-deoxymannose with an enzyme that converts the GDP-4-keto-6-deoxymannose to GDP-L-fucose;
- g. contacting the GDP-L-fucose with a disaccharide, an oligosaccharide or an antibody-glycan conjugate with an enzyme that fucosylates the disaccharide, oligosaccharide or the antibody-glycan conjugate; and
- h. obtaining a fucosylated disaccharide, oligosaccharide or a fucosylated antibody-glycan conjugate.
- wherein each of the enzymes is immobilized and wherein the process contains a set of regeneration enzyme systems to convert ADP to ATP, PPi to Pi, GDP to GTP, and NADP+ to NADPH.
- In certain embodiments, the process comprises immobilized regeneration enzymes formate dehydrogenase, pyruvate oxidase, acetate kinase, catalase, and inorganic pyrophosphatase. In certain embodiments, the immobilized regeneration enzymes are phosphite dehydrogenase, pyruvate oxidase, acetate kinase, catalase, and inorganic pyrophosphatase. In certain embodiments, the immobilized regeneration enzymes are formate dehydrogenase, polyphosphate kinase, and inorganic pyrophosphatase. In certain embodiments, the immobilized regeneration enzymes are phosphite dehydrogenase, polyphosphate kinase, and inorganic pyrophosphatase.
- In certain embodiments, the enzyme that converts the glucose to mannose is an immobilized D-mannose isomerase. In certain embodiments, the enzyme that converts the fructose to mannose is an immobilized N-acetyl-d-glucosamine-2-epimerase. In certain embodiments, the enzyme that converts mannose to mannose-6-phosphate is an immobilized hexokinase. In certain embodiments, the enzyme that converts mannose-6-phosphate to mannose-1-phosphate is an immobilized phosphomannomutase. In certain embodiments, the enzyme that converts mannose-1-phophate to GDP-D-mannose is an immobilized GDP-mannose pyrophosphorylase. In certain embodiments, the enzyme that converts GDP-D-Man to GDP-4-keto-6-deoxymannose is an immobilized GDP-mannose-4,6-dehydratase. In certain embodiments, the enzyme that converts GDP-4-keto-6-deoxymannose to GDP-L-fucose is an immobilized GDP-fucose synthase.
- In some embodiments, the enzyme that fucosylates the disaccharide, oligosaccharide, or antibody-glycan conjugate is an immobilized fucosyl transferase. In some embodiments, the GDP-mannose is polymerized to mannans via transferase enzymes. In certain embodiments, the oligosaccharide is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′″3,3′″6-di-O-α-Sia-
LNnH 3′″3,3′″6-di-O-α-Sia-(3″3,3″6-di-O-α-Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, α-2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary lacto-N-neohexaoses and heptaoses. In certain embodiments, the glycans are 3′SL LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, 2′-FL, LNnH, DSLNnH, or DSDFLNNH. In other embodiments, the glycans are 3′SL, LNTII, 2′-FL, LNFPI, LSTa. In certain embodiments, the oligosaccharide is lactose, LNT, LNnT, LNnH, or LNH. In certain embodiments, the fucosylated oligosaccharide is 2′FL or 3-FL. In certain embodiments, the d fucosylated oligosaccharide is a fucosylated HMO. In certain embodiments, the fucosylated oligosaccharide is fucosylated LDFT, fucosylated LNFP I, fucosylated LNFP II, fucosylated LNFP V, fucosylated LNDFH I, fucosylated LNDFH II, fucosylated DFLNH a, or fucosylated DFLNHc. - In certain embodiments, the process occurs in a single reaction vessel. In some embodiments, the invention provides a machine, comprising the immobilized enzymes of any one of the invention's embodiments wherein the machine produces a fucosylated disaccharide, fucosylated oligosaccharide, or fucosylated antibody-glycan conjugate. In certain embodiments, immobilized enzymes are contained within a single reaction vessel.
- In certain embodiments, the pathway uses immobilized enzymes, such as enzymes that are immobilized within bionanocatalysts (BNCs) that in turn are embedded within scaffolds. Bionanocatalysts (BNCs) according to this invention comprise an enzyme self-assembled with magnetic nanoparticles (MNPs). The BNCs self-assemble with the scaffolds. In certain embodiments, each enzyme is immobilized within the BNC.
- In certain embodiments, fucosylated human milk oligosaccharides (HMOs) are produced.
- The one-pot integrated fucosylation synthesis may be done in batch or flow. It should be understood that modifying Examples 11-15 to be in-flow is within the scope of this invention. In a flow reactor, such as a packed bed reactor, the mixture of reagents is flowed through the flow reactor.
- In certain embodiments, the scaffolded BNCs are inside of modular flow cells for flow manufacturing. In certain embodiments, the invention provides continuous flow processing where each step of synthesis is conducted in modules. In production mode, these modules contain full systems of enzymes—sugar activation and sugar transfer—for specifically building glycans. In some embodiments, the glycans are oligosaccharides.
- In some embodiments, the scaffolds comprise magnetic metal oxides. In some embodiments, the scaffolds are high magnetism and high porosity composite blends of thermoplastics comprising magnetic particles that form powders. They may be single-layered or multiple-layered materials that hold the BNCs. Such designed objects may be produced using 3D printing by sintering composite magnetic powders. In some embodiments, Selective Laser Sintering (SLS) is used. The modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process. In preferred embodiments, human milk oligosaccharides (HMOs) are produced.
- In certain some embodiments the immobilized enzymes are non-magnetic. In certain the immobilized enzymes do not comprise nanoparticles.
- Thus, the invention provides cell-free productions of defined glycans with combinatorial bionanocatalysts (BNCs) organized in sequential modules.
-
FIG. 1A depicts a summary of galactosylation using sucrose to obtain LNT, LNnT, or lactose and a legend relevant to all figures herein (“2: Lac Synthase” should be “1d) Lac Synthase”).FIG. 1B depicts LNT obtained from LNTII.FIG. 1C depicts LNnT obtained from LNTII.FIG. 1D depicts LNT obtained from lactose.FIG. 1E depicts lactose obtained from glucose.FIG. 1F depicts GOS obtained from galactose and sucrose. -
FIGS. 2A-2D depict sialylations with sialoside and lactose hydrolysis.FIG. 2A depicts the route for obtaining LSTa from LNT.FIG. 2B depicts the route for obtaining LSTc from LNnT.FIG. 2C depicts the route for obtaining LSTd from LNnT.FIG. 2D depicts the route for obtaining DSLNT from LNT. -
FIGS. 3A-3C depict fucosylation using fucoside and lactose hydrolysis.FIG. 3A depicts the route for obtaining LNFPI from LNT.FIG. 3B depicts the route for obtaining LNFPII from LNT.FIG. 3C depicts the route for obtaining LNFPII from LNnT. -
FIG. 4 depicts the addition of N-Acetylglucosamine to prepare LNTII from lactose and chitin. -
FIG. 5 depicts lactose and its functional derivatives. -
FIG. 6 depicts a general embodiment of this invention and an overview of the methods employed in this invention. -
FIG. 7 depicts a general embodiment and methods of this invention employing an auxiliary enzyme. -
FIG. 8 depicts a legend depicting the symbols used inFIGS. 9-12 . -
FIG. 9A depicts a summary of galactosylation using sucrose to obtain LNT, LNnT, or lactose. -
FIG. 9B depicts a route to LNT obtained from LNTII.FIG. 9C depicts a route to LNnT obtained from LNTII.FIG. 9D depicts a route to LNT obtained from lactose.FIG. 9E depicts a route to lactose obtained from glucose.FIG. 9F andFIG. 9G depict routes to obtain lactose from glucose.FIG. 9H depicts a route to Galactooligosaccharides obtained from galactose and sucrose. -
FIGS. 10A-10D depict sialylations with sialoside and lactose hydrolysis.FIG. 10A depicts the route for obtaining LSTa from LNT.FIG. 10B depicts the route for obtaining LSTc from LNnT.FIG. 10C depicts the route for obtaining LSTd from LNnT.FIG. 10D depicts the route for obtaining DSLNT from LNT. -
FIGS. 11A-11C depict fucosylation using fucoside and lactose hydrolysis.FIG. 11A depicts the route for obtaining LNFPI from LNT.FIG. 11B depicts the route for obtaining LNFPII from LNT.FIG. 11C depicts a route for obtaining LNFPII from LNnT.FIG. 11D depicts the route for obtaining DFL from 2′-FL.FIG. 11E depicts a route for obtaining 3-FL from 2′-FL. -
FIG. 12A depicts N-acetylglucosaminylation using lacto-N-biose as a GlcNAc donor.FIG. 12B depicts a branched HMO from Lacto-N-biose (LNB) and LNnT. -
FIG. 13 depicts a general embodiment of this invention and an overview of the methods employed in this invention that provide a processing enzyme to convert a principal product to a principal product derivative. -
FIG. 14 depicts a general embodiment and methods of this invention employing an auxiliary enzyme and a Processing Enzyme to convert a Principal Product to a Principal Product Derivative. -
FIGS. 15-18 relate to the integrated fucosylation pathway provided by this invention. -
FIG. 15 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (Pyruvate-AcK/PyrOx+FDH regeneration). See Example 12. -
FIG. 16 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (Pyruvate-AcK/PyrOx+PtxD regeneration). See Example 13. -
FIG. 17 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (PolyP-PPK+FDH regeneration). See Example 14. -
FIG. 18 depicts the in situ GDP-L-fucose production for 2′-FL synthesis or other fucosylation reactions (PolyP-PPK+PtxD regeneration). See Example 15. - The present invention provides integrated streamlined pathways using enzymes and activated sugars to obtain sugar compounds, oligosaccharides, and their derivatives. In certain embodiments the oligosaccharides are complex oligosaccharides, including
glycans 4 sugar units or larger, and including glycans. - In one aspect, the invention provides cell-free de-novo synthesis of glycans employing in situ generated activated sugar donors and catalytic amounts of nucleotides. Integrated pathways of enzymes lead to glycosylated (sugar-containing compounds) including, but not limited to, saccharides, oligosaccharides, or antibody-glycan conjugates starting from sugars, including, but not limited to, plant sugars. The benefits of the systems of reactants and enzymes of this aspect of the invention comprise, consist essentially of, or consist of:
-
- Avoiding enzymes that recycle cofactors.
- Avoiding nucleotides in stoichiometric or excess quantities relative to either the sugar donor precursor or the acceptor or both the sugar donor precursor and the acceptor.
- Lower cost by using a nucleotide starting material compared to using a nucleotide-sugar as a starting material.
- Ability to use nucleotides at less than 0.1 molar equivalents (<10%) compared to acceptor molecule or limiting reagent.
- Ability to use nucleotides at less than 0.1 molar equivalents (<50%) compared to sugar donor molecule or limiting reagent.
- Avoiding nucleotide triphosphates
- Avoiding inorganic phosphate byproducts
- Achieving high reaction conversions via the hydrolysis of the high energy sugar donor precursor into a product that is in some embodiments enzymatically processed by processing enzymes for enhanced conversion.
- Avoiding enzyme inhibition by organic phosphates.
- Avoiding enzyme inactivation and reaction inhibition by using magnesium (Mg) rather than manganese (Mn).
- Requiring relatively low molar sucrose concentrations equivalents concentrations (1-4 eq.) relative to acceptor.
-
FIG. 6 depicts a general embodiment of this invention and an overview of the methods employed in this invention. As used herein, an “acceptor” is the moiety that accepts transfer of a sugar unit from a sugar-nucleotide donor. A transferase, designated here as GT1, catalyzes the sugar transfer thereby producing a “principal product” that is the glycosylated product provided by this invention. The sugar-nucleotide donor is a compound comprising a sugar unit and a nucleotide obtained from a reaction of a sugar donor precursor and a nucleotide in the presence of a transferase, here designated at GT2. GT2 is acting in the reverse direction relative to GT1. GT1 transfers a sugar unit to an acceptor form a sugar-acceptor compound. GT2 acts to remove a sugar unit. The nucleotide is present in less than stoichiometric amounts and therefore the sugar-nucleotide donor is regenerated and used in another reaction cycle. The reaction of a sugar donor precursor and a nucleotide in the presence of a transferase produces a secondary product in addition to the sugar-nucleotide donor. The breakdown of the sugar donor precursor into smaller sugar units is an energy source for the methods of this invention. The secondary product may be transformed into a secondary product derivative in the presence of a processing enzyme. - Accordingly, in one embodiment, this invention provides a method for obtaining a glycosylated compound (herein, “glycosylated principal product” by combining in a reaction vessel the following: a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide. The method involves iterative reaction cycles to produce a glycosylated principal product and a secondary product. Without being bound by theory, once combined in a reaction mixture, the nucleotide reacts with the sugar donor precursor in the presence of a transferase to form a sugar-nucleotide donor. The sugar of the sugar-nucleotide donor is transferred to an acceptor to provide the glycosylated compound, a secondary product, and a regenerated nucleotide. As the nucleotide is present in catalytic quantities, the sugar-nucleotide donor will be formed in about catalytic quantities. The reaction then cycles through additional iterations of the reaction.
-
FIG. 7 depicts a general embodiment and methods of this invention employing a sugar-nucleotide donor precursor. As depicted the product of the reaction between a nucleotide and a sugar donor precursor in the presence of a transferase provides a sugar-nucleotide donor precursor that undergoes a further reaction in the presence of an auxiliary enzyme to obtain the sugar-nucleotide donor employed in the methods of this invention. -
FIG. 13 andFIG. 14 depict general embodiments of this invention that employ a processing enzyme to convert a principal product to a principal product derivative. In Example 10, LSTb is obtained from LNT by employing this method. DSLNT is the Principal Product that is converted to LSTb by the neuraminidase. -
FIGS. 1A-1F depict a summary of galactosylation reactions using sucrose and a legend. LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see (FIG. 1B-1D ). -
FIG. 1B depicts a route for adding galactose to LNTII to obtain LNT. UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP. The UDP-galactose is obtained from UDP-glucose in the presence of GalE. Galactose from UDP-galactose is transferred to the LNTII in the presence of a transferase that forms aβ 3 type linkage (as depicted, Cvb3GalT or B3GALT5). See Example 2a A. -
FIG. 1C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as inFIG. 1B . In this scheme however a transferase that forms aβ 4 type linkage (as depicted NmLgtB or B4LAGT1) is present. Galactose is transferred to LNTII to provide LNnT. See Example 2a B. -
FIG. 1D depicts a route for obtaining LNT from lactose. N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water. N-acetylglucosamine is transferred to lactose via a β3 linkage to provide LNTII. UDP-gaFIGS. 1A-1F depict a summary of galactosylation reactions using sucrose and a legend. LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see (FIG. 1B-1D ). -
FIG. 1B depicts a route for adding galactose to LNTII to obtain LNT. UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP. The UDP-galactose is obtained from UDP-glucose in the presence of GalE. Galactose from UDP-galactose is transferred to the LNTII in the presence of a transferase that forms aβ 3 type linkage (as depicted, Cvb3GalT or B3GALT5). See Example 2a A. -
FIG. 1C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as inFIG. 1B . In this scheme however a transferase that forms aβ 4 type linkage (as depicted NmLgtB or B4LAGT1) is present. Galactose is transferred to LNTII to provide LNnT. See Example 2a B. -
FIG. 1D depicts a route for obtaining LNT from lactose. N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water. N-acetylglucosamine is transferred to lactose via a (33 linkage to provide LNTII. UDP-galactose and fructose are obtained as described in FIG. Ba. In the presence of a transferase (as depicted Cvb3GalT), galactose is transferred to the acceptor LNTII to provide LNT. -
FIG. 1E depicts lactose obtained from glucose. UDP-galactose is obtained as described inFIG. 1B . Galactose is transferred to glucose in the presence of lactose synthase to obtain lactose. See Example 2a D. -
FIG. 1F depicts GOS obtained from galactose and sucrose. UDP-galactose and fructose are obtained as described inFIG. 1B . The galactose is transferred to a galactooligosaccharide (wherein n is 3-15) to increase the galactose chain by 1. UDP-galactose is obtained as described inFIG. 1B . See Example 2a E. -
FIGS. 2A-2D depict sialylations with sialoside and lactose hydrolysis. CMP-N-acetyl neuraminic acid (Neu5Ac) is the nucleotide-sugar employed in each ofFIGS. 2A-2C . As depicted in each figure, lactose is converted to galactose and glucose in the presence of lactase. CMP-Neu5Ac is obtained in the presence of 3′-SL and the transferase ST3GAL4. -
FIG. 2A depicts a route for obtaining LSTa is from LNT. In the presence of the transferase ST3GAL3, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain LSTc. -
FIG. 2B depicts a route for obtaining LSTc from LNnT. In the presence the transferase ST6GAL1, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTc. -
FIG. 2C depicts a route LSTd is obtained from LNnT. In the presence the transferase ST3GAL3, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTd. - In
FIG. 2D DSLNT is obtained from LNT. In the presence the transferase ST6GAL3 and ST6GALNAC5, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain DSLNT. -
FIGS. 3A-3C depicts fucosylation using fucoside and lactose hydrolysis. GDP-1-fucose is the nucleotide-sugar used in each ofFIG. 3 a -3 c. 2′-FL in the presence of a transferase (HmFucT), lactose, lactase, and GDP provides GDP-1-fucose (GDP-Fuc), galactose, and glucose. -
FIG. 3A depicts a route for obtaining LNFPI from LNT. GDP-Fuc in the presence of LNT and Te2FT provides LNFPI. -
FIG. 3B depicts a route for obtaining LNFPII from LNT. GDP-Fuc in the presence of LNT and a transferase (Hp34FT) provides LNFPII. -
FIG. 3C depicts a route for obtaining LNFPIII from LNnT. GDP-Fuc in the presence of LNnT and a transferase (FUT9) provides LNFPIII. -
FIG. 4 depicts a route for adding N-acetylglucosamine to prepare LNTII from lactose and chitin. UDP-N-Acetylglucosamine (UDP-GlcNAc) is prepared from UDP, lactose, chitin in the presence chitin synthase and the presence of a transferase. (B3GNT2 or NmLgtA) and the GlcNAc is transferred to lactose to obtain LNTII. In the presence of a transferase (as depicted Cvb3GalT), galactose is transferred to the acceptor LNTII to provide LNT. -
FIG. 5 depicts lactose and its functional derivatives. -
FIG. 8 depicts a legend forFIGS. 9-12 . N-acetylglucosamine (GlcNAc) is depicted by a solid black square. L-fucose (fuc) is depicted by a solid white triangle. Lactose is depicted by a solid white circle linked by a line to a hatched circle, with a 4 indicating bonding. D-galactose (Gal) is depicted by a solid circle. N-acetyl neuraminic acid (Neu5Ac) is depicted as a solid white diamond. D-glucose is depicted by a hatched circle. -
FIGS. 9A-9H depict a summary of galactosylation reactions using sucrose. LNTII and glucose are acceptor molecules that are galactosylated to provide LNT, LNnT, or lactose depending on the conditions (see (FIG. 9B-9D ). -
FIG. 9B depicts a route for adding galactose to LNTII to obtain LNT. UDP-glucose and fructose are obtained from sucrose in the presence of sucrose synthase and UDP. The UDP-galactose is obtained from UDP-glucose in the presence of GalE. - Galactose from UDP-galactose is transferred to the LNTII in the presence of a transferase that forms a
β 3 type linkage (as depicted, Cvb3GalT). See Example 6A. -
FIG. 9C depicts a route for adding galactose to LNTII to obtain LNnT. Formation of UDP-galactose and fructose follows the same route as inFIG. 9B . In this scheme however a transferase that forms aβ 4 type linkage (as depicted NmLgtB) is present. Galactose is transferred to LNTII to provide LNnT. See Example 6B. -
FIG. 9D depicts a route for obtaining LNT from lactose. N-acetylglucosamine is converted into an oxazoline in the presence of DMC, triethylamine, and water. N-acetylglucosamine is transferred to lactose via a (33 linkage in the presence of an aminidase (here Bbh1) to provide LNTII. UDP-galactose and fructose are obtained as described inFIG. 9B . In the presence of a transferase (as depicted Cvb3GalT), galactose is transferred to the acceptor LNTII to provide LNT. -
FIG. 9E depicts lactose obtained from glucose. UDP-galactose is obtained as described inFIG. 9B . Galactose is transferred to glucose in the presence of lactose synthase to obtain lactose. See Example 6C. -
FIG. 9F depicts lactose obtained from glucose, sucrose, and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase). See Example 7. -
FIG. 9G depicts lactose obtained from glucose, sucrose, fructose and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase). See Example 8. -
FIG. 9H depicts GOS obtained from galactose and sucrose. UDP-galactose and fructose are obtained as described inFIG. 9B . The galactose is transferred to a galactooligosaccharide (wherein n is 3-15) to increase the galactose chain by 1. - In some embodiments, the transferase is a galactosyltransferase that catalyzes the transfer of activated UDP-Galactose (UDP-Gal) to Glucose, Galactose or GlcNAc.
- In certain embodiments, the galactosyltransferase is a β-1,3-galactosyltransferase (EC 2.4.1.122). In particular embodiments, the β-1,3-galactosyltransferase is Cvβ3GalT from Chromobacterium violaceum, WbgO from Escherichia coli, CgtB from Campylobacter jejuni, B3GALT1 from Homo sapiens, B3GALT2 from Homo sapiens, B3GALT4 from Homo sapiens, or B3GALT5 from Homo sapiens.
- In certain embodiments, the galactosyltransferase is β-1,4-galactosyltransferase (EC 2.4.1.22, EC 2.4.1.38, EC 2.4.1.133, EC 2.4.1.275). In particular embodiments, the β-1,4-galactosyltransferase is NmLgtB from Neisseria meningitidis, NmLgtB-StGalE from Neisseria meningitidis and Streptococcus thermophilus, HpLgtB from Helicobacter pylori, B4GALT1 from Homo sapiens, B4GALT2 from Homo sapiens, B4GALT3 from Homo sapiens, B4GALT4 from Homo sapiens, B4GALT5 from Homo sapiens, B4GALT6 from Homo sapiens, B4GALT7 from Homo sapiens.
- In certain embodiments, the galactosyltransferase is a β-1,6-galactosyltransferase. In a particular embodiment, the β-1,6-galactosyltransferase is GalT29A from Arabidopsis thaliana.
- In certain embodiments, the galactosyltransferase is a α-1,3-galactosyltransferase (EC 2.4.1.87, EC 2.4.1.37). In particular embodiments, the α-1,3-galactosyltransferase is GTB (human proteins) synthetic gene expressed in E. coli or WbnL from E. coli.
- In certain embodiments, the galactosyltransferase is a α-1,6-galactosyltransferase (EC 2.4.1.241).
- In certain embodiments, the galactosyltransferase is selected from the galactosyltransferases depicted in the Figures.
- In certain embodiments, an auxiliary enzyme is employed in a route from a sugar donor precursor to a sugar-nucleotide donor. In those embodiments employing an auxiliary enzyme, a sugar donor precursor is converted to a sugar-nucleotide donor precursor in the presence of a transferase. The sugar-nucleotide donor precursor is then converted a sugar-nucleotide donor in the presence of the auxiliary enzyme. In certain embodiments, the auxiliary enzyme is a UDP-glucose 4-epimerase. In the galactosylation routes depicted in
FIG. 9A-H , the auxiliary enzyme is a UDP-glucose 4-epimerase from Bifidobacterium longum. - In some embodiments, an auxiliary enzyme is an oxidase (UDP-Glc-6-dehydrogenase, EC 1.1.1.22) that catalyzes the conversion of UDP-Glc to UDP-GlcA (UDP-Glucuronic acid).
- In some embodiments, an auxiliary enzyme is an enzyme that isomerize activated sugar nucleotides. In certain embodiments, the enzyme that isomerizes activated sugar nucleotides is an epimerase (UDP-Gal-4-epimerase, EC 5.1.3.2) that catalyzes the conversion of UDP-Glc to UDP-Gal. In a particular embodiment, the epimerase is EcGalE from Escherichia coli. In another particular embodiments, the epimerase is StGalE from Streptococcus thermophilus.
-
FIGS. 10A-10D depict sialylations with low cost sialoside and lactose hydrolysis. CMP-N-acetyl neuraminic acid (Neu5Ac) is the nucleotide-sugar employed in each ofFIGS. 10A-10D . As depicted in each figure, lactose is converted to galactose and glucose in the presence of lactase, and CMP-Neu5Ac is obtained in the presence of 3′-SL and the transferase ST3GAL4. -
FIG. 10A depicts a route for obtaining LSTa from LNT. In the presence of the transferase ST3GAL4, ST3GAL3, and lactase, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain LSTa. -
FIG. 10B depicts a route for obtaining LSTc from LNnT. In the presence the transferase ST3GAL4, ST6GAL1, and lactase, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTc. -
FIG. 10C depicts a route LSTd is obtained from LNnT. In the presence the transferase ST3GAL4, ST3GAL3, and lactase N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNnT to obtain LSTd. - In
FIG. 10D depicts a route for obtaining DSLNT from LNT. In the presence the transferase ST3GAL3, ST6GALNAC5, ST3GAL4, and lactase, N-acetyl neuraminic acid is transferred from CMP-Neu5Ac to LNT to obtain DSLNT. - Some embodiments of this invention employ sialyltransferase to catalyze the transfer of CMP-sialic acid (e.g., CMP-Neu5Ac) onto either GlcNAc, Galactose or Neu5Ac. The methods depicted in
FIG. 2A-2D andFIG. 10A-D employ sialyltransferases to transfer a sialyl group from a sugar nucleotide donor to an acceptor. - In certain embodiments of this invention the sialyltransferase is an α-2,3-sialyltransferase (EC 2.4.99.4, EC 2.4.99.6, EC 2.4.99.7, EC 2.4.99.9). In particular embodiments, the α-2,3-sialyltransferase is PmST1 (wild type and mutants) from Pasteurella multocida, NmST1-NmCSS fusion from Neisseria meningitidis, ST3GAL1 from Homo sapiens, ST3GAL2 from Homo sapiens, ST3GAL3 from Homo sapiens, ST3GAL4 from Homo sapiens, or ST3GAL5 from Homo sapiens, ST3GAL6 from Homo sapiens.
- In certain embodiment of this invention the sialyltransferase is an α-2,6-sialyltransferase (EC 2.4.99.1, EC 2.4.99.3). In particular embodiments, the α-2,6-sialyltransferase is Pd26ST from Photobacterium damsel, ST6GAL1 from Homo sapiens, ST6GAL2 from Homo sapiens, ST6GALNAC1 from Homo sapiens, ST6GALNAC2 from Homo sapiens, ST6GALNAC3 from Homo sapiens, ST6GALNAC4 from Homo sapiens, ST6GALNAC5 from Homo sapiens, or ST6GALNAC6 from Homo sapiens.
- In certain embodiments of this invention, the sialyltransferase α-2,8-sialyltransferase (EC 2.4.99.8). In particular embodiments, the α-2,8-sialyltransferase is α-2,3/8-sialyltransferase from Campylobacter jejuni, ST8SIA1 from Homo sapiens, ST8SIA2 from Homo sapiens, ST8SIA3 from Homo sapiens, ST8SIA4 from Homo sapiens, or ST8SIA5 from Homo sapiens.
- In certain embodiments, the sialyltransferae is selected from the sialylltransferases depicted in the Figures.
-
FIGS. 11A-11E depict fucosylation using fucoside and lactose hydrolysis. GDP-1-fucose is the nucleotide-sugar used in each ofFIG. 11A-11C . -
FIG. 11A depicts a route for obtaining LNFPI from LNT. GDP-Fuc in the presence of 2′-FL, LNT, Te2FT, HmFucT, lactase, and GsAI provides LNFPI. -
FIG. 11B depicts a route for obtaining LNFPII from LNT. GDP-Fuc in the presence of 2′-FL, LNT Hp34FT, HmFucT, lactase, and GsAI provides LNFPII. -
FIG. 11C depicts a route for obtaining LNFPIII from LNnT. GDP-Fuc in the presence of 2′FL, LNnT FUT9, HmFucT, lactase, and GsAI provides LNFPIII. -
FIG. 11D depicts a route for obtaining DFL from 2′-FL. GDP-Fuc in the presence of 2′-FL, FUT1, FUT3, lactase, GsA1, and fucosidase provides 3-FL, tagatose, and glucose. -
FIG. 11E depicts a route for obtaining 3-FL from 2′-FL. GDP-Fuc in the presence of 2′-FL, FUT1, FUT3, lactase, and GsAI. Lactase depletes lactose in this route. Instead of lactase, any other enzymatic or nonenzymatic means may be used to deplete lactose. Additionally, GsAI may be added to convert galactose to tagatose to augment the reaction conversion. See Example 5a.D and Example 5a.E. - In some embodiments, a fucosyltransferase catalyzes the transfer of GDP-fucose (GDP-Fuc) onto either Galactose, Glucose, GlcNAc or GalNAc. The methods depicted in
FIG. 3A-C andFIG. 11A-E employ fucosyltransferases to transfer a fucosyl group from a sugar nucleotide donor to an acceptor. - In certain embodiments, the fucosyltransferase is an α-1,2-fucosyltransferase (EC 2.4.1.69). In particular embodiments, the α-1,2-fucosyltransferase is Te2FT from Thermosynechococcus elongatus, WbgL from Escherichia coli, HmFucT from Helicobacter mustelae, FUT1 from Homo sapiens, or FUT2 from Homo sapiens.
- In certain embodiments, the fucosyltransferase is an α-1,3-fucosyltransferase (EC 2.4.1.152, EC 2.4.1.214). In particular embodiments, the α-1,3-fucosyltransferase is HpFucT from Helicobacter pylori, Bf1,3FT from Bacteroides fragilis, Hp3/4FT from Helicobacter pylori, FUT3 from Homo sapiens, FUT4 from Homo sapiens, FUT5 from Homo sapiens, FUT6 from Homo sapiens, FUT7 from Homo sapiens, FUT9 from Homo sapiens, or FUT11 from Homo sapiens.
- In certain embodiments, the fucosyltransferase is an α-1,4-fucosyltransferase (EC 2.4.1.65). In particular embodiments, the α-1,4-fucosyltransferase is Hp3/4FT from Helicobacter pylori or FUT2 from Homo sapiens.
- In certain embodiments, the fucosyltransferase is an α-1,6-fucosyltransferase (EC 2.4.1.68). In a particular embodiment, α-1,6-fucosyltransferase is FUT8 from Homo sapiens.
- In certain embodiments, the fucosyltransferase is selected from the fucosyltransferases depicted in the Figures.
-
FIG. 12A andFIG. 12B depict routes N-acetylglucosaminylation using lacto-N-biose (LNB) as a GlcNAc donor. -
FIG. 12A depicts a route for obtaining LNTII and tagatose from LNB and lactose. UDP-N-Acetylglucosamine (UDP-GlcNAc) is prepared from UDP in the presence of NmLgtA and GsAI. -
FIG. 12B depicts a route for obtaining branched human milk oligosaccharides from LNB and LNnT in the presence of UDP, NmLgtA, GCNT2, and GsAI. β-2,6-GlcNAc-LNnT and tagatose is obtained. In the route depicted GsAI is present to deplete galactose. Any other enzymatic or nonenzymatic means to deplete galactose may be used instead of GsAI. - In some embodiments, an N-acetylglucosaminyltransferase catalyzes the transfer of UDP-N-acetylglucosamine (UDP-GlcNAc) to Galactose, Mannose or GlcNAc.
- In certain embodiments, the N-acetylglucosaminyltransferase is β-1,3-N-acetylglucosaminyltransferase (EC 2.4.1.79, EC 2.4.1.149, EC 2.4.1.222). In particular embodiments, the β-1,3-N-acetylglucosaminyltransferase is HpLgtA form Helicobacter pylori, NmLgtA from Neisseria meningitidis, HP1105 from Helicobacter pylori, B3GNT2 from Homo sapiens, B3GNT3 from Homo sapiens, B3GNT4 from Homo sapiens, B3GNT7 from Homo sapiens, B3GNT8 from Homo sapiens, or B3GNT9 from Homo sapiens.
- In certain embodiments, the N-acetylglucosaminyltransferase α-1,4-N-acetylglucosaminyltransferase (EC 2.4.1.223, EC 2.4.1.224).
- In certain embodiments, the N-acetylglucosaminyltransferase is a β-1,2-N-acetylglucosaminyltransferase (EC 2.4.1.101, EC 2.4.1.143). In particular embodiments, the β-1,2-N-acetylglucosaminyltransferase is MGAT1(GlcNAcT-I) from Homo sapiens or MGAT2 (GlcNAcT-II) from Homo sapiens.
- In certain embodiments, the N-acetylglucosaminyltransferase is a β-1,4-N-acetylglucosaminyltransferase (EC 2.4.1.144, EC 2.4.1.212). In particular embodiments, the β-1,4-N-acetylglucosaminyltransferase is MGAT3 (GlcNAcT-III) from Homo sapiens, MGAT4A (GlcNAcT-IV) from Homo sapiens, MGAT4B (GlcNAcT-IV) from Homo sapiens, or MGAT4C (GlcNAcT-IV) from Homo sapiens.
- In certain embodiments, the N-acetylglucosaminyltransferase is a β-1,6-N-acetylglucosaminyltransferase (EC 2.4.1.102, EC 2.4.1.150, EC 2.4.1.155). In particular embodiments, the β-1,6-N-acetylglucosaminyltransferase is GCNT2A from Homo sapiens, GCNT2B from Homo sapiens, GCNT2C from Homo sapiens, GCNT3 from Homo sapiens, GCNT4 from Homo sapiens, or MGAT5 (G1cNACT-V) from Homo sapiens.
- In certain embodiments, the N-acetylglucosaminyltransferase is selected from the N-acetylglucosaminyltransferases depicted in the Figures.
- In certain embodiments of this invention, the starting systems of reactants and enzymes comprise, consist essentially of, or consist of those described in
FIGS. 1-12 . - The invention uses sugars as an energy source. An activated sugar (sugar-nucleotide or sugar-nucleotide compound) is therefore a starting material and an energy source. The energy source is hydrolysis of more complex sugars into more simple sugars. This aids in driving reactions of this invention to completion. In one embodiment, sucrose is employed for galactosylation, and hydrolysis of lactose is used for both sialylation and fucosylation. In another embodiment, lacto-N-biose is used as a GlcNAc donor in N-acetylglucosaminylation reactions. In another embodiment, hydrolysis of 3′-SL is used in sialylation reactions. In another embodiment, 2′-FL is used in fucosylation reactions.
- The energy driver is a larger saccharide being converted to smaller saccharide. For example, energy is derived from a disaccharide breaking down, hydrolyzing, into a monosaccharide, such as sucrose breaking down into fructose and glucose. That is sucrose and water being converted into fructose and glucose via hydrolysis.
- The activated sugar is regenerated in the reaction mixture. This allows the nucleotide to be present in catalytic amounts. As depicted in each Figure, transfer of a sugar to an acceptor then results in formation of a free nucleotide. The nucleotide then reacts with a sugar to form an activated sugar. In
FIG. 1 , the nucleotide is added to glucose to form UDP-glucose, inFIG. 2 the nucleotide is added to N-acetyl neuraminic acid to form CMP-Neu5Ac, and inFIG. 3 the nucleotide is added to 2′-FL to form GDP-2′-FL. - Without being bound by theory, manganese (Mn) and high sucrose concentrations lead to enzyme deactivation. In certain embodiments, a process of this invention employs magnesium (Mg) instead of manganese (Mn). For example, Mn catalyzes the decomposition of UDP to UMP, and UMP leads to the reductive inactivation of a co-factor NAD+ in GalE. In certain embodiments, a process of this invention employs magnesium (Mg) instead of manganese (Mn) and relatively low concentrations of sucrose, for example, 50-100 mM.
- Manganese (Mn) and inorganic phosphate form insoluble byproducts, particularly at higher industrially relevant concentrations, that make it unsuitable for packed bed reactor applications and that result in the removal of the critical metal cofactor (Mn) from the solution phase which reduces the activity of many glycosyltransferases. Embodiments of this invention employ Mg and therefore avoid these disadvantages.
- Sugar nucleotides that have affinity for the enzymes of the invention may be employed in the processes disclosed herein. Enzymes that may be employed in this invention include those bioengineered for affinity. In certain embodiments, the activated sugar comprises, consists essentially of, or consists of: Galactose-UDP, Galactose-ADP, Sialic Acid-CMP, and Fucose-GDP. In certain embodiments, the activated sugar comprises, consists essentially of, or consists of: Galactose-UDP, Sialic Acid-CMP, and Fucose-GDP.
- In one embodiment, this invention provides a biocatalytic process for preparing a saccharide-acceptor comprising the steps of:
-
- a. contacting a saccharide and a nucleotide to form a saccharide-nucleotide, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the saccharide-nucleotide and an acceptor in the presence of a transferase to form the saccharide-acceptor.
- In certain embodiments, the saccharide is a monosaccharide. In certain embodiments, the monosaccharide is galactose, sialic acid, or 1-fucose.
- In another embodiment, this invention provides a process for preparing a saccharide compound, comprising the steps of:
-
- a. contacting a monosaccharide selected from galactose, sialic acid, and 1-fucose and a catalytic amount of a nucleotide selected from UDP, ADP, CMP, and GDP to form a saccharide-nucleotide compound; and
- b. contacting the saccharide-nucleotide compound and an acceptor compound in the presence of a transferase to obtain the saccharide.
- In another embodiment, this invention provides a process for preparing a saccharide compound, comprising the steps of:
-
- a. contacting a galactose saccharide unit and a catalytic amount of a nucleotide selected from UDP and ADP or a sialic acid or 1-fucose saccharide unit and a catalytic amount of a nucleotide selected from CMP, and GDP to form a saccharide-nucleotide compound.
- b. contacting the saccharide-nucleotide compound and an acceptor compound in the presence of a transferase to obtain the saccharide.
- In another embodiment, this invention provides for galactosylation of an acceptor compound, comprising the steps of:
-
- a. contacting galactose and a nucleotide to form a galactose-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the galactose-nucleotide compound and an acceptor compound in the presence of a transferase to galactosylate the acceptor compound.
- In certain embodiments, the galactose is obtained from sucrose in situ.
- In other embodiments, the process is driven to high conversion via the conversion of Sucrose to Glc-UDP and fructose.
- In another embodiment, this invention provides for a process for sialylation of an acceptor compound, comprising the steps of:
-
- a. contacting sialic acid and a nucleotide to form a sialyl-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the sialyl-nucleotide compound and a compound with an acceptor compound in the presence of a transferase to sialylate the acceptor compound.
- In certain embodiments, the sialic acid is obtained from 3′-SL or 6′-SL in situ.
- In other embodiments, the process is driven to high conversion via the conversion of lactose to galactose and glucose.
- In another embodiment, this invention provides for a process for fucosylation of an acceptor compound, comprising the steps of:
-
- a. contacting a fucose and a nucleotide to form a fucose-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the fucose-nucleotide compound and an acceptor compound in the presence of a transferase to fucosylate the acceptor compound.
- In certain embodiments the fucose is 1-fucose and is obtained from 2′-FL in situ. In other embodiments the process is driven to high conversion via the conversion of sucrose to Glc-UDP and fructose. In yet other embodiments of this invention, the acceptor compound is a monosaccharide, a disaccharide, an oligosaccharide, or a polysaccharide. In yet other embodiments of this invention there is substantially no ATP added to the process or generated by the process.
- In another embodiment, this invention provides a process for producing LNT and fructose, comprising the step of contacting LNTII, sucrose, a transferase, a sucrose synthase, an epimerase, and UDP to produce LNT and fructose, wherein galactose-UDP is produced, and wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or the sucrose. In certain embodiments, the transferase is Cvb3GalT. In other embodiments, the transferase transferase is B3GALT5. In certain embodiments the epimerase is GalE.
- In another embodiment, this invention provides a process for producing LNnT and fructose, comprising contacting LNTII, sucrose, a glycosyltransferase, a sucrose synthase, an epimerase, and UDP to produce LNnT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or sucrose. In certain embodiments the glycosyltransferase is a LgtB. In other embodiments the LgtB is NmLgtB. In certain embodiments, the glycosyltransferase is B4GALT1. In certain embodiments, the glycosyltransferase is B4GALT1. In certain embodiments, the epimerase is GalE.
- In another embodiment, this invention provides a process for preparing LNT and fructose, comprising the steps of contacting GlcNAc, 2-chloro-1,3-dimethylimidazolinium chloride, and a base to obtain a reaction mixture comprising GlcNAc-Oxa; and contacting the reaction mixture comprising GlcNAc-Oxa, lactose, sucrose, an aminidase, a transferase, a sucrose synthase, and an epimerase, to provide LNT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10% molar percent of the lactose or the sucrose.
- In certain embodiments, the aminidase is Bbh1. In certain embodiments, the transferase is Cvb3GalT. In certain embodiments, the epimerase is GalE. In certain embodiments, the base is triethylamine.
- In another embodiment, this invention provides a process for preparing lactose and fructose, comprising contacting glucose, sucrose, a lactose synthase, a sucrose synthase, an epimerase, and UDP, to provide lactose and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the glucose and or the sucrose. In certain embodiments, the epimerase is GalE.
- In another embodiment, this invention provides a process for preparing LSTa, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide LSTa, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL. In certain embodiments the sialyltransferase is ST3GAL3.
- In another embodiment, this invention provides a process for preparing LSTb comprising contacting LNT, 3′-SL, and catalytic amounts of CMP in the presence of ST3GAL4, ST3GAL3, ST6GALNAC5, Lactase and α2-3 Neuraminidase S, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL, wherein lactose is obtained and then processed to glucose and galactose by lactase, and wherein α2-3 Neuraminidase S converts DSLNT to LSTb.
- In another embodiment, this invention provides a process for preparing LSTc, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTc, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL. In certain embodiments, the sialyltransferase is ST3GAL3.
- In another embodiment, this invention provides a process for preparing LSTd, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTd, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL. In certain embodiments, the sialyltransferase is ST3GAL3.
- In another embodiment, this invention provides a process for preparing DSLNT, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide DSLNT, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10% molar percent of the 3′-SL. In certain embodiments, the sialyltransferase is ST3GAL3 and ST6GALNAC5.
- In another embodiment, this invention provides a process for preparing LNFPI, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Te2FT, HmFucT, and lactase to provide LNFPI, galactose, and glucose wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL In certain embodiments, the transferase is Te2FT and HmFucT.
- In another embodiment, this invention provides a process for preparing LNFPII, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Hp34FT, HmFucT, and lactase, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL. In certain embodiments, the transferase is Hp34FT and HmFucT.
- In another embodiment, this invention provides a process for preparing LNFPIII, galactose, and glucose, comprising contacting 2′-FL, LNnT, GDP, FUT9, HmFucT, and lactase, to provide LNFPIII, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL. In certain embodiments, the transferase is FUT and HmFucT.
- In another embodiment, this invention provides a process for preparing 3-FL, comprising contacting 2′-FL, GDP, FUT1, FUT3, lactase, GsAI, and fucosidase to provide 3-FL, tagatose, and glucose, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- In another embodiment, this invention provides a process for preparing LNTII, comprising contacting LNB, lactose, UDP, NmLgtA, and GsAI to provide 3-FL, tagatose, and glucose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- In another embodiment, this invention provides a process for preparing LNTII, comprising contacting LNB, lactose, UDP, NmLgtA, and GsAI to provide 3-FL, tagatose, and glucose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- In another embodiment, this invention provides a process for preparing β-1,6-GlcNAc-LNnT, comprising contacting LNB, LNnT, UDP, NmLgtA, GCNT2, and GsAI to provide β-1,6-GlcNAc-LNnT and tagatose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the LNB.
- In certain embodiments, the sialic acid is N-acetyl neuraminic acid (Neu5Ac).
- In certain embodiments, the sugars are in their naturally occurring isomeric forms. In some embodiments, the glucose is D-glucose. In some embodiments, galactose is D-galactose. In some embodiments, fucose is L-fucose. In some embodiments, tagatose is D-tagatose. In some embodiments, N-acetylglucosamine (GlcNAc) is N-Acetyl-D-glucosamine. In some embodiments, fructose is D-fructose.
- In other embodiments, the nucleotide is present in the catalytic amount of about 0.01 to about 10 molar percent relative to the saccharide amount. The relevant saccharide is either the staring saccharide or the saccharide that is generated and reacts with the nucleotide.
- In some embodiments, the nucleotide monophosphates and diphosphates used in this invention are used in catalytic amounts relative to the molarity of sugar that is bound to the monophosphate or diphosphate. In another embodiment, the nucleotide monophosphates and diphosphates used in this invention are used in catalytic amounts relative to the molarity of starting material sugar or other acceptor. These nucleotides include natural, artificial, or synthetic nucleotides. As used herein, a “catalytic amount” of nucleotide ranges are in an amount of precisely, about, up to, or less than, for example 0.01% to 10% moles of nucleotide to moles of sugar, either sugar donor or acceptor molecule. As used herein, a “catalytic amount” of nucleotide ranges are in an amount of precisely, about, up to, or less than, for example 0.001% to 10% moles of nucleotide to moles of either sugar donor or acceptor molecule. In other embodiments, the nucleotide monophosphates or nucleotide diphosphates are in an amount of precisely, about, up to, or less than, for example 0.001% to 1% (mol percent). In certain embodiments, the nucleotide monophosphates and diphosphates are in an amount of precisely, about, up to, or less than, for example 0.01% to 10% (mol percent). In other embodiments, the nucleotide monophosphates or nucleotide diphosphates are in an amount of precisely, about, up to, or less than, for example 0.1% to 1% (mol percent). In other embodiments, precisely, about, up to, or less than, for example, the nucleotide monophosphates and nucleotide diphosphates are added in an amount of 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, or 0.09%, (mol percent). In other embodiments, the nucleotide monophosphates and nucleotide diphosphates are added in an amount of precisely, about, up to, or less than, for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1.0% (mol percent). In other embodiments, the nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely, about, up to, or less than, for example, the monophosphates and diphosphates are added in an amount of 0.01%, 0.1%, 0.3%, 1.0%, or 10% (mol percent). In other embodiments, the nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely, about, up to, or less than, for example, the monophosphates and diphosphates are added in amount of 0.1, 0.3, or 1.0% (mol percent). In other embodiments, the nucleotide monophosphates and nucleotide diphosphates are added in amounts of precisely or about 0.001%, 0.01%, 0.1%, 1.0%, or 10%. In other embodiments, the monophosphates and diphosphates are added in amounts of precisely or about 0.1%, 1.0%, or 10%. In other embodiments, the monophosphates and diphosphates are added in amounts of precisely or about 0.1%, 0.3%, or 1.0% (mol percent).
FIG. 1-14 depict embodiments employing catalytic nucleotides. - In some embodiments, plant sugars are used to create glycosylated compounds including, but not limited to, galactosylated compounds, sialylated compounds, and fucosylated compounds, wherein the galactose, sialic acid, and fucose is added to a hydroxy group including, but not limited to, a hydroxy group of a sugar. In another embodiment lacto-N-biose is used as a GlcNAc donor to be added to a hydroxy group of a sugar in an N-acetylglucosaminylation reaction. Accordingly, plant sugars or simple HMOs produced by microbial fermentation, or from animal origin, are used to create more complex saccharides including, but not limited to, oligosaccharides found in animals. In certain embodiments, the compounds include, but are not limited to LNT, LNnT, lactose, GOS, LSTa, LSTc, LSTd, DSLNT, LNFPI, LNFPII, LNFPIII. In other embodiments, the compounds include, but are not limited to, LSTb and 3-FL. In other embodiments, plant sugars are used to synthesize lactose derivatives by chemoenzymatic processes to obtain lactose derivatives including, but not limited to, lactobionic acid, lactitol, lactosucrose, galacto-oligosaccharides (GOS), lactulose, and HMOs (see
FIG. 5 ). M. G. Ganzle et al., International Dairy Journal, 18 (2008) 685-694. - As depicted in
FIG. 5 , lactobionic acid is obtained from lactose via an oxidation reaction. Lactitol is obtained from lactose via a reduction reaction. Lactosucrose is obtained from lactose via fructosyl transfer. Galacto-oligosaccharides (β-(1,4) or (β-(1,6) linkages) are obtained from lactose via transgalactosylation. Lactulose is obtained from lactose via isomerization. - In certain embodiments, the products obtained from the processes of this invention are not animal derived. Such products are advantageous in markets where animal-free products are desired.
- This approach obviates the need for ATP and cofactor recycling. In certain embodiments, the activated sugars are activated galactose, activated Neu5Ac, activated fucose, or activated glucose. In another embodiment, the activated sugar is N-acetylglucosamine (GlcNAc). These activated sugars are generated in situ. The reactions are designed to be nucleotide triphosphate free and to avoid reagent and co-factor recycling or regeneration. This reduces the number of enzymes needed to produce each oligosaccharide and avoids acidification. This reduces costs and leads to higher yields and higher purity products.
- In certain embodiments, more than one saccharide secondary product is produced in the reaction mixture. In certain embodiments, glucose and galactose are both produced as secondary products in a single reaction mixture.
- In certain embodiments, a processing enzyme is employed to convert a secondary product into a secondary product derivative. In certain embodiments, the conversion is beneficial in driving the reaction to completion towards formation of the principal product. In other embodiment, the conversion can be tailored to obtain a more desired secondary product derivative for recovery and reuse.
- In certain embodiments, a processing enzyme is employed to convert a principal product to a principal product derivative. In certain embodiments, the conversion is beneficial to obtain a more desired principal product derivative for recovery and reuse.
- In certain embodiments, more than one processing step may be employed to further convert either a principal product derivative or a secondary product derivative. The number of processing steps employed depends on driving the reaction to completion and obtaining a desired final product. Certain galactosylation methods of this invention employs none or one processing of either the principal product or the secondary product. In certain embodiments, no processing step is employed in galactosylation methods of this invention. Certain sialylation, fucosylation, and N-acetylglucosaminylation methods employ none, one, or two processing of either the principal product or the secondary product. In certain sialylation, fucosylation, and N-acetylglucosaminylation embodiments, one processing step converts the principal product to a principal product derivative or the secondary product to a secondary product derivative.
- Some embodiments of this invention employ a processing enzyme that either hydrolyzes, oxidizes, or isomerizes a carbohydrate or oligosaccharide.
- In certain embodiments, the processing enzyme is an enzyme that hydrolyzes lactose. In particular embodiments, the enzyme the hydrolyzes lactose is Lactase (β-galactosidase) (EC 3.2.1.23). In more particular embodiments, the Lactase is (β-galactosidase from Aspergillus niger, β-galactosidase from Escherichia coli, (β-galactosidase from Aspergillus oryzae, or β-galactosidase from Kluyveromyces lactis.
- In certain embodiments, the processing enzyme is an enzyme that oxidizes lactose carbohydrates. In particular embodiments, the enzyme that oxidizes lactose carbohydrate is a glucose oxidase (EC 1.1.3.4). In more particular embodiments, the glucose oxidase is Glucose oxidase from Aspergillus niger, Glucose oxidase from Penicillium amagasakiense, Glucose oxidase from Penicillium notatum (chrysogenum), Glucose oxidase from Penicillium variabile, Galactose oxidase (EC 1.1.3.9), Galactose oxidase from Dactylium dendroides, Galactose oxidase from Polyporus circinatus, Galactose oxidase from Fusarium graminearum, Galactose oxidase from Drosophila melanogaster.
- In particular embodiments, the enzyme that oxidizes lactose carbohydrate is an enzyme that oxidizes lactose to Lactobionic acid. In more particular embodiments, the enzyme that oxidizes lactose carbohydrate is Carbohydrate oxidase from Microdochium nivale, Lactose oxidase from Myrmecridium flexuosum, Lactose oxidase from Sarocaldium oryzae, Lactose oxidase from Paraconiothyrium sp., Galactose oxidase (EC 1.1.3.9) from Polyporus circinatus, Cellobiose dehydrogenase (EC 1.1.99.18) from Sclerotium rolfsii, Cellobiose quinone oxidoreductase (EC 1.1.5.1) from Phanerochaete chrysosporium, Cellobiose quinone oxidoreductase (EC 1.1.5.1) from Spotoyrichum pulverolentum, carbohydrate oxidoreductase from Sarocladiumoryzae, carbohydrate oxidoreductase from Paraconiothyrium sp., or Glucooligosaccharide oxidase GOOX from Acremonium strictum.
- In certain embodiments, the processing enzyme is an enzyme that isomerizes carbohydrates. In particular embodiments, the enzyme that isomerizes carbohydrates is a glucose isomerase (xylose isomerase) (EC 5.3.1.5). In more particular embodiments, the glucose isomerase is Glucose isomerase from Streptomyces murinus, Glucose isomerase from Actinoplanes missouriensis, Glucose isomerase from Bacillus coagulans, Glucose isomerase from Arthrobacter, or Glucose isomerase from Xanthomonas campestris.
- In particular embodiments, the enzyme that isomerizes carbohydrates is L-Arabinose isomerase (Galactose isomerase) (EC 5.3.1.4). In more particular embodiments, the L-Arabinose isomerase is L-Arabinose isomerase from Geobacillus stearothermophilus L-Arabinose isomerase from Lactobacillus sakei, L-Arabinose isomerase from Bacillus subtilis, L-Arabinose isomerase from Escherichia coli or L-Arabinose isomerase from Thermoanaerobacter mathranii.
- In some embodiments, the processing enzyme is an enzyme that hydrolyze carbohydrates. In certain embodiments, enzyme that hydrolyze carbohydrate is a fucosidase. Fucosidases are enzymes that catalyze the hydrolysis fucose from a glycan, carbohydrate, or glycan bearing moiety. In particular embodiments, the fucosidase is α-1,2-fucosidase (EC 3.2.1.63), α-1,3-fucosidase (EC 3.2.1.111) or α-1,4-fucosidase (EC not known).
- In certain embodiments, enzyme that hydrolyze carbohydrate is a sialidase (Neuraminidase). Sialidases are enzymes that catalyze the hydrolysis of sialic acid from a glycan, carbohydrate, or glycan bearing moiety. In particular embodiments, the sialidase is an xo-α-sialidase. In more particular embodiments, the exo-a-sialidase is α2-3 Neuraminidase S, α2-3,6,8,9 Neuraminidase A, α2-3,6,8 Neuraminidase.
- In particular embodiments, the sialidase is an Endo-a-sialidase. In a more particular embodiment, the sialidase is α2,8 Neuraminidase.
- In certain embodiments, a processing enzyme is selected from the fucosyltransferases depicted in the Figures.
- In certain embodiments of the galactosylation reactions exemplified herein fructose is the secondary product produced and may be recovered or processed for further use. In certain embodiments of the sialylation and fucosylation reactions exemplified herein galactose and glucose are the secondary products produced and may be recovered or processed for further use. In certain embodiments of the acetylglucosaminylation reactions exemplified herein lactose or galactose are the secondary products produced and may be recovered or processed (e.g., to tagatose) for further use.
- The nucleotides may also be recovered. In the embodiments exemplified herein, UDP or ADP may be recovered in galactosylation reactions, CMP may be be recovered in the sialylation reactions, and GDP may be recovered in the fucosylation reactions.
- In certain embodiments, glycans are obtained in the methods of this invention.
- Glycans, are carbohydrate-based compounds featuring one or more monosaccharides linked with a glycosidic bond, including N-linked and O-linked bonds. Activated monosaccharides, oligosaccharides, polysaccharides, plant glycans, animal glycans, and microbe glycans are all within the scope of this invention as are glycoconjugates, such as glycolipid, glycopeptides, glycoproteins, and proteoglycans. Glycans also include humanized glycoproteins, humanized antibodies, and glycoconjugate vaccines. Riley, et al. “Glycosylation in health and disease” Nature Reviews Nephrology volume 15, pages 346-366 (2019). Rappuoli, “Glycoconjugate vaccines: Principles and mechanisms” Science Translational Medicine 29 Aug. 2018: Vol. 10, Issue 456. The forgoing are incorporated by reference in their entirety.
- Compounds that are acceptors may be derivatized with a glycosyl group according to this invention. Any organic compounds comprising at least one alcohol (hydroxyl) functional group may be an acceptor and therefore glycosylated by the processes of this invention. Such compounds may include, but are not limited to, rare sugars, activated sugars, HMOs, glycans with sugar modifications, glycosylated small molecules, polymerized fiber sugars, inulins, levans, gluconic acid, invert sugar, flavors, and fragrances. Organic compounds bearing at least one alcohol functional group (organic hydroxy functional group) that may be glycosylated according to this invention include, but are not limited to, Steviol, a class of compounds called Rebaudiosides, phenolic compounds, proteins with O-glycosylation and N-glycosylation sites: serine, threonine asparagine as well as compounds related thereto.
- In another aspect the present invention provides an integrated pathway using immobilized enzymes to perform a synthesis of oligosaccharides, including embodiments utilizing a one-pot synthesis of fucosolyated oligosaccharides starting from fructose or glucose. This lowers the cost of production of fucosylated HMOs vs using fucose as a starting material. A glycan to be fucosylated may be prepared separately for use a one-pot synthesis of this invention.
- The invention provides cell-free de-novo synthesis of fucosylated glycan starting from simple sugars. An integrated pathway of immobilized enzymes perform the one-pot fucosylation of oligosaccharides or antibody-glycan conjugates starting from fructose or glucose, rather than fucose. The system of immobilized enzymes comprises, consists essentially of, or consists of:
-
- An enzyme that converts fructose and/or glucose to mannose
- A set of enzymes to convert mannose to GDP-mannose
- A set of enzymes that converts GDP-mannose to GDP-fucose
- An enzyme that transfers fucose to an oligosaccharide backbone from GDP-fucose
- A set of enzymes that recycle cofactors from stochiometric reagents
- The
HMO 2′-FL may be produced from lactose. The last transferase of the enzyme cascade can be changed to fucosylate other oligosaccharides backbones. The switch to a different fucosyltransferase constitutes a separate HMO production, again via a one-pot system. For example, one fucosyl transferase would be employed to make 2′-FL, another fucosyl transferase would be employed LNFP1, and another fucosyl transferase would be employed SM to makes LNFPII etc. Thus, modularity arises from changing the last enzyme of the system (i.e., the fucosyl transferase). - The methods provide high volumetric productivity, are cost effective, and are non-GMO label.
- The immobilized enzymes may be coupled to a processing plant producing lactose, fructose, or glucose feeds for continuous flow manufacturing. The invention may be integrated to a biorefinery to convert glucose or fructose to fucosylated HMOs.
- The last transferase of the enzyme cascade can be changed to transfer GDP-fucose to other oligosaccharides backbones for fucosylation reactions.
- The cascade of enzymes can produce GDP-mannose that can also be polymerized to mannans via transferase enzymes.
- As depicted in
FIG. 15 , glucose and/or fructose is converted to GDP-L-fucose in an integrated synthesis. Enzyme E1 converts glucose to mannose. Alternatively, enzyme E1′ converts fructose to mannose. Then enzyme E2 converts mannose to mannose-6-phosphate. Enzyme E3 converts mannose-6-phosphate to mannose-1-phosphate. Enzyme E4 converts mannose-1-phosphate to GDP-D-mannose. Enzyme E5 converts GDP-D-mannose to GDP-4-keto-6-deoxymannose. Enzyme E6 converts GDP-4-keto-6-deoxymannose to GDP-L-fucose. 2′FL is obtained from GDP-L-fucose, lactose, and enzyme E7. All enzymes are immobilized - Regeneration enzymes are also depicted in
FIG. 15 . Enzymes E8, E9, E10, and E11, and E12 regenerate reagents to allow for the integrated synthesis. The following reaction occur: GDP to GTP (E10), inorganic diphosphate to inorganic phosphate (E12), carbon dioxide and hydrogen peroxide to oxygen and water (E11), ADP to ATP (E10), acetate phosphate to acetate (E10), inorganic phosphate and pyruvate to acetate phosphate (E9), and formate to carbon dioxide (E8). - In one embodiment, enzymes used are Glk, RfbK, RfbM, Gmd, and GFS along with regeneration enzymes Pyruvate-AcK, PyrOx, and FDH. The enzymes convert glucose and/or fructose to mannose, then mannose to mannose-6-phosphate, then mannose-6-phosphate to mannose-1-phosphate, then mannose-1-phosphate to GDP-D-mannose, then GDP-D-mannose to GDP-4-keto-6-deoxymannose, and then GDP-4-keto-6-deoxymannose to GDP-L-fucose. Further reactions involve fucosylation of any sugar residue including, but not limited to, oligosaccharides or fucosylated antibody-glycan conjugates. In the presence a fucosyl transferase and GDP-L-fucose, lactose is converted to 2′FL via fucosyl transferase. Similarly, an oligosaccharide is converted to a fucosylated oligosaccharide or an antibody-glycan conjugate is converted to a fucosylated antibody-glycan conjugate. The depicted fucosyl transferase of the enzyme cascade may be changed to transfer GDP-fucose to other oligosaccharides backbones for fucosylation reactions to provide fucosylated products.
- For example, the enzyme AcK transfers a phosphate from AcPi to GDP to make GTP and by product Ac (=acetate). Pi both from the PtxD step (in the examples using phosphite) and the PmPpa step will be used by PyrOx.
- Lactose, fructose, pyruvate and phosphite are primary reactants in the integrated synthesis. Buffers including, but not limited to, Tris may be used. In some embodiments, the buffer maintains the pH between about pH 6.5 and about 8.5 or about 7.5.
-
FIG. 16 depicts the same structural transformations ofFIG. 15 with a different regeneration system. Here, the regeneration enzymes are E8′, E9, E10, E11, and E12. Here, E8′ converts phosphite to inorganic phosphate and NADP+ to NADPH. Enzymes that may be employed are pyruvate-AcK, PyrOx, and PtxD. -
FIG. 17 depicts the same structural transformations ofFIG. 15 with a different regeneration system employing E8, E9′, and E12. Here the regeneration enzymes are PolyP-PPK and FDH. -
FIG. 18 depicts the same structural transformations of as inFIG. 15 , with a different regeneration system. Here, the regeneration enzymes are E8′, E9′, and E12. E9′ is involved in converting ADP to ATP and GDP to GTP, and E8′ converts phosphite to Pi. E12 converts PPi to Pi and converts NADP+ to NADPH. Enzymes that may be used include PolyP-PPK and PtxD. - Feed solutions are also employed in the reactions depicted in
FIGS. 15-18 . - For example, the feed solution comprises lactose, fructose, formate, MgCl2, Tris, pyruvate, NADP+, GDP, and ATP (
FIG. 15-18 ). - For example, a feed solution comprises lactose, fructose, phosphite, MgCl2, a buffer (e.g., Tris buffer), GDP, NADP+, pyruvate, and ATP (
FIG. 16 ). - Alternatively, the feed solution comprises lactose, fructose, formate, MgCl2, Tris, polyphosphate, a buffer (such as Tris buffer), GDP, NADP+, and ATP (
FIG. 17 ). - Alternatively, the feed solution comprises lactose, fructose, phosphite, MgCl2, a buffer (such as Tris buffer), GDP, NADP+, polyphosphate, and ATP (
FIG. 18 ). - Glucose or fructose are interchangeable, however the first enzyme must match the starting sugar. Accordingly, either glucose and fructose are interchangeable with the addition of appropriate enzymes E1 or E1′, respectively.
- In certain embodiments, compounds that may be fucosylated according to methods of this invention include, but are not limited to, rare sugars, activated sugars, HMOs, and glycans.
- Without being bound by theory, manganese (Mn) in combination with high sucrose concentrations leads to enzyme inactivation. In certain embodiments, a process of this invention employs magnesium (Mg) instead of manganese (Mn) and does not include UMP. Under these conditions, high sucrose does not lead to reductive inactivation of GalE.
- In certain embodiments the sugars are plant derived. Accordingly, any of the embodiments of this invention may be employed to obtain a compound from non-animal based plant materials. In certain embodiments, the products obtained from the processes of this invention are not animal derived. Such products are advantageous in markets where animal-free products are desired.
- Glycans synthesized as described herein may be simple or complex glycan that may be linear or branched. In certain embodiments, the glycans to be fucosylated may be simple glycans or complex glycan, including linear or branched. Glycans having one or more sugar units are included. In certain embodiments, the glycans have two, three, four, or five sugar units or more units. In some embodiments, the glycans have 1-18 units. In some embodiments, the glycans have 1-10 units. In some embodiments, the glycans have 1-5 units. In certain embodiments, the glycans have five sugar units or more. In certain embodiments, the glycans have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 units. In certain embodiments, the glycans have 1 unit, 2 units, 3 units, 4 units, 5 units, or 6 units. In some embodiments, the glycans are oligosaccharides. In some embodiments, the glycans are straight chained or branched chained. In certain embodiments, the glycans have 1-6 units and are straight chained. In other embodiments, the glycans have 1-6 units and are branched. In certain embodiments, the glycans have 1-5 units and are straight chained. In other embodiments, the glycans have 1-5 units and are branched. In
FIG. 1F n is 3-15. In certain embodiments, n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. - Compounds obtained according to this invention including, but not limited to, galactosylated, sialylated, fucosylated, and N-acetylglucosaminylation compounds, may be used as components in the synthesis of any glycan-containing compound. In certain embodiments, compounds obtained according to this invention include, but are not limited to, galactosylated compounds. The materials functionalized with enzymes, or enzyme systems, have applications for the production of pharmaceuticals, biologicals, nutraceuticals, cosmeceuticals, and food ingredients. In certain embodiments, the sugars and oligosaccharides are non-animal derived.
- In one embodiment, fucosylated compounds obtained according to this invention may be used as components in the synthesis of any glycan-containing compound. With the ability to immobilize any enzymes for any processes, the materials functionalized with enzymes, or enzyme systems, have applications for the production of pharmaceuticals, biologicals, actives nutraceutical, actives cosmeceutical and food ingredients.
- In certain embodiments, the methods provide fucosylated oligosaccharides or fucosylated antibody-glycan conjugates. In preferred embodiments, fucosylated human milk oligosaccharides (HMOs) are produced.
- In certain embodiments, the methods provide galactosylated oligosaccharides or galactosylated antibody-glycan conjugates. In preferred embodiments, galactosylated human milk oligosaccharides (HMOs) are produced.
- In certain embodiments, the glycan to be reacted (e.g., galactosylated, sialylated, or fucosylated) is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′″3,3′″6-di-O-α-Sia-
LNnH 3′″3,3′″6-di-O-α-Sia-(3″3,3″6-di-O-α-Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, α-2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary lacto-N-neohexaoses and heptaoses. - In certain embodiments, the glycan to be fucosylated is 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd and DSLNT, LNnH, 3′″3,3′″6-di-O-α-Sia-
LNnH 3′″3,3′″6-di-O-α-Sia-(3″3,3″6-di-O-α-Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, α-2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary lacto-N-neohexaoses and heptaoses. In certain embodiments, the glycans are 3′SL LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, 2′-FL, LNnH, DSLNnH, or DSDFLNNH. In other embodiments, the glycans are 3′SL, LNTII, 2′-FL, LNFPI, LSTa. - In certain embodiments, the glycan to be reacted (e.g., galactosylated) is 2′-FL, 3′SL, LNTII, LNT, LNnT, LNFPI, LNFPII, LNFPIII, LSTa, LSTb, LSTc, LSTd, DSLNT, LNnH, 3′″3,3′″6-di-O-α-Sia-
LNnH 3′″3,3′″6-di-O-α-Sia-(3″3,3″6-di-O-α-Fuc)-LNnH, biantennary sialylated or fucosylated lacto-N-neohexaoses and neoheptaoses, α-2,3-sialyl lacto-N-neopentaose, linear fucosyl- and sialyl-lacto-N-neo-pentaoses, linear lacto-N-neopentaoses, or biantennary lacto-N-neohexaoses and heptaoses. - The enzymes used herein may be natural or synthetic, bioengineered enzymes, including fusion enzymes. For example, enzymes may be engineered for affinity towards immobilization scaffolds (tags). Enzymes may also be engineered for improved kinetic properties (e.g., lower Km).
- In certain embodiments, the enzymes are immobilized. The immobilization of the enzymes may be through covalent immobilization, entrapment, adsorption, molecular tagging with affinity tags, protein affinity tags, noncovalent adsorption, noncovalent deposition, entrapment, physical entrapment, bioconjugation, chelation, cross-linking, or disulfide bonds. See, e.g., Basso & Serban Mol. Catal. 479 (2019) 110607; Xu et al. Frontiers in Bioeng & Biotech., Published 30 Jun. 2020 publdoi: and Sheldon & van Pelt Chem. Soc. Rev., 2013, 42, 6223. The foregoing are incorporated by reference herein in their entirety.
- In embodiments that employ immobilized enzymes, such enzymes include, but are not limited to, enzymes immobilized within bionanocatalysts (BNCs) that in turn are embedded within scaffolds. Bionanocatalysts (BNCs) according to this invention comprise an enzyme self-assembled with magnetic nanoparticles (MNPs). The BNCs self-assemble with the scaffolds.
- In some embodiments the immobilized enzymes are non-magnetic. In certain embodiments, such as for oligosaccharides to be used in food ingredients, the immobilized enzymes do not comprise nanoparticles.
- In other embodiments, the immobilized enzymes involve permanent molecular entrapment of enzymes within self-assembling nanoparticle (NP) clusters. The self-assembly is purely driven by the materials' electrostatic and magnetic interactions. Ionic strength, buffer pH, and NP concentration are the main parameters impacting the immobilization yield and optimized enzyme activity. The clusters are then magnetically templated onto magnetic scaffolds or shapeable magnetic scaffolds.
- In these embodiments, immobilized bionanocatalysts are magnetic materials with one or more enzymes that are immobilized and associated with scaffolds. In some embodiments, the scaffolds are high magnetism and high porosity metal oxides or composite blends of thermoplastics or thermosets comprising magnetic particles that form powders. In some embodiments, Selective Laser Sintering (SLS) is used to design and produce objects via 3D printing by sintering composite magnetic powders.
- Certain immobilized enzymes, MNPs, macroporous powders, scaffolds, their structures, organizations, suitable enzymes, and uses are described in WO2012/122437, WO2014/055853, WO2016/186879, WO2017/011292, WO2017/180383, WO2018/34877, WO2018/102319, WO2020/051159, WO2020/69227, as well as WO2022/119982 (U.S. App. Nos. 63/120,669), 63/285,082, and 63/430,271, and 63/448,218. The foregoing are incorporated by reference herein in their entirety.
- Bionanocatalysts (BNCs) comprise an enzyme self-assembled with magnetic nanoparticles (MNPs). Self-assembled mesoporous aggregate of magnetic nanoparticles comprise a glycan synthesis enzyme, wherein the mesoporous aggregate is immobilized on a magnetic macroporous scaffold. In one embodiment, the immobilized enzymes comprise (i.) a glycan synthesis enzyme self-assembled in magnetic nanoparticles, and (ii.) a magnetic scaffold. A glycan enzyme is immobilized on nanoparticles where the nanoparticles coat a scaffold, and the enzyme is immobilized in or on the mesoporous structure formed by the nanoparticles.
- In one embodiment, the nanoparticles comprise magnetite (Fe3O4) or maghemite (Fe2O3). In another embodiment, the nanoparticles comprise a product synthesized from FeCl2 and FeCl3, particularly synthesized via continuous coprecipitation of FeCl2*4H2O and FeCl3. FeCl2*4H2O (Iron (II) chloride tetrahydrate and FeCl3*6H2O (Iron (III) chloride hexahydrate. Accordingly, in one embodiment, the nanoparticles comprise magnetite (Fe3O4).
- A glycan synthesis enzyme is any enzyme that can be used in the synthesis of a glycan. Steps in glycan synthesis may include activating a sugar, transferring a sugar unit thereby extending a sugar, cofactor recycling, and equilibrium shifting. Glycan synthesis enzymes include, but are not limited to, a sugar activation enzyme, a sugar extension enzyme, a reagent regeneration enzyme, and a sugar functionalization enzyme. In another embodiment, glycan synthesis enzymes include, but are not limited to, a sugar activation enzyme, a sugar extension enzyme, a reagent regeneration enzyme, a sugar functionalization enzyme, a sugar support enzyme, a sugar removal enzyme.
- Some immobilized enzyme materials, and in particular, magnetic materials, for producing glycans use one or more enzymes that are immobilized within bionanocatalysts (BNCs) which in turn are embedded within macroporous scaffolds to provide scaffolded bionanocatalysts (scaffolded BNCs). The scaffolded BNCs may be inside of modular flow cells for flow manufacturing. The modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing processes. The scaffolded BNCs are used in reactions for synthesizing glycans by contacting a glycan subunit or substrate with a scaffolded BNC to produce a second glycan, contacting a first glycan subunit and a second glycan subunit to produce a glycan comprising the first and second glycan subunits, or contacting a first glycan with a scaffolded BNC to produce a second glycan. Included are processes to modifying a glycan subunit and to connect glycans.
- Magnetic enzyme immobilization involves the entrapment of enzymes in mesoporous magnetic clusters that self-assemble around the enzymes (level 1). The immobilization efficiency depends on a number of factors that include the initial concentrations of enzymes and nanoparticles, the nature of the enzyme surface, the electrostatic potential of the enzyme, the nature of the nanoparticle surface, and the time of contact. Enzymes used for industrial purposes in biocatalytic processes should be highly efficient, stable before and during the process, reusable over several biocatalytic cycles, and economical.
- Mesoporous aggregates of magnetic nanoparticles may be incorporated into continuous or particulate macroporous scaffolds (level 2). The scaffolds may or may not be magnetic. Such scaffolds are discussed in, e.g., WO2014/055853, WO2017/180383, and Corgie et al., Chem. Today 34(5):15-20 (2016), incorporated by reference herein in their entirety. Highly magnetic scaffolds are designed to immobilize, stabilize, and optimize any enzyme. This includes full enzyme systems, at high loading and full activity, and for the production of, e.g., small molecules.
- Immobilized enzymes may be employed in process of this invention (WO2022/119982). For example, immobilized enzymes may be prepared as follows. In a first step, strontium ferrite (SFE) scaffold material is coated with magnetic nanoparticles (MNPs) by lowering the pH from 10.0 to 7.5. In a second step, the glycan synthesis enzymes are added to the product from the first step to the scaffolded BNCs. Type B scaffolded BNC compositions are made by this method.
- Certain immobilized enzymes are prepared when glycan synthesis enzymes are contacted with magnetic nanoparticles to form a bionanocatalyst (“BNC”) and then the BNCs are contacted with a magnetic scaffold material. Type A scaffolded BNC compositions are made by this method. In certain embodiments, the magnetic scaffold material is strontium ferrite. In one embodiment the strontium ferrite is a spherical particle with a tight size distribution of an average particle diameter of either 20 μm (S20) or 40 μm (S40W; wrinkled). Strontium ferrite in accordance with this invention available upon request from Powdertech International.
- Without being bound by theory, combining enzyme(s) and nanoparticles then adding that combination to the scaffold, the enzymes are entrapped (embedded) within the MNPs (Type A). By adding enzyme(s) to nanoparticle coated scaffold a Type B composition is obtained, wherein the enzymes remain more exposed at the surface and are not buried as much. As used herein, scaffold-MNP complex, scaffold-MNP matrix, and scaffold-MNP material each indicate the combination of a scaffold and a MNP according to this invention, comprising, consisting essentially of, or consisting of, magnetite nanoparticles and a strontium ferrite matrix.
- In certain embodiments, this invention employs enzymes immobilized using iron oxide materials including, but not limited to, hematite, magnetite, and strontium ferrite. In certain embodiments the immobilized enzyme is a Type A scaffolded BNC or a Type B scaffolded BNC.
- Accordingly, this invention provides a glycan synthesis enzyme scaffolded BNC made by the process of contacting strontium ferrite with magnetite nanoparticles to form a scaffold-MNP Complex and adding a glycan synthesis enzyme to the scaffold-MNP Complex to form the scaffolded BNC. Another embodiment provides a glycan synthesis enzyme scaffolded BNC made by the process of combining magnetite nanoparticles and a glycan synthesis enzyme to form a BNC and then contacting the BNC with a scaffold or matrix to form a scaffolded BNC. Without being bound by theory, the bionanocatalyst coats the magnetic microporous scaffold material.
- One embodiment of this invention a scaffolded BNC composition comprises a self-assembled mesoporous aggregate of magnetic nanoparticles and a glycan synthesis enzyme and a magnetic microporous material. A scaffolded BNC according to this invention comprises a glycan synthesis enzyme immobilized on magnetic nanoparticles, wherein the magnetic nanoparticles coat a magnetic macroporous material. In certain embodiments, the scaffolded BNCs comprises a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme In certain embodiments, the scaffolded BNCs consists of, or consists essentially of, a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme. In any embodiments, the scaffolded BNC comprises any elementary enzyme module described herein or is in a system module.
- A scaffolded BNC composition comprises a self-assembled mesoporous aggregate of magnetic nanoparticles and a glycan synthesis enzyme and a magnetic microporous material. A scaffolded BNC that may be used in the methods of this invention comprises a glycan synthesis enzyme immobilized on magnetic nanoparticles, wherein the magnetic nanoparticles coat a magnetic macroporous material. In certain embodiments, the scaffolded BNCs consist of a magnetic macroporous matrix material comprising self-assembled mesoporous aggregates of magnetic nanoparticles magnetically entrapping an immobilized glycan synthesis enzyme. In certain embodiments, the scaffolded BNC is used in an integrated pathway as disclosed herein.
- The invention provides for the ability to perform syntheses in one-pot reactions. The one-pot synthesis may be done in batch or flow including, but not limited to, repetitive batch or continuous flow. In a flow reactor, such as a packed bed reactor, the mixture of reagents is passed through the flow. Thus, in one embodiment, the invention provides a commercially applicable biocatalysis in flow.
- The immobilized enzymes provide a series of highly tunable materials and processes for universal enzyme immobilization based on magnetic metamaterials. The unique enzyme hierarchical immobilization platform provides optimal conditions to immobilize single and full systems of enzymes and allows optimal conditions to be found and adapted for single and full systems of enzymes. It affords enzyme stability, maximal use of substrates (including co-factors) and imparts modularity to flow processes. Accordingly, certain methods of this invention use a stabilized enzyme composition comprising a bionanocatalyst and a magnetic scaffold, wherein the bionanocatalyst comprises a glycan synthesis enzyme and magnetic nanoparticles and the magnetic scaffold stabilizes the bionanocatalyst.
- One embodiment provides a modular process for producing a glycan, comprising a module that may be a flow cell wherein: the module comprises a magnetic macroporous powder comprising magnetic microparticles, wherein the powder has immobilized a preparation of self-assembled mesoporous aggregates of magnetic nanoparticles containing a glycan synthesis enzyme; wherein a substrate is introduced into the module (or passed through a flow cell) and the substrate is modified to provide a glycan.
- Continuous flow reactors include, but are not limited to, packed-bed and fixed-bed reactors in tubular format can be combined with upstream and downstream processes that are not continuous making the overall process semi-continuous. For example, the reaction feed for the LNTII reaction (Example 3c-A) may be produced in a continuous stirred tank reactor, the product of which is continuously added to the flow reactor. Microfluidic reactors may also be employed in connection with this invention.
- Certain embodiments involve methods comprising 1 or more modules. In a method comprising more than a first module, a first substrate is passed through the first modular flow cell to create a modified substrate; wherein the modified substrate is a second substrate to pass through a second module to create a second modified substrate. The invention provides for sets of modules to be combined allowing the synthesis of complex glycans.
- In one embodiment, the invention provides methods for making glycans by immobilizing an enzyme with magnetic nanoparticles and contacting the immobilized enzyme with appropriate synthetic reagents. The methods may be conducted in batch, flow, semi-continuous, or continuous-flow.
- Scaffolds according to the invention are chemically inert, structurally tunable to fit any process, and highly magnetic to ensure full capture of the enzyme-containing cluster. In one embodiment, the magnetic macroporous material comprises a metal oxide or a metal oxide complex. In one embodiment, the scaffold comprises a metal oxide. In one embodiment, the metal oxide is strontium ferrite (SrFe12O19). In certain embodiments, the magnetic macroporous material is a metal oxide and consists essentially of, or consists of, metallic materials or ceramic and does not include a polymer. In certain embodiments, the scaffold is a metal oxide and is not a nanoparticle.
- The invention also provides a process for preparing a scaffolded bionanocatalyst by combining a magnetic nanoparticle and a glycan synthesis enzyme to form a bionanocatalyst and then contacting the bionanocatalyst with a scaffold to obtain the scaffolded bionanocatalyst, and a process for preparing a scaffolded bionanocatalyst by combining a scaffold and a magnetic nanoparticle to form a scaffolded magnetic nanoparticle complex and then contacting the scaffolded magnetic nanoparticle complex with a glycan synthesis enzyme. Also provided is a scaffolded BNC made by either of these processes.
- The process for preparing the magnetic scaffolds is flexible as employed in this invention provides for convenient, flexible glycosylation reactions.
- In one embodiment, the process for preparing the magnetic scaffolds is flexible as employed in this invention provides for convenient, flexible fucosylation reactions.
- The process for preparing the magnetic scaffolds is flexible and tunable to manufacture objects using 3D designs that magnetically capture the BNCs. A large surface area may result from the sintering process itself. Materials can also be recycled by removing the BNCs and then re-functionalized them for repeated use. See PCT/US19/53307, incorporated by reference herein in its entirety.
- In some embodiments, thermoplastics are Polyethylene (PE) (varying densities, e.g. LDPE, HDPE), Polypropylene (PP), Acrylics: Polyacrylic acids (PAA), Poly(methyl methacrylate) (PMMA), Polyvinyl alcohol (and polyvinyl acetals), Polyamides (Nylon), Polylactic acid (PLA), Polycarbonate (PC), Polyether sulfone (PES), Polystyrene (PS), Polyvinyl chloride (PVC), Acrylonitrile butadiene styrene (ABS), Polybenzimidazole (PBI), Polyoxymethylene (POM), Polyetherether ketone (PEEK), Polyetherimide (PEI), Polyvinylidene fluoride (PVDF), Polytetrafluoroethylene (PTFE/Teflon), Polyacrylonitrile (PAN)) blended with magnetic materials (e.g. magnetite MMP) via melting/extrusion or via coating of the magnetic material by dissolving the plastic in a solvent. In other embodiments, the powders are sintered by a laser using SLS. Porosity may be formed during SLS.
- Selective laser sintering (SLS) is an additive manufacturing (AM) technique that uses a laser as the power source to sinter powdered materials such as plastic, metal, ceramic, glass powders, nylon or polyamide. A laser automatically aimed at points in space, defined by a 3D model (e.g. an Additive Manufacturing File, AMF, or a CAD file), binds the material together to create a solid structure. After each cross-section is scanned, the powder bed is lowered by a one-layer thickness, a new layer of material is applied on top, and the process is repeated until the part is completed. There are many different technologies, such as stereolithography (SLA) or fused deposit modeling (FDM).
- SLS is similar to direct metal laser sintering (DMLS) but differs in technical details. DSLM uses a comparable concept, but in DSLM the material is fully melted rather than sintered. This allows one to manufacture materials with different properties (e.g. crystal structure and porosity). SLS is a relatively new technology that may be expanded into commercial-scale manufacturing processes.
- In one embodiment, polypropylene-magnetite materials can be 3D-printed in any shape and form via SLS.
- In other embodiments, an extruded composite material is size reduced via cryomilling or another form of milling. In other embodiments, composite powders are sieved to an ideal particle size. In preferred embodiments, the particle sizes are 60+/−20 μm.
- Powders or 3D printed objects can be functionalized with BNCs containing one or more enzymes or enzyme systems. BNCs are magnetically trapped at the surface of the powders or 3D printed objects.
- They may be single-layered or multiple-layered materials that hold the BNCs. Such designed objects may be produced using 3D printing by sintering composite magnetic powders. In some embodiments, Selective Laser Sintering (SLS) is used. The modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process.
- Composite powders may also be optimized for flowability. In some embodiments, 3D objects can be printed to optimize flow within to be used in flow reactors.
- In some embodiments, 3D objects and composite powders can be washed from the BNCs by an acid wash, rinsed with water, and then re-functionalized with fresh BNCs.
- Highly magnetic scaffolds (Macroporous Magnetic Scaffolds or MMP) are designed to immobilize, stabilize and optimize any BNCs containing enzymes. This includes full enzyme systems at high loading and full activity for the production of small molecules. By combining natural or engineered enzymes, and in some embodiments with cofactor recycling systems, the scaffolds allow one to scale up biocatalysis to innovations to manufacturing scale and production.
- Included are highly magnetic and highly porous composite blends of thermoplastics with magnetic particles to form powders that may be single-layered or multiple-layered materials that hold the BNCs. Such designed objects may be produced using 3D printing by sintering composite magnetic powders. In some embodiments, Selective Laser Sintering (SLS) is used. The modular flow cells may be mixed and matched for a highly customizable and highly efficient manufacturing process.
- MMP made of thermoplastic and magnetic materials of the invention can take the form of magnetic powders that are suitable for flow chemistry application. These powders can be 3D printed by SLS as structures, as functional objects, or as flow cells or plate reactors. High surface areas allow one to maximize the enzyme loading and flow can be engineered within the materials to enable biocatalysis at maximal productivity.
- SLS can be used to process nearly any kind of material from metals, ceramics, plastics, and combinations thereof, for tailor-made composite materials. It is critical, however, that the material is available in fine powder form and that the powder particles are operative to fuse when exposing them to heat (Kruth et al., Assembly Automation 23(4):357-371(2003), incorporated by reference herein in its entirety.
- When the material lacks those features or is prone to phase transitions at the temperature range or conditions of the sintering process, the addition of a sacrificial binder can make this process still feasible for that material. Commonly, polymers are used as sacrificial binders in order to expand the range of materials suitable for this technology. After sintering, the sacrificial binder can be either removed by thermal decomposition or kept as part of the composition.
- This concept applies to magnetite that loses its permanent magnetic properties above 585° C. This is significantly lower than its melting temperature (1538° C.). Another advantage of using a polymeric matrix to incorporate magnetite particles is that the former can act as a protective barrier to prevent oxidation and corrosion as well as aiding to disperse the magnetite particles. Also, magnetite can mechanically reinforce the polymer. (Shishkovsky et al., Microelectronic Engineering 146:85-91 (2015), incorporated by reference herein in its entirety).
- Laser sintering of plastic parts is one of two additive manufacturing processes used for Rapid Manufacturing (Wegner, Physics Procedia 83:1003-1012 (2016), incorporated by reference herein in its entirety). There are several polymer properties that determine its capability to be sintered and produce good quality 3D objects. These include structural properties such crystalline structure (i.e. thermal properties such as Tm, Tg, and Tc), mechanical properties (Young's modulus and elongation at break, etc.), density, particle size, and shape.
- In SLS, the temperature-processing window is determined from the difference between the melting and crystallization temperatures of the polymer. For instance, nylon 12 (PA 12) has one of the highest operational windows and is thus a widely used SLS material. In theory, the higher this value is, the easier the material can be sintered. In practice, however there are many more parameters that can still make this process difficult for any specific polymer (Shishkovsky et al., Microelectronic Engineering 146:85-91 (2015)), incorporated by reference herein in its entirety). In order to prevent curling of the sintered part, a low polymer crystallization rate is desired together with a melt index that provides a suitable rheology and surface tension.
- Additionally, the bulk density, particle shape, and size distribution of the powder are key factors (Wegner, Physics Procedia 83:1003-1012 (2016), incorporated by reference herein in its entirety). It has been determined that the in certain embodiments, the optimal particle size range is about 40 to about 90 microns. Smaller particles prevent flowability and their rapid vaporization is detrimental to the optical sensors of the sintering device. This can fog the device and lead to inaccurately sintered parts (Goodridge et al. Materials Science 57:229-267 (2012), incorporated by reference herein in its entirety). The powders should have good flowing properties and preferably an approximately round particle shape. This allows good powder spreading during the process. High heat conductivity of the material is desired at the CO2 laser beam wavelength (10.6 microns). This is not the case for most polymers. The last two requirements can be met by the incorporation of additives such as high-energy absorption materials, e.g. carbon black, to improve heat absorption, and fume silica nanoparticles (talc) to aid the particle flowability with irregularly-shaped particles.
- Additive manufacturing (AM), also referred to as 3D printing, involves manufacturing a part by depositing material layer-by-layer. This differs from conventional processes such as subtractive processes (i.e., milling or drilling), formative processes (i.e., casting or forging), and joining processes (i.e., welding or fastening). Quick production time, low prototyping costs, and design flexibility make 3D printing a valuable tool for both prototyping and industrial manufacturing. The three most common types of 3D printers are fused filament fabrication, stereolithography, and selective laser sintering.
- Fused filament fabrication (FFF) melts a thermoplastic continuous filament and builds the object layer by layer until the print is complete. Although alternative materials exist, the two most popular filament materials are polylactic acid (PLA) and acrylonitrile butadiene styrene (ABS). FFF printers and materials are among the cheapest on the market but currently have a lower print resolution and build quality.
- Stereolithography (SLA) uses a laser to polymerize photosensitive resins. Uncured liquid resin is placed in a vat where a laser is used to cure resin into solid plastic and build the object layer by layer. SLA printers have a much higher resolution than FFF printers due to the fine spot size of the laser and thus can print intricate features and complex shapes. The resins, however, are more expensive than filaments and completed prints currently require post processing with solvents to optimize the surface finish and material characteristics.
- Selective laser sintering (SLS) is a powder-based layer-additive manufacturing process generally meant for rapid prototyping and rapid tooling. Laser beams either in continuous or pulse mode are used as a heat source for scanning and joining powders in predetermined sizes and shapes of layers. The geometry of the scanned layers corresponds to the various cross sections of the computer-aided design (CAD) models or stereolithography (STL) files of the object. After the first layer is scanned, a second layer of loose powder is deposited over it, and the process is repeated from bottom to top until the artifact (3D object) is complete.” Kumar, JOM, 55(10), 43-47 (2003), incorporated by reference herein in its entirety.
- SLS provides advantages for printing objects with magnetic properties that can be used for immobilizing BNCs. This is because the printing process creates porosity and a high surface area. The surrounding, unsintered powder acts as a natural support that eliminates the need for dedicated support structures. The lack of support structures allows for complex geometries that would otherwise be impossible to manufacture using alternative 3D printing methods. In addition, the nature of sintering itself creates macro and microporous volumes. During the printing process, the laser flashes thermoplastic crystalline thermoplastic powders (e.g. Polypropylene, polystyrene) between their glass transition temperature and melting temperature to generate stiff parts. By avoiding amorphous behavior with a quick laser scan speed (>100 mm/s), powders are sintered in place to form small bonds amongst themselves. The low-density powders trap air in their structures resulting in remarkable porosity and surface area in three dimensions. These pores increase the surface area for enzyme immobilization.
- In recent years, industrial use of enzymes has garnered significant attention due to the wide range of potential manufacturing applications. Using enzymes in industrial processes offers several advantages over conventional chemical methods. This includes high catalytic activity, the ability to perform complex reactions, and promoting greener chemistry by reducing by-products and the need for toxic chemicals (Singh et al., Microbial enzymes: industrial progress in 21st century. 3 Biotech. 6(2):174 (2016), incorporated by reference herein in its entirety).
- One of the biggest hindrances to widespread biocatalysis use in industrial production is low enzyme stability. This is further hampered by relatively harsh process conditions that can destabilize enzymes and decrease their lifespan (Mohamad et al., Biotechnology, Biotechnological Equipment 29(2):205-220 (2015), incorporated by reference herein in its entirety). Furthermore, the use of free enzymes in these processes are generally lost from the system as waste products and therefore become a costly operating cost. The primary solution to these issues is immobilization of enzymes onto scaffolding to enhance their operational stability and catalytic activity. Enzyme immobilization also provides a method for enzyme recovery, making biocatalytic processes more economically feasible.
- Currently, biocatalytic processes for industrial production are generally carried out in batch reactors due to their simplicity and ease of operation. Despite the benefits of using batch reactors, continuous flow systems enable higher productivity and better process control (Wiles C et al., Green Chem. (14):38-54 (2012)). The rapid development of flow chemistry in biocatalytic processes has primarily been driven by a growing interest in process intensification and green chemistry. Continuous flow systems facilitate process intensification by decreasing residence times (often from hours to minutes), reducing the size of equipment required, and enabling production volume enhancement (Tamborini et al., Cell. 36(1):73-78 (2018)). From a green chemistry standpoint, these systems offer significant improvements in safety, waste generation, and energy efficiency due to heat management and mixing control (Newman and Jensen, Green Chem. (15):1456-1472 (2013)). The foregoing are incorporated by reference herein in their entirety.
- The invention has many benefits over the prior art. It enables the efficient and economical production of glycans, such as complex polysaccharides, including but not limited to, HMOs using enzymes captured in modular flow processing cells. The flow cells may contain materials having large macropores or a high magnetic surface area for BNC immobilization. Flexible compositions for sintered magnetic scaffolds can be made with any meltable thermoplastics and magnetic material composition. The flow cells can have one or multiple enzyme systems that may be pieced together for particular sugar manufacturing processes.
- A solution to combining biocatalysis and continuous flow systems is with functionalized flow cells. Biocatalytic flow cells are scaffolds containing immobilized enzymes for use in reactors such as continuous stirred tank reactors (CSTRs) and packed bed reactors (PBRs). Both types of reactors are known in the art but are primarily chosen based on the type of immobilization used. With a total market value of $5.8B in 2010, immobilized enzymes are used in a diverse range of large-scale processes including high fructose corn syrup production (107 tons/year), transesterification of food oils (105 tons/year), biodiesel synthesis (104 tons/year), and chiral resolution of alcohols and amines (103 tons/year) (DiCosimo et al., Chem. Soc. Rev. (42):6437-6474 (2013), incorporated by reference herein in its entirety). These systems allow for improved downstream process management for enzymatic systems compared to batch reactors in terms of in-line control, enzyme reuse, and production scalability.
- For the foregoing reasons, the methods of this invention employ biocatalytic systems for small-to-large scale manufacturing using BNCs in scaffolds that are shaped by 3D printing. In some embodiments, the biocatalytic systems are continuous flow.
- Scaffolds may comprise cross-linked water-insoluble polymers and an approximately uniform distribution of embedded magnetic microparticles (MMP). The scaffolds may contain thermoset resins including Epoxy resins, Polyesters, Polyurethanes, Melamine resins, Vinyl esters, Silicones (polysiloxanes), Furan resins, Polyurea, Phenolic resins, phenol-formaldehyde, Urea-formaldehyde, Diallyl-phthalate (DAP), Benzoxazine, Polyimides and bismaleimides, Cyanate esters can be used. By combining natural or engineered enzymes, and in some embodiments with cofactors and cofactor recycling systems, the scaffold technology disclosed herein allows one to quickly translate innovation in biocatalysis to innovation in production for batch and flow processes. The magnetic powders are suitable for use flow chemistry applications such as pack-bed reactors.
- Self-assembled mesoporous nanoclusters comprising entrapped enzymes are highly active and robust. The technology is a powerful blend of biochemistry, nanotechnology, and bioengineering at three integrated levels of organization:
Level 1 is the self-assembly of enzymes with magnetic nanoparticles (MNP) for the synthesis of magnetic mesoporous nanoclusters. This level uses a mechanism of molecular self-entrapment to immobilize and stabilize enzymes.Level 2 is the stabilization of the MNPs into other matrices.Level 3 is product conditioning and packaging forLevel 1+2 delivery. The assembly of magnetic nanoparticles adsorbed to enzyme is herein also referred to as a “bionanocatalyst” (BNC). - MNPs allow for a broader range of operating conditions such as temperature, ionic strength and pH. The size and magnetization of the MNPs affect the formation and structure of the NPs, all of which have a significant impact on the activity of the entrapped enzymes. By virtue of their surprising resilience under various reaction conditions, MNPs can be used as improved enzymatic or catalytic agents where other such agents are currently used. Furthermore, they can be used in other applications where enzymes have not yet been considered or found applicable.
- The BNC contains mesopores that are interstitial spaces between the magnetic nanoparticles. The enzymes are preferably embedded or immobilized within at least a portion of mesopores of the BNC. As used herein, the term “magnetic” encompasses all types of useful magnetic characteristics, including permanent magnetic, superparamagnetic, paramagnetic, ferromagnetic, and ferrimagnetic behaviors.
- The magnetic nanoparticle or BNC has a size in the nanoscale, i.e., generally no more than 500 nm. As used herein, the term “size” can refer to a diameter of the magnetic nanoparticle when the magnetic nanoparticle is approximately or substantially spherical. In a case where the magnetic nanoparticle is not approximately or substantially spherical (e.g., substantially ovoid or irregular), the term “size” can refer to either the longest the dimension or an average of the three dimensions of the magnetic nanoparticle. The term “size” may also refer to an average of sizes over a population of magnetic nanoparticles (i.e., “average size”).
- In different embodiments, the magnetic nanoparticle has a size of precisely, about, up to, or less than, for example, 500 nm, 400 nm, 300 nm, 200 nm, 100 nm, 50 nm, 40 nm, 30 nm, 25 nm, 20 nm, 15 nm, 10 nm, 5 nm, 4 nm, 3 nm, 2 nm, or 1 nm, or a size within a range bounded by any two of the foregoing exemplary sizes.
- In the BNC, the individual magnetic nanoparticles can be considered to be primary nanoparticles (i.e., primary crystallites) having any of the sizes provided above. The aggregates of nanoparticles in a BNC are larger in size than the nanoparticles and generally have a size (i.e., secondary size) of at least about 5 nm. In different embodiments, the aggregates have a size of precisely, about, at least, above, up to, or less than, for example, 5 nm, 8 nm, 10 nm, 12 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 200 nm, 300 nm, 400 nm, 500 nm, 600 nm, 700 nm, or 800 nm, or a size within a range bounded by any two of the foregoing exemplary sizes.
- Typically, the primary and/or aggregated magnetic nanoparticles or BNCs thereof have a distribution of sizes, i.e., they are generally dispersed in size, either narrowly or broadly dispersed. In different embodiments, any range of primary or aggregate sizes can constitute a major or minor proportion of the total range of primary or aggregate sizes. For example, in some embodiments, a particular range of primary particle sizes (for example, at least about 1, 2, 3, 5, or 10 nm and up to about 15, 20, 25, 30, 35, 40, 45, or 50 nm) or a particular range of aggregate particle sizes (for example, at least about 5, 10, 15, or 20 nm and up to about 50, 100, 150, 200, 250, or 300 nm) constitutes at least or above about 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% of the total range of primary particle sizes. In other embodiments, a particular range of primary particle sizes (for example, less than about 1, 2, 3, 5, or 10 nm, or above about 15, 20, 25, 30, 35, 40, 45, or 50 nm) or a particular range of aggregate particle sizes (for example, less than about 20, 10, or 5 nm, or above about 25, 50, 100, 150, 200, 250, or 300 nm) constitutes no more than or less than about 50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% of the total range of primary particle sizes.
- The aggregates of magnetic nanoparticles (i.e., “aggregates”) or BNCs thereof can have any degree of porosity, including a substantial lack of porosity depending upon the quantity of individual primary crystallites they are made of. In particular embodiments, the aggregates are mesoporous by containing interstitial mesopores (i.e., mesopores located between primary magnetic nanoparticles, formed by packing arrangements). The mesopores are generally at least 2 nm and up to 50 nm in size. In different embodiments, the mesopores can have a pore size of precisely or about, for example, 2, 3, 4, 5, 10, 12, 15, 20, 25, 30, 35, 40, 45, or 50 nm, or a pore size within a range bounded by any two of the foregoing exemplary pore sizes. Similar to the case of particle sizes, the mesopores typically have a distribution of sizes, i.e., they are generally dispersed in size, either narrowly or broadly dispersed. In different embodiments, any range of mesopore sizes can constitute a major or minor proportion of the total range of mesopore sizes or of the total pore volume. For example, in some embodiments, a particular range of mesopore sizes (for example, at least about 2, 3, or 5, and up to 8, 10, 15, 20, 25, or 30 nm) constitutes at least or above about 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% of the total range of mesopore sizes or of the total pore volume. In other embodiments, a particular range of mesopore sizes (for example, less than about 2, 3, 4, or 5 nm, or above about 10, 15, 20, 25, 30, 35, 40, 45, or 50 nm) constitutes no more than or less than about 50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% of the total range of mesopore sizes or of the total pore volume.
- The magnetic nanoparticles can have any of the compositions known in the art. In some embodiments, the magnetic nanoparticles are or include a zerovalent metallic portion that is magnetic. Some examples of such zerovalent metals include cobalt, nickel, and iron, and their mixtures and alloys. In other embodiments, the magnetic nanoparticles are or include an oxide of a magnetic metal, such as an oxide of cobalt, nickel, or iron, or a mixture thereof. In some embodiments, the magnetic nanoparticles possess distinct core and surface portions. For example, the magnetic nanoparticles may have a core portion composed of elemental iron, cobalt, or nickel and a surface portion composed of a passivating layer, such as a metal oxide or a noble metal coating, such as a layer of gold, platinum, palladium, or silver. In other embodiments, metal oxide magnetic nanoparticles or aggregates thereof are coated with a layer of a noble metal coating. The noble metal coating may, for example, reduce the number of charges on the magnetic nanoparticle surface, which may beneficially increase dispersibility in solution and better control the size of the BNCs. The noble metal coating protects the magnetic nanoparticles against oxidation, solubilization by leaching or by chelation when chelating organic acids, such as citrate, malonate, or tartrate are used in the biochemical reactions or processes. The passivating layer can have any suitable thickness, and particularly, at least, up to, or less than, about for example, 0.1 nm, 0.2 nm, 0.3 nm, 0.4 nm, 0.5 nm, 0.6 nm, 0.7 nm, 0.8 nm, 0.9 nm, 1 nm, 2 nm, 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, or 10 nm, or a thickness in a range bounded by any two of these values.
- Magnetic materials useful in the invention are well-known in the art. Non-limiting examples comprise ferromagnetic and ferromagnetic materials including ores such as iron ore (magnetite or lodestone), cobalt, and nickel. In other embodiments, rare earth magnets are used. Non-limiting examples include neodymium, gadolinium, sysprosium, samarium-cobalt, neodymium-iron-boron, and the like. In yet further embodiments, the magnets comprise composite materials. Non-limiting examples include ceramic, ferrite, and alnico magnets. In preferred embodiments, the magnetic nanoparticles have an iron oxide composition. The iron oxide composition can be any of the magnetic or superparamagnetic iron oxide compositions known in the art, e.g., magnetite (Fe3O4), hematite (α-Fe2O3), maghemite (γ-Fe2O3), or a spinel ferrite according to the formula AB2O4, wherein A is a divalent metal (e.g., Xn2+, Ni2+, Mn2+, Co2+, Ba2+, Sr2+, or combination thereof) and B is a trivalent metal (e.g., Fe3+, Cr3+, or combination thereof).
- The individual magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable degree of magnetism. For example, the magnetic nanoparticles, BNCs, or BNC scaffold assemblies can possess a saturated magnetization (Ms) of at least or up to about 5, 10, 15, 20, 25, 30, 40, 45, 50, 60, 70, 80, 90, or 100 emu/g. The magnetic nanoparticles, BNCs, or BNC-scaffold assemblies preferably possess a permanent magnetization (Mr) of no more than (i.e., up to) or less than 5 emu/g, and more preferably, up to or less than 4 emu/g, 3 emu/g, 2 emu/g, 1 emu/g, 0.5 emu/g, or 0.1 emu/g. The surface magnetic field of the magnetic nanoparticles, BNCs, or BNC-scaffold assemblies can be about or at least, for example, about 0.5, 1, 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 Gauss (G), or a magnetic field within a range bounded by any two of the foregoing values. If microparticles are included, the microparticles may also possess any of the above magnetic strengths.
- The magnetic nanoparticles or aggregates thereof can be made to adsorb a suitable amount of enzyme, up to or below a saturation level, depending on the application, to produce the resulting BNC. In different embodiments, the magnetic nanoparticles or aggregates thereof may adsorb about, at least, up to, or less than, for example, 1, 5, 10, 15, 20, 25, or 30 pmol/m2 of enzyme. Alternatively, the magnetic nanoparticles or aggregates thereof may adsorb an amount of enzyme that is about, at least, up to, or less than, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of a saturation level.
- The magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable pore volume. For example, the magnetic nanoparticles or aggregates thereof can possess a pore volume of about, at least, up to, or less than, for example, about 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1 cm3/g, or a pore volume within a range bounded by any two of the foregoing values.
- The magnetic nanoparticles or aggregates thereof or BNCs thereof possess any suitable specific surface area. For example, the magnetic nanoparticles or aggregates thereof can have a specific surface area of about, at least, up to, or less than, for example, about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200
m 2/g. - The magnetic macroporous matrix material for use according to this invention has a size of precisely, about, up to, or less than, for example, 100-1000, 50-100, 10-50 μm, or 5-10, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5, less than 5, greater than 100, an average size of 150, an average size of 75, an average size of 40, an average size of 20 or an average size of about 15. In certain embodiments, the material has an average particle diameter of precisely, about, up to, or less than, 20-40 μm, 20 μm, or 40 μm. In certain embodiments, the material has a tight size distribution of an average particle diameter of either 20 μm or 40 μm.
- In some embodiments, the methods described herein use recombinant cells that express the enzymes used in the invention. Recombinant DNA technology is known in the art. In some embodiments, cells are transformed with expression vectors such as plasmids that express the enzymes. In other embodiments, the vectors have one or more genetic signals, e.g., for transcriptional initiation, transcriptional termination, translational initiation and translational termination. Here, nucleic acids encoding the enzymes may be cloned in a vector so that they are expressed when properly transformed into a suitable host organism. Suitable host cells may be derived from bacteria, fungi, plants, or animals as is well-known in the art.
- Although BNCs (Level 1) provide the bulk of enzyme immobilization capability, they are sometimes too small to be easily captured by standard-strength magnets. Thus, sub-micrometric magnetic materials (Level 2) are used to provide bulk magnetization and added stability to
Level 1. Commercially available free magnetite powder, with particle sizes ranging from 50-500 nm, is highly hydrophilic and tends to stick to plastic and metallic surfaces, which, over time, reduces the effective amount of enzyme in a given reactor system. In addition, powdered magnetite is extremely dense, thus driving up shipping costs. It is also rather expensive—especially at particle sizes finer than 100 nm. To overcome these limitations, low-density hybrid materials consisting of magnetite, non-water-soluble cross-linked polymers such as poly(vinylalcohol) (PVA) and carboxymethylcellulose (CMC), have been developed. These materials are formed by freeze-casting and freeze-drying water-soluble polymers followed by cross-linking. These materials have reduced adhesion to external surfaces, require less magnetite, and achieveLevel 1 capture that is at least comparable to that of pure magnetite powder. - In one embodiment, the continuous macroporous scaffold has a cross-linked polymeric composition. The polymeric composition can be any of the solid organic, inorganic, or hybrid organic-inorganic polymer compositions known in the art, and may be synthetic or a biopolymer that acts as a binder. Preferably, the polymeric s scaffold does not dissolve or degrade in water or other medium in which the hierarchical catalyst is intended to be used. Some examples of synthetic organic polymers include the vinyl addition polymers (e.g., polyethylene, polypropylene, polystyrene, polyacrylic acid or polyacrylate salt, polymethacrylic acid or polymethacrylate salt, poly(methylmethacrylate), polyvinyl acetate, polyvinyl alcohol, and the like), fluoropolymers (e.g., polyvinylfluoride, polyvinylidenefluoride, polytetrafluoroethylene, and the like), the epoxides (e.g., phenolic resins, resorcinol-formaldehyde resins), the polyamides, the polyurethanes, the polyesters, the polyimides, the polybenzimidazoles, and copolymers thereof. Some examples of biopolymers include the polysaccharides (e.g., cellulose, hemicellulose, xylan, chitosan, inulin, dextran, agarose, and alginic acid), polylactic acid, and polyglycolic acid. In the particular case of cellulose, the cellulose may be microbial- or algae-derived cellulose. Some examples of inorganic or hybrid organic-inorganic polymers include the polysiloxanes (e.g., as prepared by sol gel synthesis, such as polydimethylsiloxane) and polyphosphazenes. In some embodiments, any one or more classes or specific types of polymer compositions provided above are excluded as macroporous scaffolds. In some embodiments the 3D model is an electronic file.
- Any of these compositions and methods may be used in the embodiments of this invention to immobilize an enzyme.
- It should be understood that ‘comprise’ is, where context permits, to be interpreted non-exhaustively. Where context permits, each comprise is alternatively “consist essentially of”, or “consist of”
- 1. A biocatalytic process for preparing a saccharide-acceptor comprising the steps of:
-
- a. contacting a saccharide and a nucleotide to form a saccharide-nucleotide, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the saccharide-nucleotide and an acceptor in the presence of a transferase to form the saccharide-acceptor.
- 2. The process according to
embodiment 1, wherein the saccharide is galactose, sialic acid, or 1-fucose. - 3. A process for preparing a saccharide compound, comprising the steps of:
-
- a. contacting a monosaccharide selected from galactose, sialic acid, and 1-fucose and a catalytic amount of a nucleotide selected from UDP, ADP, CMP, and GDP to form a saccharide-nucleotide compound.
- b. contacting the saccharide-nucleotide compound and an acceptor compound in the presence of a transferase to obtain the saccharide.
- 4. A process for preparing a saccharide compound, comprising the steps of:
-
- a. contacting a galactose saccharide unit and a catalytic amount of a nucleotide selected from UDP and ADP or a sialic acid or 1-fucose saccharide unit and a catalytic amount of a nucleotide selected from CMP, and GDP to form a saccharide-nucleotide compound.
- b. contacting the saccharide-nucleotide compound and an acceptor compound in the presence of a transferase to obtain the saccharide.
- 5. A process for galactosylation of an acceptor compound, comprising the steps of:
-
- a. contacting galactose and a nucleotide to form a galactose-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the galactose-nucleotide compound and an acceptor compound in the presence of a transferase to galactosylate the acceptor compound.
- 6. The process according to embodiment 5, wherein the galactose is obtained from sucrose in situ.
- 7. The process according to embodiment 5 or
embodiment 6, wherein the process is driven to high conversion via the conversion of Sucrose to Glc-UDP and fructose. - 8. A process for sialylation of an acceptor compound, comprising the steps of:
-
- a. contacting sialic acid and a nucleotide to form a sialyl-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the sialyl-nucleotide compound and a compound with an acceptor compound in the presence of a transferase to sialylate the acceptor compound.
- 9. The process according to embodiment 8, wherein the sialic acid is obtained from 3′-SL or 6′-SL in situ.
- 10. The process according to embodiment 8 or embodiment 9, wherein the process is driven to high conversion via the conversion of lactose to galactose and glucose
- 11. A process for fucosylation of an acceptor compound, comprising the steps of:
-
- a. contacting a fucose and a nucleotide to form a fucose-nucleotide compound, wherein the nucleotide is present in a catalytic amount; and
- b. contacting the fucose-nucleotide compound and an acceptor compound in the presence of a transferase to fucosylate the acceptor compound.
- 12. The process according to embodiment 11, wherein the fucose is 1-fucose and is obtained from 2′-FL in situ.
- 13. The process according to embodiment 11 or embodiment 12, wherein the process is driven to high conversion via the conversion of sucrose to Glc-UDP and fructose
- 14. The process according to any one of embodiments 1-13, wherein the acceptor compound is a monosaccharide, a disaccharide, an oligosaccharide, or a polysaccharide.
- 15. The process according to any one of embodiments 1-14, wherein substantially no ATP is added to the process or generated by the process.
- 16. The process according to any one of embodiments 1-15, wherein the nucleotide is present in the catalytic amount is about 0.01 to about 10 molar percent relative to the saccharide amount.
- 17. A process for producing LNT and fructose, comprising the step of contacting LNTII, sucrose, a transferase, a sucrose synthase, an epimerase, and UDP to produce LNT and fructose, wherein galactose-UDP is produced, and wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or the sucrose.
- 18. The process according to embodiment 17, wherein the transferase is Cvb3GalT.
- 19. The process according to
embodiment 18, wherein the transferase is B3GALT5 - 20. The process according to any one of embodiments 17-19, wherein the epimerase is GalE.
- 21. A process for producing LNnT and fructose, comprising contacting LNTII, sucrose, a glycosyltransferase, a sucrose synthase, an epimerase, and UDP to produce LNnT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the galactose or sucrose.
- 22. The process according to embodiment 21, wherein the glycosyltransferase is a LgtB.
- 23. The process according to embodiment 22, wherein the LgtB is NmLgtB.
- 24. The process according to embodiment 23, wherein the glycosyltransferase is B4GALT1.
- 25. The process according to any one of embodiments 21-24, wherein the epimerase is GalE.
- 26. A process for preparing LNT and fructose, comprising the steps of contacting GlcNAc, 2-chloro-1,3-dimethylimidazolinium chloride, and a base to obtain a reaction mixture comprising GlcNAc-Oxa; and contacting the reaction mixture comprising GlcNAc-Oxa, lactose, sucrose, an aminidase, a transferase, a sucrose synthase, and an epimerase, to provide LNT and fructose, wherein the UDP is present in about 0.01 molar percent to about 10% molar percent of the lactose or the sucrose.
- 27. The process according to embodiment 26, wherein the aminidase is Bbh1.
- 28. The process according to embodiment 26 or embodiment 27, wherein the transferase is Cvb3GalT.
- 29. The process according to any one of embodiments 26-28, wherein the epimerase is GalE.
- 30. The process according to any one of embodiments 26-29, wherein the base is triethylamine.
- 31. A process for preparing lactose and fructose, comprising contacting glucose, sucrose, a lactose synthase, a sucrose synthase, an epimerase, and UDP, to provide lactose and fructose, wherein the UDP is present in about 0.01 molar percent to about 10 molar percent of the glucose and or the sucrose.
- 32. The process according to embodiment 31, wherein the epimerase is GalE.
- 33. A process for preparing LSTa, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide LSTa, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- 34. The process according to embodiment 33, wherein the sialyltransferase is ST3GAL3.
- 35. A process for preparing LSTc, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTc, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- 36. The process according to embodiment 35, wherein the sialyltransferase is ST3GAL3.
- 37. A process for preparing LSTd, galactose, and glucose, comprising contacting 3′-SL, LNnT, CMP, a sialyltransferase, and a lactase to provide LSTd, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10 molar percent of the 3′-SL.
- 38. The process according to embodiment 37, wherein the sialyltransferase is ST3GAL3.
- 39. A process for preparing DSLNT, galactose, and glucose, comprising contacting 3′-SL, LNT, CMP, a sialyltransferase, and a lactase to provide DSLNT, galactose, and glucose, wherein the CMP is present in about 0.01 molar percent to about 10% molar percent of the 3′-SL.
- 40. The process according to embodiment 39, wherein the sialyltransferase is ST3GAL3 and ST6GALNAC5.
- 41. A process for preparing LNFPI, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Te2FT, HmFucT, and lactase to provide LNFPI, galactose, and glucose wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- 42. The process according to embodiment 41, wherein the transferase is Te2FT and HmFucT.
- 43. A process for preparing LNFPII, galactose, and glucose, comprising contacting 2′-FL, LNT, GDP, Hp34FT, HmFucT, and lactase, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- 44. The process according to embodiment 43, wherein the transferase is Hp34FT and HmFucT.
- 45. A process for preparing LNFPIII, galactose, and glucose, comprising contacting 2′-FL, LNnT, GDP, FUT9, HmFucT, and lactase, to provide LNFPIII, wherein the GDP is present in about 0.01 molar percent to about 10 molar percent of the 2′-FL.
- 46. The process according to embodiment 45, wherein the transferase is FUT and HmFucT.
- 47. The process according to any one of embodiments 1-46, wherein one or more of the enzyme is immobilized.
- 48. The process according to any one of embodiment 47, wherein each of the enzyme is immobilized.
- 49. The process according to any one of embodiments 1-48, wherein the process occurs in a single reaction vessel.
- 50. A machine configured for the process of any one of embodiments 1-49.
- 51. The machine of embodiment 50, wherein the process is within a single reaction vessel.
- 52. LNT prepared by the process according to any one of embodiments 1-7, 14-20, and 47-49.
- 53. LNnT prepared by the process according to any one of embodiments 1-7, 14-16, 21-30, and 47-49.
- 54. Lactose prepared by a process according to any one of embodiments 1-7, 14-16, 31-32, and 47-49.
- 55. LSTa prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 33-34, and 47-49.
- 56. LSTc prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 35-36, and 47-49.
- 57. LSTd prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 37-38, and 47-49.
- 58. DSLNT prepared by a process according to any one of embodiments 1-4, 7-9, 14-16, 39-40, and 47-49.
- 59. LNFPI prepared by a process according to any one of embodiments 1-4, 10-15, 41-42, and 47-49.
- 60. LNFPII prepared by a process according to any one of embodiments 1-4, 10-16, 43-44, and 47-49.
- 61. LNFPIII prepared by a process according to any one of embodiments 1-7, 10-16, and 45-49.
- 62. A lactose derivative prepared by a process according to any one of embodiments 1-7, 14-16, and 47-49.
- 63. The lactose derivative according to embodiment 62 selected from Lactobionic Acid, Lactitol, Lactosucrose, Galacto-oligosaccharides, Lactulose, and a HMO. 64. A compound prepared by a process according to any one of embodiments 1-49, wherein the compound is obtained from non-animal based plant materials.
- Other embodiments are as follows.
- 1. A method for producing a glycosylated principal product, comprising the steps of:
-
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor in the presence of a transferase to obtain a glycosylated principal product and a catalytic amount of a nucleotide; and
- regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain the regenerated sugar-nucleotide donor and a secondary product.
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor in the presence of a transferase to obtain a glycosylated principal product and a catalytic amount of a nucleotide; and
- 2. The method of
embodiment 1, further comprising -
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor in the presence of a transferase to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain the regenerated sugar-nucleotide donor and the secondary product.
- 3. A method for producing a glycosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- 4. The method according to
embodiment 3, wherein the sugar donor precursor and the nucleotide provides a sugar-nucleotide donor. - 5. The method according to any one of embodiments 1-4, wherein the sugar donor precursor and the nucleotide provides a sugar-nucleotide donor precursor and wherein an auxiliary enzyme and the sugar-nucleotide donor precursor provides the sugar-nucleotide donor.
- 6. The method according to any one of embodiments 1-5, wherein the sugar donor precursor is a sugar comprising 2 or more sugar units.
- 7. The method according to
embodiment 6, wherein the sugar donor precursor is a sugar comprising 2, 3, or 4 sugar units. - 8. The method according to embodiment 7, wherein the sugar donor precursor is a disaccharide.
- 9. The method according to embodiment 7, wherein the sugar donor precursor is a trisaccharide.
- 10. The method according to any one of embodiments 1-9, wherein the sugar donor precursor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine.
- 11. The method according to embodiment 10, wherein the galactose, sialic acid, fucose, or N-acetylglucosamine is in a terminal position in the sugar donor precursor.
- 12. The method according to any one of embodiments 1-9, wherein the sugar-nucleotide donor comprises a galactose, sialic acid, fucose, or N-acetylglucosamine
- 13. The method according to any one of embodiments 1-9, wherein the sugar-nucleotide donor is a galactosyl-nucleotide, sialyl-nucleotide, fucosyl-nucleotide, or N-acetylglucosaminyl-nucleotide.
- 14. The method according any one of embodiments 1-13, wherein the secondary product is a monosaccharide, disaccharide, or trisaccharide.
- 15. The method according to any one of embodiments 1-14, wherein the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative.
- 16. The method according to any one of embodiments 1-15, wherein the secondary product derivative, in the presence of a second processing enzyme, is converted to a modified secondary product derivative.
- 17. The method according any one of embodiments 1-16, wherein the acceptor is an organic compound containing a hydroxy group.
- 18. The method according to embodiment 17, wherein the organic compound containing a hydroxy group is a sugar.
- 19. The method according to any one of embodiments 1-18, wherein the acceptor is obtained from the processing enzyme converting the secondary product into the acceptor.
- 20. The method according to any one of embodiments 1-19, wherein the nucleotide is a uridine diphosphate, cytidine monophosphate, or guanosine diphosphate.
- 21. The method according to any one of embodiments 1-20, wherein the nucleotide is in an amount of 0.001 mol percent to 10 mol percent relative to the sugar donor precursor or the acceptor.
- 22. The method according to any one of embodiments 1-21, wherein the nucleotide is in an amount of 0.01 mol percent to 1 mol percent relative to the sugar donor precursor or the acceptor.
- 23. The method according to any one of embodiments 1-22, wherein the transferase is a β-1,3-galactosyl transferase, sucrase synthase, β-1,4-galactosyl transferase, sialyl transferase, fucosyl transferase, or glucosaminyl (N-acetyl)
transferase 2. - 24. The method according to any one of embodiments 1-23, wherein the transferase comprises a first transferase and a second transferase.
- 25. The method according to any one of embodiments 1-24, wherein the first transferase catalyzes a transfer of a sugar from the sugar-nucleotide donor to the acceptor to obtain the glycosylated principal product and the second transferase catalyzes a reaction of the nucleotide and the sugar donor precursor to obtain the sugar-nucleotide donor and the secondary product.
- 26. A method for producing a galactosylated principal product, comprising the steps of:
-
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a galactosylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- 27. The method of embodiment 26, further comprising
-
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- 28. A method for producing a galactosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
- 29. The method according to any one of embodiments 26-28, wherein the acceptor is lacto-N-triose II (LNTII), glucose, or galactooligosaccharide.
- 30. The method according to any one of embodiments 26-29, wherein the secondary product is fructose.
- 31. The method according to any one of embodiments 26-30, comprising the step of obtaining the glucose by contacting the fructose in the presence of a glucose isomerase to obtain the glucose.
- 32. The method according to any one of embodiments 26-31, comprising the step of obtaining the LNTII by contacting lactase and N-acetylglucosamine in the presence of β-N-acetylhexosaminidase (Bbh1) to obtain the LNTII.
- 33. The method according to any one of embodiments 26-32, wherein the sugar donor precursor is sucrose.
- 34. The method according to any one of embodiments 26-33, wherein the sugar-nucleotide donor precursor is a glucose nucleotide.
- 35. The method according to any one of embodiments 26-34, wherein the secondary product is fructose.
- 36. The method according to any one of embodiments 26-35, wherein the auxiliary enzyme is a galactose epimerase.
- 37. The method according to any one of embodiments 26-36, wherein the nucleotide is uridine diphosphate.
- 38. The method according to any one of embodiments 26-36, wherein the transferase comprises a first transferase and a second transferase.
- 39. The method according to embodiment 38, wherein the first transferase is β-1,3-galactosyltransferase from Chromobacterium violaceum (Cvb3GalT), β-1,4-Galactosyltransferase from Neisseria meningitidis (NmLgtB), and the second transferase is sucrose synthase from Arabidopsis thaliana (AtSuSy1).
- 40. A method for producing a sialylated principal product, comprising the steps of:
-
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a sialylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- 41. The method of embodiment 40, further comprising
-
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- 42. A method for producing a sialylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a sialylated principal product and a secondary product.
- 43. The method according to any one of embodiments 40-42, wherein the sugar donor precursor is 3′-sialyllactose.
- 44. The method according to any one of embodiments 40-43, wherein the sugar-nucleotide donor is a N-acetyl neuraminic acid nucleotide.
- 45. The method according to any one of embodiments 40-44, wherein the secondary product is lactose.
- 46. The method according to any one of embodiments 40-45, wherein the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative.
- 47. The method according to embodiment 46, wherein the processing enzyme is lactase.
- 48. The method according to embodiment 47, wherein the secondary product derivative is glucose and galactose.
- 49. The method according to any one of embodiments 40-48, wherein the nucleotide is cytidine monophosphate.
- 50. The method according to any one of embodiments 40-49, wherein the transferase comprises a first transferase and a second transferase.
- 51. The method according to embodiment 50, wherein the first transferase is beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase (ST3GAL3) or Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) and second transferase is CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (ST3GAL4).
- 52. The method according to embodiments 50, wherein the first transferase ST3GAL3 and ST6GALNAC5.
- 53. A method for producing a fucosylated principal product, comprising the steps of:
-
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a fucosylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- 54. The method of embodiment 53, further comprising
-
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- 55. A method for producing a fucosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a fucosylated principal product and a secondary product.
- 56. The method according to any one of embodiments 53-55, wherein the sugar donor precursor is a 2′-fucosyllactose.
- 57. The method according to any one of embodiments 53-56, wherein the sugar-nucleotide donor is a fucose nucleotide.
- 58. The method according to any one of embodiments 53-57, wherein the secondary product is lactose.
- 59. The method according to any one of embodiments 53-58, wherein the secondary product, in the presence of a processing enzyme, is converted to a secondary product derivative.
- 60. The method according to embodiment 59, wherein the processing enzyme is lactase.
- 61. The method according to embodiment 59 or embodiment 60, wherein the secondary product derivative is glucose and galactose.
- 62. The method according to any one of embodiments 59-61, wherein the secondary product derivative, in the presence of a second processing enzyme, is converted to a modified secondary product derivative.
- 63. The method according to claim 62, wherein the second processing enzyme is D-Galactose isomerase source from Geobacillus stearothermophilus (GsAI) and the modified secondary product derivative is tagatose.
- 64. The method according to any one of embodiments 53-63, wherein the nucleotide is guanosine diphosphate.
- 65. The method according to any one of embodiments 53-64, wherein the transferase comprises a first transferase and a second transferase.
- 66. The method according to embodiment 65, wherein the first transferase is α-1,2-fucosyltransferase from Thermosynechococcus vestitus (Te2FT), fucosyl transferase 9 (FUT9) or fucosyl transferase 3 (FUT3) and second transferase is α-1,2-fucosyltransferase from Helicobacter mustelae (HmFucT) or fucosyl transferase (FUT1).
- 67. A method for producing a N-acetylglucosaminylated principal product, comprising the steps of:
-
- a. adding a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a N-acetylglucosaminylated principal product and a catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of the nucleotide with a stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and a secondary product.
- The method of
embodiment 1, further comprising -
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- The method of
embodiment 1, further comprising -
- a. adding a catalytic amount of the regenerated sugar-nucleotide donor to the stoichiometric amount of an acceptor to obtain the glycosylated principal product and the catalytic amount of a nucleotide; and
- b. regenerating the nucleotide into the regenerated sugar-nucleotide donor by contacting the catalytic amount of a nucleotide with the stoichiometric amount of a sugar donor precursor to obtain the regenerated sugar-nucleotide donor and the secondary product.
- 69. A method for producing a N-acetylglucosaminylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a N-acetylglucosaminylated principal product and a secondary product.
- 70. The method according to any one of embodiments 67-69, wherein the sugar donor precursor is lacto-N-biose.
- 71. The method according to any one of embodiments 67-70, wherein the sugar-nucleotide donor is a N-acetylglucosamine nucleotide.
- 72. The method according to any one of embodiments 67-71, wherein the secondary product is galactose.
- 73. The method according to claim any one of embodiments 67-72, wherein the secondary product derivative is tagatose.
- 74. The method according to any one of embodiments 61-73, wherein the processing enzyme D-galactose isomerase sourced from Geobacillus stearothermophilus (GsAI).
- 75. The method according to any one of embodiments 61-74, wherein the nucleotide is uridine diphophate.
- 76. The method according to any one of embodiments 61-75, wherein the transferase is β-1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- 77. The method according to any one of embodiments 61-76, wherein the transferase comprises a first transferase and a second transferase.
- 78. The method according to embodiment 77, wherein the first transferase is glucosaminyl (N-acetyl) transferase 2 (GCNT2) and second transferase is β-1,3-N-Acetyl-Hexosaminyl-transferase from Neisseria meningitidis (NmLgtA).
- 79. The method according to any one of embodiments 1-78, wherein glucose is D-glucose
- 80. The method according to any one of embodiments 1-79, wherein galactose is D-galactose.
- 81. The method according to any one of embodiments 1-80, wherein fucose is L-fucose.
- 82. A glycosylated compound prepared according to any one of embodiments 1-81.
- 83. A galactosylated compound prepared according to any one of embodiments 1-39.
- 84. A sialylated compound prepared according to any one of embodiments 1-25, 40-52, or 79-81.
- 85. A fucosylated compound prepared according to any one of embodiments 1-25, 53-66, or 79-81.
- 86. A N-acetylglucosaminylated compound prepared according to any one of embodiments 1-25, 67-78, or 79-81.
- 87. A lactose derivative prepared by a process according to any one of embodiments 1-81.
- 88. The lactose derivative according to claim 87 selected from lactobionic acid, lactitol, lactosucrose, galacto-oligosaccharides, lactulose, and an HMO.
- 89. A compound prepared by a method according to any one of embodiments 1-81, wherein the compound is obtained from non-animal based plant materials.
- 90. A machine configured for the method of any one of embodiments 1-81
- 91. The machine according to embodiments 90, wherein the process is within a single reaction vessel.
- In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
- Abbreviations
-
- 3′-SL: 3′Sialyllactose
- 2′-FL: 2′-Fucosyllactose
- LNFPI: Lacto-N-fucopentaose I
- LNFPII: Lacto-N-fucopentaose II
- LNFPIII: Lacto-N-fucopentaose III
- LNT: Lacto-N-tetraose
- LNnT: Lacto-N-neotetraose
- LNTII: Lacto-N-triose II
- DSLNT: Disialyllacto-N-tetraose
- UDP: Uridine 5′-diphosphate
- UTP: Uridine 5′-triphosphate
- ADP: Adenosine 5′-diphosphate
- ATP: Adenosine 5′-triphosphate
- CMP: Cytidine 5′-monosphate
- CDP: Cytidine 5′-diphosphate
- CTP: Cytidine 5′-triphosphate
- GDP: Guanosine 5′-diphosphate
- GTP: Guanosine 5′-triphosphate
- TDP: Thymidine 5′-diphosphate
- Tris: Tris(hydroxymethyl)aminomethane
- DMC: 2-Chloro-1,3-dimethylimidazolinium chloride
- Bbh1: β-N-acetylglucosaminidase
- GOS: Galactooligosaccharide
- DFL: Difucosyllactose
- 3-FL: 3-Fucosyllactose
- LSTa: Sialyllacto-N-tetraose a LS-Tetrasaccharide a
- LSTb: Sialyllacto-N-tetraose b/LS-Tetrasaccharide b
- LSTc: Sialyllacto-N-neotetraose c/LS-Tetrasaccharide c
- LSTd: Sialyllacto-N-neotetraose d/LS-Tetrasaccharide d
- Cvb3GalT: β-1,3-Galactosyl transferase from Chromobacterium violaceum
- AtSuSy1: Sucrose synthase from Arabidopsis thaliana
- Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1)
- ST3GAL3: CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-
sialyltransferase 3 - ST3GAL4: CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-
sialyltransferase 4 - ST6GALNAC5: alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5
- ST3GAL4: CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-
sialyltransferase 4 - Te2FT: α-1,2-Fucosyltransferase from Thermosynechococcus vestitus
- Hp34FT: α1-3/4-Fucosyltransferase from Helicobacter pylori
- FUT9: Fucosyl transferase 9
- FUT3:
Fucosyl transferase 3 - HmFucT: α-1,2-Fucosyltransferase from Helicobacter mustelae (HmFucT)
- FUT1: Fucosyl transferase
- Pyr: Pyruvate
- AcPi: Acetyl phosphate
- PPi: Inorganic pyrophosphate
- Pi: Inorganic phosphate
- NADP+: Nicotinamide adenine dinucleotide phosphate oxidized form
- NADPH: Nicotinamide adenine dinucleotide phosphate reduced form
- PolyPn and PolyPn-1: Polyphosphate; n indicates number of phosphate units
- HK: Hexokinase
- FDH: Formate dehydrogenase
- PtxD: Phosphite Oxidoreductase
- GOS: Galactooligosaccharide
- Lactose synthase E.C. 2.4.1.22: Generates lactose from glucose and UDP-galactose. It consists of a 1:1 complex of galactosyltransferase (B4GALT1 or B4GALT2) and alpha-lactalbumin.
- UDP-sugar pyrophosphorylase (USP) E.C. 2.7.7.64: Catalyzes a reversible transfer of the uridyl group from UTP to sugar-1-phosphate, producing UDP-sugar and pyrophosphate (PPi)
- UTP-Glucose 1-phosphate uridylyltransferase (GalU) E.C. 2.7.7.9: Catalyzes the conversion of glucose-1-phosphate or galactose-1-phosphate to UDP-glucose or UDP-galactose, respectively.
- Galactokinase (GalK) E.C. 2.7.1.6: Catalyzes the phosphorylation of galactose to galactose-1-phosphate (Gal-1P) via consumption of one ATP unit.
- Inorganic pyrophosphatase (Ppa) E.C. 3.6.1.1: Catalyzes the hydrolysis of pyrophosphate (PPi) to two monophosphate ions (Pi).
- Alkaline Phosphatases E.C. 3.1.3.1: Catalyzes the hydrolysis of a nucleotide (NMP, NDP, NTP) into the corresponding nucleoside (N) and a phosphate.
- CIAP: Calf Intestinal Alkaline Phosphatase
- 1a. Reagents and Materials:
- The following chemicals reagents are used to synthesize the carbohydrates, glycans or human milk oligosaccarides: Sucrose (Carbosynth: OS02339), Glucose (α-D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine 5′-monophosphate disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), GDP (Guanosine 5′-diphosphate disodium salt; Carbosynth: NG09782), 2′-Fucosyllactose (2′-FL; Carbosynth: OF06739), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), GlcNAc (N-Acetyl-D-glucosamine; Sigma Aldrich: A8625), Tris (TRIS, 1.0M buffer solution., pH 7.5; Alfa Aesar: J62993AP), HEPES (Thermo Scientific: AAA1477730), PIPES (Thermo Scientific: AC172615000) and MgCl2 (Magnesium Chloride; Macron Fine Chemicals: 595804). All water is obtained from a BarnStead Nanopure water purifier (Thermo Scientific, 18.5 MOhm-cm). LNTII, LNT and LNnT are produced in-house from lactose.
- Mammalian enzymes ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, B3GNT2, FUT9 and ST6GalNAc5 are purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase is purchased from Sunson Enzymes, and human a-lactalbumin is purchased from Athens Research & Technology. SuSy (Sucrose synthase; source: Glycine Max), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum), NmLgtB (β-1,4-Galactosyltransferase; source: Neisseria meningitidis), Cvβ3GalT (β-1,3-galactosyl transferase; source: Chromobacterium violaceum), Te2FT (α-1,2-fucosyltransferase; source: Thermosynechococcus vestitus), HmFucT (α-1,2-fucosyltransferase; source: Helicobacter mustelae), and Hp34FT (α1-3/4-fucosyltransferase; source: Helicobacter pylori) are produced in-house recombinantly in E. coli (BL21/DE3). The enzymes are purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer is exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes are supplemented with 10% (w/w) glycerol and frozen at −80° C. for storage. The plasmids used for protein expression are produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- 1b. Reagents and materials: The following chemicals reagents were used to synthesize Lactose, LSTa and LNT: Sucrose (Carbosynth: OS02339), Glucose (α-D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Tris (TRIS, 1.0M buffer solution, pH 7.5; Alfa Aesar: J62993AP), HEPES (Thermo Scientific: AAA1477730), PIPES (Thermo Scientific: AC172615000) and MgCl2 (Magnesium Chloride; Macron Fine Chemicals: 595804). All water was obtained from a BarnStead Nanopure water purifier (Thermo Scientific, 18.5 MOhm-cm). LNTII and LNT were produced in-house from lactose.
- Mammalian enzymes ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, B3GNT2, FUT9 and ST6GalNAc5 were purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase was purchased from Sunson Enzymes, and human a-lactalbumin was purchased from Athens Research & Technology. SuSy (Sucrose synthase; source: Glycine max), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum), NmLgtB (β-1,4-Galactosyltransferase; source: Neisseria meningitidis), Cvβ3GalT (β-1,3-galactosyl transferase; source: Chromobacterium violaceum), Te2FT (α-1,2-fucosyltransferase; source: Thermosynechococcus vestitus), HmFucT (α-1,2-fucosyltransferase; source: Helicobacter mustelae), and Hp34FT (α1-3/4-fucosyltransferase; source: Helicobacter pylori) were produced in-house recombinantly in E. coli (BL21/DE3). The enzymes were purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer was exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes were supplemented with 10% (w/w) glycerol and frozen at −80° C. for storage. The plasmids used for protein expression were produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- The following examples illustrate the step-by-step syntheses of LNT, LNnT, lactose, GOS, LNFPI, LNFPII, LNFPIII, LSTa, LSTc, LSTd and DSLNT as shown in
FIGS. 1-3 . The target glycans may be synthesized step-by-step by sequentially combining below examples. Alternatively, the target glycans may be synthesized from any advanced glycan building block. - A. Synthesis of LNT from LNTII
- LNT is produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, SuSy and GalE (
FIG. 1B ). The reaction mixture is composed of 25 mM LNTII, 50 mM sucrose, 5 mM UDP, 400 μg/ml SuSy, 800 μg/ml Cvb3GalT, 400 μg/m1GalE and 10 mM MgCl2 in 50 mM Tris pH 7.0 at 37° C. - B. Synthesis of LNnT from LNTII
- LNnT is produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB or B4GALT1, SuSy and GalE (
FIG. 1C ). The reaction mixture is composed of 25 mM LNTII, 50 mM sucrose, 0.1-10 mM UDP, 400 μg/ml SuSy, 800 μg/ml Cvb3GalT, 400 μg/ml GalE and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - C. Synthesis of Lactose from Glucose
- Lactose is produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes B4GALT1, α-lactalbumin, SuSy and GalE (
FIG. 1E ). The reaction mixture is composed of 25 mM Glucose, 100 mM sucrose, 0.1-10 mM UDP, 100 μg/ml B4GALT1, 100 μg/ml α-lactalbumin, 400 μg/ml SuSy, 400 μg/ml GalE and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - D. Synthesis of Galacto-oligosaccharide (GOS) from Sucrose
- GOS is produced from sucrose and catalytic amounts of UDP using the three enzymes β-1,4-galactosyltransferase, SuSy and GalE (
FIG. 1F ). The reaction mixture is composed of 2 M sucrose, 0.1-10 mM UDP, 400 μg/ml SuSy, 800 μg/ml β-1,4-galactosyltransferase, 400 μg/ml GalE and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - A. Synthesis of LSTa from LNT
- LSTa is produced from LNT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase (
FIG. 2A ). The reaction mixture is composed of 25 mM LNT, 30mM 3′-SL, 0.1-10 mM CMP, 100 μg/ml ST3GAL4, 150 μg/ml ST3GAL3, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - B. Synthesis of LSTc from LNnT
- LSTc is produced from LNnT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST6GAL1 and Lactase (
FIG. 2B ). The reaction mixture is composed of 25 mM LNnT, 30mM 3′-SL, 0.1-10 mM CMP, 400 μg/ml ST3GAL4, 400 μg/ml ST6GAL1, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - C. Synthesis of LSTd from LNnT
- LSTd is produced from LNnT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase (
FIG. 2C ). The reaction mixture is composed of 25 mM LNnT, 30mM 3′-SL, 0.1-10 mM CMP, 400 μg/ml ST3GAL4, 400 μg/ml ST3GAL3, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - D. Synthesis of DSLNT from LNT
- DSLNT is produced from LNT, 3′-SL, and catalytic amounts of CMP using the four enzymes ST3GAL4, ST3GAL3, ST6GALNAC5 and Lactase (
FIG. 2D ). The reaction mixture is composed of 25 mM LNT, 60mM 3′-SL, 0.1-10 mM CMP, 400 μg/ml ST3GAL4, 400 μg/ml ST3GAL3, 400 μg/ml ST6GALNAC5, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - A. Synthesis of LNFPI from LNT
- LNFPI is produced from LNT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, Te2FT and Lactase (
FIG. 3A ). The reaction mixture is composed of 25 mM LNT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Te2FT, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - B. Synthesis of LNFPII from LNT
- LNFPII is produced from LNT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, Hp34FT or FUT5, and Lactase (
FIG. 3B ). The reaction mixture is composed of 25 mM LNT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Hp34FT or FUT5, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - C. Synthesis of LNFPIII from LNnT
- LNFPIII is produced from LNnT, 2′-FL, and catalytic amounts of CMP using the three enzymes HmFucT, FUT9 and Lactase (
FIG. 3C ). The reaction mixture is composed of 25 mM LNnT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml FUT9, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - A. Synthesis of LNT from LNTII
- LNT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, SuSy and GalE (
FIG. 1B ). The reaction mixture was composed of 25 mM LNTII, 50 mM sucrose, 5 mM UDP, 400 μg/ml SuSy, 800 μg/ml Cvb3GalT, 400 μg/ml GalE and 10 mM MgCl2 in 50 mM Tris pH 7.0 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Thermo Vanquish, Trinity P1 column, charged aerosol detector). Conversions of 10.6%, 37.4% and 77.7% were observed at 0.5 hr, 1 hr and 17 hrs, respectively. - B. Synthesis of Lactose from Glucose
- Lactose was produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes B4GALT1, α-lactalbumin, SuSy and GalE (
FIG. 1E ) in a four-steps process. In step one, the lactose synthase complex was assembled in the mixture composed of 25 mM Glucose, 200 μg/ml B4GALT1, 80 μg/ml α-lactalbumin, 10 mM MnCl2, 1 mM CaCl2, and 50 mM HEPES pH 6.8, incubated at 4° C. for 1 hour. In step two, UDP-galactose was synthesized in a s reaction mixture composed of 100 μg/ml SuSy, 100 μg/ml GalE, 6 mM UDP, 50 mM Sucrose and 10 mM MnCl2 in 50 mM HEPES pH 6.8, incubated for 1 hour at 37° C. In step three, equal volumes of the two mixtures from step one and step two were combined and incubated at 4° C. for 30 minutes. In this, the UDP-galactose produced in step two was used to stabilize the lactose synthase complex. In step four, the reaction mixture was transferred to 37° C. to facilitate the conversion of glucose to lactose. Conversion from Glucose to lactose was monitored by HPLC (Thermo Vanquish, Trinity P1 column, charged aerosol detector). Conversions of 8.9%, 14.3%, 20.8% and 25.4% were observed at 0.25 hr, 0.5 hr, 1 hr and 17 hrs, respectively. - Synthesis of LSTa from LNT
- LSTa was produced from LNT, 3′-SL, and catalytic amounts of CMP using
- the three enzymes ST3GAL4, ST3GAL3 and Lactase (
FIG. 2A ). The reaction mixture was composed of 25 mM LNT, 30mM 3′-SL, 5 mM CMP, 100 μg/ml ST3GAL4, 150 μg/ml ST3GAL3, 400 μg/ml lactase and 10 mM MgCl2 in 50 mM Tris pH 7.0 at 37° C. Conversion from LNT to LSTa was monitored by HPLC (Thermo Vanquish, Trinity P1 column, charged aerosol detector). A conversion of approximately 5% was observed after 21 hours. - 4a. Reagents and Materials
- The following chemical reagents are used to synthesize the carbohydrates,
- glycans or human milk oligosaccarides: Sucrose (Carbosynth: OS02339), Glucose (α-D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), CMP (Cytidine disodium salt; Carbosynth: NC05637), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), GDP (Guanosine 5′-diphosphate disodium salt; Carbosynth: NG09782), 2′-Fucosyllactose (2′-FL; Carbosynth: OF06739), 3′-Sialyllactose (3′-SL; Carbosynth: OS04397), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Lacto-N-biose (LNB; Chemily GlycoScience: OS03002); GlcNAc (N-Acetyl-D-glucosamine; Sigma Aldrich: A8625), Tris (TRIS, 1.0M buffer solution., pH 7.5; Alfa Aesar: J62993AP), HEPES (Thermo Scientific: AAA1477730), PIPES (Thermo Scientific: AC172615000) and MgCl2 (Magnesium Chloride; Macron Fine Chemicals: 595804). All water is obtained from a BarnStead Nanopure water purifier (Thermo Scientific, 18.5 MOhm-cm). LNTII, LNT and LNnT are produced in-house from lactose.
- Mammalian enzymes ST3GAL3, ST3GAL4, ST6GAL1, B4GALT1, B3GALT5, GCNT2, B3GNT2, FUT1, FUT3, FUT9 and ST6GalNAc5 are purchased from Glyco Expression Technologies Inc. (Athens, Georgia). Lactase is purchased from Sunson Enzymes, and human a-lactalbumin is purchased from Athens Research & Technology. SuSy (Sucrose synthase; source: Glycine max), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum), NmLgtB (β-1,4-Galactosyltransferase; source: Neisseria meningitidis), NmLgtA (β-1,3-N-Acetyl-Hexosaminyl-transferase; source: Neisseria meningitidis), Cvβ3GalT (β-1,3-galactosyl transferase; source: Chromobacterium violaceum), Te2FT (α-1,2-fucosyltransferase; source: Thermosynechococcus vestitus), HmFucT (α-1,2-fucosyltransferase; source: Helicobacter mustelae), GsAI (D-Galactose isomerase; source: Geobacillus stearothermophilus) and Hp34FT (α1-3/4-fucosyltransferase; source: Helicobacter pylori) are produced in-house recombinantly in E. coli (BL21/DE3). The enzymes are purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer is exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes are supplemented with 10% (w/w) glycerol and frozen at −80° C. for storage. The plasmids used for protein expression are produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- 4b. Reagents and Materials:
- The following chemicals reagents were used to synthesize Lactose, LNT and LNnT: Sucrose (Carbosynth: OS02339), Glucose (α-D(+)-Glucose, 99+%, anhydrous, Thermo Scientific: AC170080010), UDP (Uridine 5′-diphosphate disodium salt; Carbosynth: NU03399), Lactose (D-Lactose monohydrate; Fisher Scientific: L5-500), Sodium Phosphate Dibasic Heptahydrate (Fisher Chemical: S373-500) and MgCl2 (Magnesium Chloride; Macron Fine Chemicals: 595804). All water was obtained from a BarnStead Nanopure water purifier (Thermo Scientific, 18.5 MOhm-cm). LNTII was produced in-house from lactose.
- AtSuSy1 (Sucrose synthase; source: Arabidopsis thaliana), GalE (UDP-glucose 4-epimerase; source: Bifidobacterium longum), NmLgtB (β-1,4-Galactosyltransferase; source: Neisseria meningitidis) and Cvβ3GalT galactosyl transferase; source: Chromobacterium violaceum) were produced in-house recombinantly in E. coli (BL21/DE3). The enzymes were purified from the soluble lysate by affinity chromatography (NiNTA) and the buffer was exchanged by dialyzing against 50 mM Tris pH 7.5. The enzymes were supplemented with 10% (w/w) glycerol and frozen at −80° C. for storage. The plasmids used for protein expression were produced by Genewiz or Genscript by custom synthesis of the insert and splicing into a commercial pET28a vector (Novagen).
- A. Synthesis of LNFPI from LNT
- LNFPI is produced from LNT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, Te2FT, Lactase and GsAI (
FIG. 11A ). The reaction mixture is composed of 25 mM LNT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Te2FT, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - B. Synthesis of LNFPII from LNT
- LNFPII is produced from LNT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, Hp34FT, Lactase and GsAI (
FIG. 11B ). The reaction mixture is composed of 25 mM LNT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Hp34FT or FUT5, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - C. Synthesis of LNFPIII from LNnT
- LNFPIII is produced from LNnT, 2′-FL, and catalytic amounts of GDP using the four enzymes HmFucT, FUT9, Lactase and GsAI (
FIG. 11C ). The reaction mixture is composed of 25 mM LNnT, 30mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml FUT9, 400 μg/ml lactase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - D. Synthesis of DFL from 2′-FL
- HP34FT, Lactase and GsAI (
FIG. 11D ). The reaction mixture is composed ofmM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Hp34FT, 400 μg/ml lactase, 400 μg/ml GsAI and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - E. Synthesis of 3-FL from 2′-FL
- 3-FL is produced from 2′-FL and catalytic amounts of GDP using the five enzymes HmFucT, HP34FT, Lactase, GsAI and Fucosidase (
FIG. 11E ). The reaction mixture is composed of 50mM 2′-FL, 0.1-10 mM GDP, 400 μg/ml HmFucT, 400 μg/ml Hp34FT, 400 μg/ml lactase, 400 μg/ml GsAI, 400 μg/ml Fucosidase and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - A. Synthesis of LNTII from Lacto-N-biose (LNB).
- LNTII is produced from LNB, lactose, and catalytic amounts of UDP using the two enzymes NmLgtA, and GsAI (
FIG. 12A ). The reaction mixture is composed of 25 mM LNB, 30 mM lactose, 0.1-10 mM UDP, 400 μg/ml NmLgtA and 400 μg/ml GsAI and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - B. Synthesis of β-1,6-GlcNAc-LNnT from LNnT.
- β-1,6-GlcNAc-LNnT is produced from LNnT, LNB, and catalytic amounts of UDP using the three enzymes NmLgtA (or B3GNT2), GCNT2, and GsAI (
FIG. 12B ). The reaction mixture is composed of 25 mM LNnT, 30 mM LNB, 0.1-10 mM UDP, 400 μg/ml NmLgtA, 400 μg/ml GCNT2 and 400 μg/ml GsAI and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 4.5 to 7.5 at 37° C. - A. Synthesis of LNT from LNTII
- LNT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes Cvb3GalT, AtSuSy1, and GalE (
FIG. 9B ). The reaction mixture was composed of 250 mM LNTII, 1.0 M sucrose, 1 mM UDP, 250 μg/ml AtSuSy1, 500 μg/ml Cvb3GalT, 500 μg/ml GalE and 10 mM MgCl2 in 50 mM phosphate buffer pH 6.6 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Agilent 1100, amino column, evaporative light scattering detector). Conversion of 86% was observed after 16 hrs., 1 hr and 17 hrs. - B. Synthesis of LNnT from LNTII
- LNnT was produced from LNTII, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB, AtSuSy1 and GalE (
FIG. 9C ). The reaction mixture was composed of 500 mM LNTII, 1.0 M sucrose, 5 mM UDP, 400 μg/ml AtSuSy1, 200 μg/ml NmLgtB, 400 μg/ml GalE and 10 mM MgCl2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from LNTII to LNT was monitored by HPLC (Agilent 1100, amino column, evaporative light scattering detector). Conversions of 36%, 64%, 77% and 96% were observed at 2 hrs, 4 hrs, 6 hrs. and 24 hrs., respectively resulting in the production of 500 mg of LNnT product. - C. Synthesis of Lactose from Glucose
- Lactose was produced from Glucose, sucrose, and catalytic amounts of UDP using the three enzymes NmLgtB, AtSuSy1 and GalE (
FIG. 9E ). The reaction mixture was composed of 500 mM Glucose, 1.0 M sucrose, 5 mM UDP, 400 μg/ml NmLgtB, 400 μg/ml AtSuSy1, 400 μg/ml GalE and 10 mM MgCl2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose was monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 50% was observed after 24 hrs. resulting in the production of 2.5 g of lactose product. - Lactose is produced from Glucose, sucrose, and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase) (
FIG. 9F ). The reaction mixture is composed of 500 mM Glucose, 1.0 M sucrose, 5 mM UDP, 400 μg/ml NmLgtB, 400 μg/ml AtSuSy1, 400 μg/ml GalE, 400 μg/ml Glucose isomerase and 10 mM MgCl2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose is monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 70% is observed after 24 hrs. resulting in the production (predicted) of 3.0 g of lactose product. - Lactose is produced from Glucose, sucrose, fructose and catalytic amounts of UDP using the four enzymes NmLgtB, AtSuSy1, GalE and Glucose (xylose) isomerase (EC 5.3. 1.5, D-xylose aldose-ketose-isomerase) (
FIG. 9G ). The reaction mixture is composed of 500 mM Glucose, 500 mM fructose, 500 mM sucrose, 5 mM UDP, 400 μg/ml NmLgtB, 400 μg/ml AtSuSy1, 400 μg/ml GalE, 400 μg/ml Glucose isomerase and 10 mM MgCl2 in 250 mM phosphate pH 6.0 at 37° C. Conversion from Glucose to lactose is monitored by TLC using a p-anisaldehyde stain. An approximate conversion of 70% is observed after 24 hrs. resulting in the production (predicted) of 3.0 g of lactose product. - LSTa was produced from LNT, 3′-SL, and catalytic amounts of CMP using the three enzymes ST3GAL4, ST3GAL3 and Lactase. The reaction mixture was composed of 5 mM LNT, 25
mM 3′-SL, 5 mM CMP, 300 μg/ml ST3GAL4, 300 μg/ml ST3GAL3, 300 μg/ml lactase and 20 mM MgCl2 in 25 mM Phosphate pH 6.0 at 37° C. Formation of LSTa was confirmed by comparing it with the commercially purchased LSTa (purchased from Biosynth) via silica gel TLC using a butanol/water/acetic acid mobile phase system (4:2.5:2) with Rf (LSTa) 0.16 and Rf (LNT) 0.33Sss. - Further optimization of LSTa synthesis was performed by varying buffers (50 mM NaOAc; pH 5.5 and 50 mM Na3PO4; pH 6.0), equivalents of 3′-SL (500 mM and 1M), CMP (5 mM and 25 mM) at 250 mM LNT with and without lactase in the reaction mixture. It was observed that presence of lactase and using higher concentration of 3′-SL (1M as compared to 500 mM) led to greater conversion LSTa (˜20-25% based on TLC). Both 5 mM and 25 mM CMP reactions gave similar results. Both NaOAc buffer (pH 5.5) and Na3PO4 (pH 6.0) buffer gave similar results as well.
- LSTb is produced from LNT, 3′-SL, and catalytic amounts of CMP using the five enzymes ST3GAL4, ST3GAL3, ST6GALNAC5, Lactase and α2-3 Neuraminidase S. The reaction mixture is composed of 25 mM LNT, 60
mM 3′-SL, mM CMP, 400 μg/ml ST3GAL4, 400 μg/ml ST3GAL3, 400 μg/ml ST6GALNAC5, 400 μg/ml lactase. 100 μg/ml α2-3 Neuraminidase S and 10 mM MgCl2 in 20-100 mM buffer in the pH range of 6.5 to 7.5 at 37° C. - The enzymes in Table 1 are used in the methods of the invention. Other enzymes are disclosed herein. Table 1 provides the E number, enzyme name, E.C. number, and an example of an enzyme that may be used. Table 1 may refer to enzymes or genes encoding the enzymes.
-
TABLE 1 Selected Enzymes Enzyme Name E.C. No. Examples Hexosyl transferase EC 2.4.1 β-1,3-galactosyl transferase from Chromobacterium violaceum (Cvb3GalT) β-N-acetylhexosaminidase EC 3.2.1.52 Bbh1 Glycosyl transferase EC 2.4 sucrose synthase Sucrose synthase EC 2.4.1.13 sucrose synthase from Arabidopsis thaliana (AtSuSy 1) Epimerase EC 5.1.3.2 GalE UDP-glucose 4-epimerase Hexosyl transferase EC 2.4.1.22 B4GALT1 Not an enzyme: cofactor N/A α-lactalbumin for B4GALT1 Hexosyl transferase EC 2.4.1 β-1,4-galactosyltransferase from Neisseria meningitidis (NmLgtB) Hexosyl transferase EC 2.4.1 B3GALT5 Sialyl transferase EC 2.4.99 ST3GAL3 Sialyl transferase EC 2.4.99 ST3GAL4 Sialyl transferase EC 2.4.99 ST6GAL1 Sialyl transferase EC 2.4.99 ST6GALNAC5 Glycosidase 3.2.1 Lactase Fucosyl transferase EC 2.4.1 Te2FT Fucosyl transferase EC 2.4.1 HmFucT Fucosyl transferase EC 2.4.1 Hp34FT Fucosyl transferase EC 2.4.1 FUT9 Fucosyl transferase EC 2.4.1 FUT1 Fucosyl transferase EC 2.4.1 FUT3 Galactose isomerase (L- GsAI (Gene: araA) arabinose isomerase) Fucosidase See examples disclosed herein Glucosaminyl (N-acetyl) GCNT2 transferase 2 Oxidase See examples disclosed herein Isomerase See examples disclosed herein Hydrolase See examples disclosed herein Neuraminidase See examples disclosed herein - Enzymes E1, E1′, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11, and E12 used in Example 1 are immobilized. All reagents and cofactors, buffer, salts are added at the beginning. The enzymes are immobilized, and in an example of a flow reactor (e.g. packed bed reactor) the above mixture of reagents is flowed through this flow reactor. Glucose, fructose, or a mixture of glucose and fructose along with feed stock and immobilized enzymes are introduced into the reactor. The
FIG. 15 depicted conversions are carried out to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate. - D-mannose isomerase converts glucose or converts fructose to mannose. Glk (HK) coverts mannose into mannose-6-phosphate, along with ATP conversion to ADP. RfbK (ManB) converts mannose-6-phosphate to mannose-1-phosphate. RfbM (ManC) converts mannose-1-phosphate to GDP-D-Man, along with conversion of GTP to PPi. Gmd converts GDP-D-Man to GDP-4-keto-6-deoxymannose. GFS (WcaG) converts GDP-4-keto-6-deoxymannose to GDP-L-fucose along with conversion of NADPH to NADP+. Fucosyl transferase converts lactose and GDP-L-fucose to 2′FL. In the same reactor, the following reactions occur. PmPpa converts inorganic diphosphate to inorganic phosphate. AcK and pyruvate oxidase converts pyruvate and inorganic phosphate (generated by PmPpa) to CO2 and peroxide (with catalase converting the CO2 and peroxide to oxygen and water). FDH converts formate to CO2 along with conversion of NADP+ to NADPH. Also in the same reactor, GDP is converted to GTP. 2′FL is obtained. See
FIG. 15 . - Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8′, E9, E10, E11, and E12 are combined with feedstock to carry out the reactions depicted in
FIG. 16 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate. - Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8, E9′, and E12 are combined with feedstock to carry out the reactions depicted in
FIG. 17 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate. - Enzymes (in immobilized form) E1, E1′, E2, E3, E4, E5, E6, E7, E8′, E9′, and E12 are combined with feedstock to carry out the reactions depicted in
FIG. 18 to provide 2′FL or another fucosylated oligosaccharide or fucosylated antibody-glycan conjugate. - The enzymes in Table 2 are used in the methods of the invention. Table 2 provides the E number used in
FIGS. 15-18 , enzyme name, E.C. number, and an example of an enzyme that may be used. Table 2 may refer to enzymes or genes encoding the enzymes. -
TABLE 2 Integrated Fucosylation Pathway Enzymes E# Enzyme Name E.C. No. Examples E10 Acetate Kinase 2.7.2.1 AcK E11 Catalase 1.11.1.6 Cat E1 D-mannose isomerase 5.3.1. D-Mannose-2-epimerase, 5.3.1.7 E1’ Epimerase-isomerase EC 5.3.1.7 AGEase (P. geniculata) EC 5.3.1.15, EC 5.3.1.11 E8 Formate dehydrogenase 1.17.1.9 FDH E7 Fucosyl transferase 2.4.1 HmFucT, Hp34FT, FUT9 E6 GDP-Fucose Synthase 1.1.1.271 GFS (WcaG) E4 GDP-Man Pyrophosphorylase 2.7.7.13 RfbM (ManC) E5 GDP-Mannose-4,6- 4.2.1.47 Gmd dehydratase E2 Hexokinase 2.7.1.1 Glucokinase (GlK) E12 Inorganic Pyrophosphatase 3.6.1.1 PmPpa E8' Phosphite dehydrogenase 1.20.1.1 PtxD (PTDH) E3 Phosphomannomutase 5.4.2.8 RfbK (ManB) E9' Polyphosphate Kinase 2.7.4.1 PPK2 E9 Pyruvate Oxidase 1.2.3.3 PyrOx - https://www.researchgate.net/figure/Production-of-D-mannose-from-D-fructose-and-D-glucose-using-different-enzymes-MIase_fig1_336675669. Lui et al., Foods, 9(12), 1809.
- All publications and patent documents disclosed or referred to herein are incorporated by reference in their entirety.
- The foregoing description has been presented only for purposes of illustration and description. This description is not intended to limit the invention to the precise form disclosed. It is intended that the scope of the invention be defined by the claims appended hereto.
Claims (30)
1. A method for producing a glycosylated principal product, comprising the steps of:
a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor in the presence of a transferase to obtain a glycosylated principal product and a catalytic amount of a nucleotide; and
b. regenerating said nucleotide into a regenerated sugar-nucleotide donor by contacting said catalytic amount of said nucleotide with a stoichiometric amount of a sugar donor precursor in the presence of a transferase to obtain said regenerated sugar-nucleotide donor and a secondary product.
2. The method of claim 1 , further comprising
a. contacting a catalytic amount of said regenerated sugar-nucleotide donor and a said stoichiometric amount of an acceptor in the presence of a transferase to obtain said glycosylated principal product and said catalytic amount of a nucleotide; and
b. regenerating said nucleotide into said regenerated sugar-nucleotide donor by contacting said catalytic amount of said nucleotide with said stoichiometric amount of said sugar donor precursor in the presence of a transferase to obtain said regenerated sugar-nucleotide donor and said secondary product.
3. A method for producing a glycosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
4. The method according to claim 3 , wherein said sugar donor precursor and said nucleotide provides a sugar-nucleotide donor.
5. The method according to claim 1 , wherein said sugar donor precursor and said nucleotide provides a sugar-nucleotide donor precursor and wherein an auxiliary enzyme and said sugar-nucleotide donor precursor provides said sugar-nucleotide donor.
6.-27. (canceled)
28. A method for producing a galactosylated principal product, comprising the steps of:
a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a galactosylated principal product and a catalytic amount of a nucleotide; and
b. regenerating said nucleotide into a regenerated sugar-nucleotide donor by contacting said catalytic amount of said nucleotide and a stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and a secondary product.
29. The method of claim 28 , further comprising
a. contacting a catalytic amount of said regenerated sugar-nucleotide donor and said stoichiometric amount of an acceptor to obtain said glycosylated principal product and said catalytic amount of a nucleotide; and
b. regenerating said nucleotide into said regenerated sugar-nucleotide donor by contacting said catalytic amount of a nucleotide and said stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and said secondary product.
30. A method for producing a galactosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a glycosylated principal product and a secondary product.
31. The method according to claim 28 , wherein said acceptor is lacto-N-triose II (LNTII), glucose, or galactooligosaccharide (GOS).
32.-45. (canceled)
46. A method for producing a sialylated principal product, comprising the steps of:
a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a sialylated principal product and a catalytic amount of a nucleotide; and
b. regenerating said nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of said nucleotide and a stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and a secondary product.
47. The method of claim 46 , further comprising:
a. contacting a catalytic amount of said regenerated sugar-nucleotide donor and said stoichiometric amount of an acceptor to obtain said glycosylated principal product and said catalytic amount of a nucleotide; and
b. regenerating said nucleotide into said regenerated sugar-nucleotide donor by contacting said catalytic amount of a nucleotide and said stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and said secondary product.
48. A method for producing a sialylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a sialylated principal product and a secondary product.
49. The method according to claim 46 , wherein said sugar donor precursor is 3′-sialyllactose.
50-69. (canceled)
70. A method for producing a fucosylated principal product, comprising the steps of:
a. contacting a catalytic amount of a sugar-nucleotide donor to a stoichiometric amount of an acceptor to obtain a fucosylated principal product and a catalytic amount of a nucleotide; and
b. regenerating said nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of said nucleotide with a stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and a secondary product.
71. The method of claim 70 , further comprising
a. contacting a catalytic amount of said regenerated sugar-nucleotide donor and said stoichiometric amount of an acceptor to obtain said glycosylated principal product and said catalytic amount of a nucleotide; and
b. regenerating said nucleotide into said regenerated sugar-nucleotide donor by contacting said catalytic amount of a nucleotide and said stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and said secondary product.
72. A method for producing a fucosylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a fucosylated principal product and a secondary product.
73. The method according to claim 70 , wherein said sugar donor precursor is a 2′-fucosyllactose.
74.-95. (canceled)
96. A method for producing a N-acetylglucosaminylated principal product, comprising the steps of:
a. contacting a catalytic amount of a sugar-nucleotide donor and a stoichiometric amount of an acceptor to obtain a N-acetylglucosaminylated principal product and a catalytic amount of a nucleotide; and
b. regenerating said nucleotide into a regenerated sugar-nucleotide donor by contacting a catalytic amount of said nucleotide and a stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and a secondary product.
97. The method of claim 1 , further comprising:
a. contacting a catalytic amount of said regenerated sugar-nucleotide donor and said stoichiometric amount of an acceptor to obtain said glycosylated principal product and said catalytic amount of a nucleotide; and
b. regenerating said nucleotide into said regenerated sugar-nucleotide donor by contacting said catalytic amount and a nucleotide with said stoichiometric amount of a sugar donor precursor to obtain said regenerated sugar-nucleotide donor and said secondary product.
98. A method for producing a N-acetylglucosaminylated principal product comprising the step of adding a sugar donor precursor, an acceptor, a transferase, and a catalytic amount of a nucleotide to obtain a N-acetylglucosaminylated principal product and a secondary product.
99. The method according to claim 96 , wherein said sugar donor precursor is lacto-N-biose.
100.-129. (canceled)
130. A machine configured for said method of claim 1 .
131. The machine according to claim 130 , wherein said method occurs within a single reaction vessel.
132. A process for producing a fucosylated oligosaccharide or a fucosylated antibody-glycan conjugate, comprising the steps of.
a. contacting glucose or fructose in the presence of an enzyme that converts said fructose or glucose to mannose;
b. contacting said mannose with an enzyme that converts mannose to mannose-6-phosphate;
c. contacting said mannose-6-phosphate with an enzyme that converts mannose-6-phosphate to mannose-1-phosphate;
d. contacting said mannose-1-phophate with an enzyme that converts said mannose-1-phophate to GDP-D-mannose;
e. contacting said GDP-D-mannose with an enzyme that converts GDP-D-mannose to GDP-4-keto-6-deoxymannose;
f. contacting said GDP-4-keto-6-deoxymannose with an enzyme that converts said GDP-4-keto-6-deoxymannose to GDP-L-fucose;
g. contacting said GDP-L-fucose with a disaccharide, an oligosaccharide or an antibody-glycan conjugate with an enzyme that fucosylates said disaccharide, oligosaccharide or said antibody-glycan conjugate; and
h. obtaining a fucosylated disaccharide, oligosaccharide or a fucosylated antibody-glycan conjugate.
wherein each of said enzymes is immobilized and wherein said process contains a set of regeneration enzyme systems to convert ADP to ATP, PPi to Pi, GDP to GTP, and NADP+ to NADPH.
133.-153. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/199,842 US20230407357A1 (en) | 2022-05-20 | 2023-05-19 | Biomanufacturing of oligosaccharides and derivatives from simple sugar |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263344507P | 2022-05-20 | 2022-05-20 | |
US202263430271P | 2022-12-05 | 2022-12-05 | |
US202363448175P | 2023-02-24 | 2023-02-24 | |
US18/199,842 US20230407357A1 (en) | 2022-05-20 | 2023-05-19 | Biomanufacturing of oligosaccharides and derivatives from simple sugar |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230407357A1 true US20230407357A1 (en) | 2023-12-21 |
Family
ID=88836024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/199,842 Pending US20230407357A1 (en) | 2022-05-20 | 2023-05-19 | Biomanufacturing of oligosaccharides and derivatives from simple sugar |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230407357A1 (en) |
WO (1) | WO2023225364A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK42594A3 (en) * | 1991-10-15 | 1994-10-05 | Scripps Research Inst | Method of production of fucosylated carbohydrates |
WO2017101958A1 (en) * | 2015-12-18 | 2017-06-22 | Glycom A/S | Fermentative production of oligosaccharides |
-
2023
- 2023-05-19 US US18/199,842 patent/US20230407357A1/en active Pending
- 2023-05-19 WO PCT/US2023/023000 patent/WO2023225364A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023225364A1 (en) | 2023-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mestrom et al. | Leloir glycosyltransferases in applied biocatalysis: A multidisciplinary approach | |
Palcic | Glycosyltransferases as biocatalysts | |
WO2022034075A1 (en) | Production of glcnac containing bioproducts in a cell | |
KR20220012834A (en) | Fermentative Production of Carbohydrates by Microbial Cells Using Mixed Feedstocks | |
Wan et al. | Efficient production of 2′-fucosyllactose from L-fucose via self-assembling multienzyme complexes in engineered Escherichia coli | |
Rexer et al. | Enzymatic synthesis of glycans and glycoconjugates | |
EP4192945A1 (en) | Cellular production of sialylated di- and/or oligosaccharides | |
EP4192946A1 (en) | Cellular production of di- and/or oligosaccharides | |
WO2023250198A1 (en) | Biocatalytic manufacture of sugar nucleotides | |
US20230407357A1 (en) | Biomanufacturing of oligosaccharides and derivatives from simple sugar | |
CN117716047A (en) | Continuous fermentation production of oligosaccharides | |
Ali et al. | Utilization of glycosyltransferases as a seamless tool for synthesis and modification of the oligosaccharides-A review | |
EP4103727A2 (en) | Production of glycosylated product in host cells | |
US20240132927A1 (en) | Modular glycan production with immobilized bionanocatalysts | |
Hussnaetter et al. | Strategies for automated enzymatic glycan synthesis (AEGS) | |
EP3954778B1 (en) | Production of a mixture of neutral non-fucosylated oligosaccharides by a cell | |
WO2022219188A1 (en) | Cellular production of sialylated di- and/or oligosaccharides | |
EP3954769A1 (en) | Production of oligosaccharide mixtures by a cell | |
JP2006271372A (en) | Method for producing sugar chain | |
WO2024047096A1 (en) | Process for purification of an oligosaccharide | |
EP4277984A1 (en) | Extracellular production of glycosylated products | |
WO2024089131A1 (en) | Saccharide importers for lacto-n-triose | |
CN117957316A (en) | Fucosyltransferase for converting lactose-N-disaccharide | |
Liu et al. | Synthesis and Modification of Carbohydrates via Metabolic Pathway Engineering in Microorganisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |